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Vascular cognitive impairment (VCI) describes a heterogeneous condition caused 
by cerebrovascular disease and disturbances in cerebral blood flow delivery.  It is the 
second leading form of dementia and vascular factors such as hypertension, diabetes 
and obesity are associated with an increased risk of developing VCI. White matter 
alterations are a prominent pathological feature observed in patients with VCI thought 
to underlie cognitive impairment. Neuroimaging studies show a positive correlation 
between the burden of white matter alterations and progressive cognitive impairment. 
Similarly associated both with white matter alterations and cognitive impairment is 
chronic cerebral hypoperfusion, sustained subtle reductions in cerebral blood flow. 
Cerebral hypoperfusion is observed before the onset of cognitive decline in humans 
and reducing cerebral blood flow in animal models replicates important aspects of 
VCI, suggesting hypoperfusion is an early driver of white matter disruption and VCI. 
Human neuropathology and preclinical animal models of chronic cerebral 
hypoperfusion studies have repeatedly identified increased inflammation and 
oxidative stress. This led to the hypothesis for this thesis; that inflammation and 
oxidative stress are key drivers of structural and functional white matter disruption 
when cerebral blood flow is reduced. 
The studies reported in this thesis were developed to investigate mechanisms 
involving inflammation and oxidative stress that can inform future treatments aimed 
at preventing the disruption of white matter and cognitive impairment in VCI. One such 
mechanism is the Nrf2 (Nuclear factor erythroid 2-related factor 2) signalling pathway. 
Nrf2 is a transcription factor that acts to detect and resolve inflammation and oxidative 
stress via induction of over 200 antioxidant and anti-inflammatory genes. Studies 
have shown that modulation of Nrf2 alters levels of inflammation and oxidative stress 
which impact on disease progression in models of Alzheimer’s disease, Parkinson’s 
disease and multiple sclerosis. To date, no one has investigated the direct role of Nrf2 
in cerebral hypoperfusion-induced white matter disruption. While Nrf2 represents a 
promising network approach, another targeted mechanism of interest is microglial 
proliferation. Many neurodegenerative diseases including human VCI demonstrate 
increases in microglia, a sign of chronic neuroinflammation thought to be detrimental 
to cells, tissues and synapses. Work by our group has found an association between 
increasing numbers of microglia and the progressive disruption of white matter 
structure and function when cerebral blood flow is reduced in a mouse model, 




The first study of this thesis aimed to test the hypothesis that deficiency of Nrf2 
exacerbates white matter pathology and cognitive decline when cerebral blood flow 
is reduced. Using wild type and Nrf2 knockout mice the study investigated cortical 
perfusion, white matter disruption and gliosis, cognitive impairment and white matter 
gene changes following sham or surgically-induced cerebral hypoperfusion (bilateral 
carotid artery stenosis). There were no differences in the severity of blood flow 
reductions between genotypes initially, however, wild type mice displayed improved 
recovery compared to Nrf2 deficient mice. Hypoperfusion induced white matter 
disruption and microgliosis in the corpus callosum and the optic tract in both 
genotypes, exacerbated by the absence of Nrf2. Further, hypoperfusion induced white 
matter astrogliosis and upregulated pro-inflammatory gene signalling in the optic tract 
and induced an impairment in spatial working memory. However, these measures 
were not affected by Nrf2 deficiency. The results demonstrate that the absence of 
Nrf2 exacerbates white matter pathology and microgliosis following cerebral 
hypoperfusion but does not impact on functional outcome. 
The second study aimed to test the hypothesis that enhancing astrocytic Nrf2-
signalling preserves white matter structure and cognitive decline when cerebral blood 
flow is reduced. Astrocytes have larger antioxidant capacity than other cell types in 
the brain and overexpressing Nrf2 in astrocytes is associated with reduced white 
matter damage in a model of multiple sclerosis, as well as improved outcome in 
models of Parkinson’s and Huntington’s disease. Similar to the first study, wild type 
mice and mice overexpressing Nrf2 in astrocytes (GFAP-Nrf2) were subjected to 
bilateral carotid artery stenosis and cortical perfusion, white matter disruption and 
gliosis, cognitive impairment and white matter gene changes were assessed. There 
were no differences in the severity of blood flow reductions between genotypes. Akin 
to the first study, hypoperfusion induced white matter disruption, micro- and 
astrogliosis and pro-inflammatory gene signalling in the optic tract. The majority of 
these alterations were ameliorated in GFAP-Nrf2 mice. In addition, the impairment in 
spatial working memory induced by cerebral hypoperfusion was modestly improved 
in GFAP-Nrf2 mice compared to wild type controls. These findings support the 
hypothesis that astrocytic Nrf2 preserves white matter structure and function following 
cerebral hypoperfusion. 
The first two studies identified structural and functional consequences of altered 
inflammation mediated via alterations in Nrf2 signalling. To thoroughly investigate the 
Nrf2 signalling pathway following cerebral hypoperfusion the next step would ideally 
xv 
have been to study microglial Nrf2, however due to the lack of a suitable animal 
model, the third and final study instead aimed to test the hypothesis that microglial 
colony-stimulating factor 1 receptor (CSF1R) signalling  is a driver of white matter 
disruption and cognitive decline when cerebral blood flow is reduced. Wild type mice 
treated with a pharmacological inhibitor of CSF1R (GW2580) or vehicle control, as an 
oral gavage or in diet, were studied by a similar experimental protocol as the first two 
studies. There were no differences in the severity of cerebral hypoperfusion between 
GW2580- or vehicle-treated animals either at one or six weeks following bilateral 
carotid artery stenosis. One week of GW2580 treatment was shown to modulate 
microglial proliferation and pro-inflammatory signalling in white matter. Remarkably, 
treatment with GW2580 for six weeks completely rescued impairments in spatial 
learning, protected against white matter disruption and prevented increased both 
white matter micro- and astrogliosis compared to wild type controls. These results 
suggest that CSF1R signalling in microglia is an important driver of the 
pathophysiological mechanisms that lead to white matter disruption and cognitive 
impairment when cerebral blood flow is reduced, and importantly, that targeted 
inhibition of this improves functional outcome. 
In conclusion, the work described in this thesis provides evidence of the 
contribution of inflammation and oxidative stress to the disruption and functional 
impairment of cerebral white matter. The results indicate that these mechanisms are 
amenable to alteration, and that direct microglial inflammatory mechanisms play an 
important role in the pathogenesis of white matter disruption and cognitive decline. 
The results demonstrate that targeted inhibition of CSF1R signalling in microglia and 
increased astrocytic Nrf2 expression leads to improved structural and functional 





Dementia is a term used to describe symptoms that disrupt the brain’s ability to 
think, plan and remember. Dementia severely impairs quality of life and always leads 
to death. In 2018, 50 million people were living with dementia without available 
disease-modifying treatments. Many mistakenly believe that dementia is an inevitable 
part of ageing whereas in fact it is caused by a number of different diseases. The 
second most common cause of dementia is vascular dementia, where the brain 
doesn’t receive a sufficient supply of blood. Animal models where blood flow to the 
brain is reduced are used to study mechanisms involved. In vascular dementia, 
cognitive functions such as thinking and planning are the most affected, as a result of 
damage to the brain’s wiring. The wiring is called white matter because of its white 
appearance under the microscope, and transmits information between different 
regions necessary for complicated cognitive functions. It is currently unknown how 
the wiring becomes damaged to cause cognitive impairment in vascular dementia, 
but studies suggest that inflammation and oxidative stress are involved. 
Inflammation is the body’s natural response to protect itself against invaders, but 
uncontrolled inflammation can lead to damage to otherwise healthy cells and tissues 
such as white matter. Oxidative stress is the result of an imbalance between 
production and clearance of harmful molecules called reactive oxygen species. 
Reactive oxygen species are produced as a by-product of cellular energy production 
and are normally swiftly neutralised by antioxidant defence mechanisms. During 
disease, production of these molecules increases and if not efficiently cleared these 
can cause damage. The body possesses defence mechanisms against both oxidative 
stress and inflammation, one of which is the Nrf2 system. This thesis firstly explores 
the role of the Nrf2 system in a model of vascular dementia. The results show that 
reducing brain blood flow in mice without Nrf2 causes more white matter damage and 
conversely, reducing brain blood flow in mice with higher levels of Nrf2 results in less 
white matter damage and also less cognitive impairment. The thesis then goes on to 
study specifically if increased inflammation is an early driver that can be targeted in 
vascular dementia. The results show that inhibiting the brain’s inflammatory cell 
microglia protects the wiring from damage and prevents learning impairment in mice 
when brain blood flow is reduced. The work presented in this thesis suggests that 
enhancing the Nrf2-system and inhibiting inflammation in a cell-specific manner is 
beneficial, and future studies should explore these mechanism further as potential 
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SEM Standard error of the mean 
SOD1 Superoxide dismutase 1 
STD Standard deviation 
tBHQ tert-butyl-hydro-quinone  
TLR Toll-Like Receptors  
TNFα Tumor necrosis factor alpha 
TRAP Translating ribosome affinity purification 
VCI Vascular cognitive impairment 
VD Vascular dementia 
VEGFα Vascular endothelial growth factor alpha 
WML White matter lesion 
βTrCP Beta-transducin repeat containing protein 
2VO Two-vessel occlusion 
3VO Three-vessel occlusion 
4VO Four-vessel occlusion 
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Introduction 




The prevalence of dementia worldwide was in 2018 estimated at 50 million people 
with a financial cost in excess of US$ 1 trillion (Patterson, 2018). Dementia is a 
devastating fatal illness that not only affects the individual but also friends and family 
who have to take greater and greater care responsibilities as the disease progresses. 
Vascular cognitive impairment (VCI) is the second leading form of dementia 
(Dichgans and Leys, 2017) and vascular contributions to other dementia subtypes 
such as Alzheimer’s Disease (AD) are becoming increasingly recognised (Kapasi et 
al., 2017, Iturria-Medina et al., 2016), implicating potentially overlapping 
pathophysiological mechanisms. 
VCI is a heterogeneous disorder resulting from large and small cerebrovascular 
disease such as large vessel occlusion, bilateral carotid artery stenosis and 
atherosclerosis (O'Brien et al., 2003, Iadecola, 2013). One major pathological feature 
observed in VCI patients is alterations to the brain’s white matter as detected by in 
vivo imaging (Wardlaw et al., 2015) and post mortem pathological evaluation (Skrobot 
et al., 2016). Longitudinal neuroimaging studies and neuropathological evidence 
demonstrate an association between white matter alterations and declining cognition 
(de Groot et al., 2000, Inzitari et al., 2009, Boyle et al., 2016, Ezzati et al., 2017). 
Hypoxia and ischaemia are suggested mechanisms underlying white matter 
pathology (Barker et al., 2013) which may be attributed to chronic cerebral 
hypoperfusion (Fernando et al., 2006, Schuff et al., 2009, Brickman et al., 2009). 
Chronic cerebral hypoperfusion; the modest, sustained reduction of blood flow to 
the brain, is a cerebrovascular feature observed before the onset of cognitive decline 
(Ruitenberg et al., 2005). It is not only associated with poorer cognition (Alosco et al., 
2013) but also predicts conversion from mild cognitive impairment to dementia (Chao 
et al., 2010, Hirao et al., 2005). This suggests that chronic cerebral hypoperfusion is 
an early alteration which may contribute to the onset of VCI and dementia (de la Torre, 
2016). Animal models of cerebral hypoperfusion, such as bilateral carotid artery 
stenosis, recapitulate important features of VCI, including white matter disruption and 
cognitive impairment (Duncombe et al., 2017). Since the molecular mechanisms 
underlying VCI are poorly understood, these animal models are essential to 
investigate hypotheses formed from neuropathology and neuroimaging studies. 
Increasing evidence suggests that inflammation and oxidative stress are 
pathophysiological mechanisms contributing to white matter disruption in humans 
(Simpson et al., 2007b, Al-Mashhadi et al., 2015), and similar changes can be 
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detected in animal models (Coltman et al., 2011, Reimer et al., 2011, Washida et al., 
2010). The transcription factor Nrf2 (Nuclear factor erythroid 2-related factor 2) is a 
master regulator of anti-inflammatory and antioxidant gene expression which has 
emerged as a potential therapeutic target for the treatment of neurodegenerative 
disease (reviewed by Johnson and Johnson, 2015). Nrf2 is critical for maintenance of 
white matter structure during normal ageing (Hubbs et al., 2007) and pharmacological 
activation of the Nrf2-pathway via dimethyl fumarate (DMF) is approved by the U.S. 
Food and Drug Administration for the treatment of multiple sclerosis (reviewed by 
Suneetha and Raja Rajeswari, 2016). It is currently unknown what the role and 
therapeutic potential of the Nrf2-pathway is in white matter disruption induced by 
chronic cerebral hypoperfusion. Further, white matter alterations in humans are 
associated with increased numbers of microglia (Simpson et al., 2007a, Simpson et 
al., 2007b) and preclinical studies suggest that expansion of the microglial population 
via proliferation is detrimental to white matter structure and function when cerebral 
blood flow (CBF) is reduced (Fowler et al., 2017, Manso et al., 2017). However, a 
causal relationship remains to be established. 
The work described in this thesis was developed to investigate the hypothesis that 
inflammation and oxidative stress drive the disruption of white matter structure and 
function following chronic cerebral hypoperfusion. The studies herein are investigating 
the Nrf2 signalling pathway and microglial proliferation, mechanisms involving 
inflammation and oxidative stress that may inform future treatments aimed at 
preventing the disruption of white matter structure and function, utilising the bilateral 
carotid artery stenosis model of chronic cerebral hypoperfusion in mice. 
1.2 Importance of the cerebrovascular system 
The brain constitutes ~2% of the body’s weight but requires as much as 20% of its 
total energy supply (Attwell and Laughlin, 2001) making it one of the most energy 
demanding organs in the body. This energy demand reflects requirements for 
synaptic transmission in grey matter (Attwell and Laughlin, 2001), as well as the 
energy required to provide and maintain structural integrity to the neuronal axons that 
transmit information between distributed neuronal networks and make up the brain’s 
white matter (Harris and Attwell, 2012). Glucose and oxygen are required for the 
production of the main energy substrate adenosine triphosphate (ATP) (Belanger et 
al., 2011), and due to a lack of endogenous energy stores the brain is critically 
dependent on a constant and adequate supply of blood (Kisler et al., 2017). Blood 
enters the brain through four major arteries, the carotid arteries and the vertebral 
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arteries (Fig 1.1a, Fig 1.2). Together these join a cerebrovascular structure called the 
Circle of Willis, found at the base of the brain (Fig 1.1a). This specialised arrangement 
provides redundancy and redistribution should a feeding artery become occluded or 
damaged in any way, to maintain the constant supply of blood that the brain requires 
for normal function (Vrselja et al., 2014). Branching off the Circle of Willis is the 
anterior, middle and poster cerebral arteries (Fig 1.1a, c), the three major vessels that 
perfuse the extensive cerebrovascular system (Iadecola, 2013). 
The human cerebrovascular system consists of a dense network of blood vessels 
measuring ~400 miles (Fig 1.1b) with highly specialised functions (Iadecola and 
Nedergaard, 2007). Autoregulation is a hemodynamic response that keeps CBF 
constant despite changes in blood pressure via myogenic and metabolic mechanisms 
altering cerebrovascular resistance (Paulson, 1990). This is an important function that 
protects the cerebrovasculature from hypertension, however conversely, may leave 
the brain more vulnerable to hypoperfusion in conditions of systemic hypotension (van 
Beek et al., 2008). Another specialised function is functional hyperaemia, (or 
neurovascular coupling) which allows for rapid increases in CBF to accommodate 
local increases in metabolic demand caused by neuronal activity (Iadecola and 
Nedergaard, 2007, Attwell et al., 2010). This response is thought to be mediated by 
neurochemical signalling involving astrocytes, strategically positioned between 
neurons and the vessels (Iadecola and Nedergaard, 2007, Attwell et al., 2010) (Fig 
1.3). Together these functions ensure that CBF remains constant, sufficient and is 
matched with the current levels of metabolic demand.  
It is well known that the interruption of CBF, such as that observed in stroke, leads 
to brain damage (Hossmann, 2006). However, it has also been demonstrated that 
subtle reductions in CBF occurring over a longer period of time, referred to as chronic 
cerebral hypoperfusion, is detrimental to the brain, in particular to the structure and 
function of the brain’s white matter (Brickman et al., 2009). This is thought to be 
because the normal rate of perfusion in white matter is already roughly half that of 
grey matter (Chen et al., 2008) and, because the cerebrovasculature is arranged in 
an outside-in distribution (Fig 1.1c). This renders deep white matter structures more 
susceptible to reductions in CBF during global chronic cerebral hypoperfusion 
(Iadecola, 2013). 
I N T R O D U C T I O N  | 5 
Figure 1.1 Anatomy of the human cerebrovasculature. (a) Cerebrovascular 
arrangement at the base of the brain including the circle of willis. Blood is supplied 
through the vertebral and internal carotid arteries and then distributed to the brain via 
the anterior, middle and posterior cerebral arteries. Adapted from 
https://www.scienceabc.com/humans/circle-of-willis-anatomy-diagram-and-
functions.html (b) Artwork based on a resin cast showing the blood vessels of the 
human brain. Credit Francis Leroy, Biocosmos / Science Photo Library, 
https://www.sciencephoto.com/media/306297/view/artwork-showing-the-blood-vessels-
of-the-brain (c) The outside-in distribution of cerebral blood vessels (adapted from 
Wardlaw et al., 2013) 
1.3 Vascular cognitive impairment 
Vascular cognitive impairment (VCI) describes a heterogeneous syndrome caused 
by cerebrovascular disease and disturbances in CBF delivery (O'Brien et al., 2003, 
Iadecola, 2013). The term encompasses alterations in cognition ranging from mild, 
subjective impairment through to severe cognitive impairment culminating in dementia 
(Dichgans and Leys, 2017, van der Flier et al., 2018). 
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 Vascular risk factors and underlying cerebrovascular causes of 
VCI 
The primary risk factor for developing dementia is age, but vascular risk factors 
such as hypertension, diabetes, hyperlipidaemia and obesity are all associated with 
VCI (Iadecola, 2013, Jellinger, 2013, Smith, 2017). These vascular risk factors are 
thought particularly detrimental if present in midlife, emphasising the early clinically 
silent changes that are hypothesised to induce cerebrovascular disease and VCI. 
Some evidence suggests that the incidence of dementia is reducing in high income 
countries as a result of improved management of vascular risk factors and 
cerebrovascular disease (Skrobot et al., 2017). However, since vascular changes 
occur years before the appearance of clinical symptoms, understanding the early 
pathophysiological mechanisms has proven difficult. 
To better understand mechanisms leading to VCI, efforts are being directed 
towards the cerebrovascular diseases that can be clinically diagnosed (Fig 1.2). 
Vascular disorders such as atherosclerosis, small vessel disease, and cerebral 
amyloid angiopathy all contribute to the development of cerebrovascular disruption 
and ischaemic lesion development (Iadecola, 2013, Jellinger, 2013). Small vessel 
disease generally leads to multiple smaller infarcts and/or microbleeds and white 
matter lesions. Cerebrovascular disease of large vessels may lead to chronic cerebral 
hypoperfusion or stroke caused either by occlusion or rupture of a large vessel. Vessel 
stiffening, narrowing, occlusion and overall reduced vessel integrity as a result of 
various vascular pathologies leads to impairments in the delivery and regulation of 
CBF (Dichgans and Leys, 2017). 
 Clinical manifestations and diagnostic criteria for VCI 
Due to its heterogeneous appearance, VCI has been difficult to diagnose clinically, 
however a recent consensus study aimed to harmonise VCI classification and 
diagnostic criteria (Skrobot et al., 2018). 
1.3.2.1 Neuropsychological evaluation of VCI 
Skrobot et al. (2018) reported that the cognitive domains that should be included 
for neuropsychological evaluation are executive function, attention, memory, 
language and visuospatial function. The key distinction between mild and major VCI 
is the disruption of instrumental activities in daily living which in mild VCI are mild or 
completely absent despite some impairment in at least one cognitive domain. Major 
VCI, in contrast, is associated with severe disruption of instrumental activities in daily 
living and significant deficits in at least one cognitive domain, but often several. The 
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neuropsychological tests are based on the National Institute of Neurological Disorders 
and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization 
standards (Hachinski et al., 2006). 
Figure 1.2 Cerebrovascular diseases associated with vascular cognitive 
impairment. (adapted from Dichgans and Leys, 2017) 
1.3.2.2 Neuroimaging features of VCI 
Furthermore, the consensus is that imaging evidence is essential for diagnosis of 
both mild and major VCI, and that magnetic resonance imaging (MRI) is the gold 
standard (Skrobot et al., 2018). A two-factor approach for diagnosis of VCI is 
emphasised also in a report by the American Heart Association/American Stroke 
Association (Gorelick et al., 2011). MRI has been used for a number of years to 
identify structural alterations associated with neurological disorders. The main 
neuroimaging features that are considered to contribute to VCI include white matter 
hyperintensities, brain atrophy; primarily white matter or hippocampal, recent small 
subcortical infarcts, lacunes (defined as small fluid-filled cavities), perivascular spaces 
and microbleeds (Wardlaw et al., 2013). Most importantly, alterations to the white 
matter are considered vital for establishing a diagnosis of VCI (Smith, 2017). 
Advances in MR technology such as diffusion weighted imaging allows for quantifiable 
evaluation of white matter integrity, shown to correlate better with cognition than 
traditional MR modalities such as fluid-attenuated inversion recovery (FLAIR) (Heiss 
et al., 2016).  
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 Vascular contributions to Alzheimer’s dementia 
Dementia was originally thought to result from vascular factors and “hardening of 
the arteries”, however following the discovery of the amyloid β peptide in the 1980’s, 
dementia research shifted heavily to the amyloid hypothesis (Iadecola, 2013). In the 
last couple of decades though, vascular contributions to dementia are receiving 
resurgent interest due to frequently observed overlap of pathological hallmarks. A 
comprehensive longitudinal study found that the presence of brain infarcts was 
associated with poorer cognition and increased prevalence of dementia compared to 
presence of AD pathology alone (Snowdon et al., 1997). In line with this is a recently 
published study describing that the effect of genetic risk factors for AD on cognition 
was partially but significantly mediated by vascular pathologies (Lin et al., 2018). 
Similarly, a meta-analysis of neuropathological evidence of probable AD identified 
vascular pathology in over 75% of cases and found that mixed pathologies lowered 
the threshold for clinical diagnosis of AD (Kapasi et al., 2017). Additional evidence 
suggests that vascular alterations represent an early event in the disease 
progression. Iturria-Medina et al. (2016) found that cerebrovascular dysfunction was 
the earliest detectable feature in patients with late onset AD, and Araque Caballero et 
al. (2018) observed white matter alterations over a decade before onset of dementia 
symptoms in patients with autosomal dominant (familial) AD. Together these studies 
suggest that early vascular alterations drive not only VCI but may also contribute to 
or even trigger neurodegenerative dementias. More efforts are therefore required to 
increase our understanding of how cerebrovascular disease induces pathological 
processes leading to cognitive impairment. 
1.4 White matter structure and function 
White matter makes up roughly 50% of the human brain (Walhovd et al., 2014) and 
contains a large proportion of the axons that transmit information between different 
brain regions (Stassart et al., 2018). Some axons are myelinated, meaning they are 
enwrapped by the lipid-rich myelin sheath which gives white matter its characteristic 
colour. Myelination is an evolutionary adaptation seen in vertebrates allowing for 
much faster conduction of nerve impulses (Aggarwal et al., 2011). The expansion of 
white matter tracts exceeds that of the neocortex (Filley and Fields, 2016, Paus et al., 
2014, Stassart et al., 2018) and since white matter provides the structural connectivity 
between distributed neural networks involved in complex functions, its role in 
cognition should not be disregarded. 
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Cellular components of white matter 
The greatest population of cells in the white matter are oligodendrocytes, the glial 
cell responsible for the production and maintenance of myelin (Walhovd et al., 2014) 
(Fig 1.3). Oligodendrocytes originate from oligodendrocyte precursor cells (OPCs), 
which remain in the adult brain and contribute to oligodendrocyte repopulation 
following injury (McQueen et al., 2014), and aid the restoration of myelin sheaths 
following demyelination (Stassart et al., 2018). The white matter is perfused by blood 
vessels, lined by endothelial cells and associated with pericytes and/or smooth 
muscle cells (Stassart et al., 2018) (Fig 1.3). Together with astrocytes and microglia 
these components make up what can be referred to as the neuro-gliovascular unit 
(Fig 1.3), a concept that emphasises the interconnection and communication between 
different cell types and the need to study these in concert rather than isolation. 
1.4.1.1 White matter astrocytes 
White matter astrocytes are star-shaped cells primarily involved in maintaining 
homeostasis (Lundgaard et al., 2014). Astrocytes are, more broadly, essential for 
maintaining the blood-brain barrier (BBB) with processes covering over 90% of the 
cerebrovasculature (Lundgaard et al., 2014), and their strategic position between the 
vasculature and neuronal synapses has led to their proposed involvement in the 
control of neurovascular coupling (Attwell et al., 2010) (Fig 1.3). Astrocytes are 
furthermore capable of buffering pH and are the only cell type in the brain with 
glycogen stores, making them important for homeostatic and metabolic support 
(Verkhratsky and Nedergaard, 2018). White matter astrocytes directly contact 
oligodendrocytes through gap junctions and a number of studies support the role for 
astrocytes in developmental myelination as well as continued support throughout 
adulthood (Lundgaard et al., 2014, Li et al., 2016a). Lastly, astrocytes also respond 
to and are capable of modulating the brain’s inflammatory response (Sofroniew, 
2014a, Sofroniew, 2014b), in conjunction with the brain resident macrophage 
microglia.  
1.4.1.2  White matter microglia 
These immune cells are sparser than oligodendrocytes and astrocytes (Walhovd 
et al., 2014), but as dynamic surveyors and early responders to damage (Nimmerjahn 
et al., 2005), microglia are important for the innate immune response and also 
regenerative white matter repair (Lloyd et al., 2017). The functions of microglia include 
phagocytosis of pathogens and myelin debris, secretion of cytokines, chemokines and 
growth factors and remodelling of the extracellular matrix (Lloyd et al., 2017, reviewed 
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by Salter and Stevens, 2017). The heterogeneity between white matter and grey 
matter microglia is less well known compared to astrocytes. Recent single cell RNA 
sequencing studies have identified immense heterogeneity of both cell types, much 
greater than previously thought (Grabert et al., 2016, Boisvert et al., 2018), however 
the functional consequence of this heterogeneity requires further investigation. More 
broadly, microglia are thought to be responsible for developmental synaptic pruning 
(Paolicelli et al., 2011) and to be involved in adult synaptic plasticity important for 
learning and memory (reviewed by Salter and Stevens, 2017). 
It also worth noting that while microglia are the only parenchymal macrophages in 
the brain, there are other macrophage populations found in very close proximity, for 
example, perivascular and meningeal macrophages, that are considered important 
components of the brain-resident immune system (Faraco et al., 2017), and as such 
should perhaps also be considered part of the neuro-gliovascular unit. 
 
Figure 1.3 Illustration of the neuro-gliovascular unit. The oligodendrocyte (blue) 
extends processes whose myelin-rich plasma membrane wraps around neuronal axons 
(brown). Astrocyte processes (green) have end-feet that contact neurons, 
oligodendrocytes and cover over 90% of cerebral blood vessels. Cerebral blood vessels 
are lined by endothelial cells (red), basement membrane proteins (white/grey) and 
contractile cells like pericytes (purple) or smooth muscle cells (not shown). Microglia 
(yellow) survey the environment and contribute to the inflammatory response essential 
for host-defence.  
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1.5 White matter vulnerability in VCI 
As previously mentioned, the white matter is essential for relaying information 
between distributed neuronal networks and as such is critical for cognitive function 
(Filley and Fields, 2016). White matter disruption leads to a functional disconnect 
(Lawrence et al., 2013) where information is no longer transmitted efficiently and 
accurately between different brain regions (Nave, 2010, Chen et al., 2016). Frontal 
white matter tracts are particularly sensitive to vascular-related disruption, thought to 
underlie the impairments of the specific cognitive domains affected in VCI (Hachinski 
et al., 2006) (see 1.3.2.1).  
Evidence from a plethora of neuroimaging studies display a clear association 
between white matter alterations and declining cognition (reviewed by Wardlaw et al., 
2015). As an example, The Rotterdam Scan Study found that white matter lesions 
detected by MRI relate to impaired cognition in a data set of ~1000 individuals. The 
cognitive impairment chiefly related to tasks that require speed of processing rather 
than memory, consistent with the cognitive changes reported in VCI (de Groot et al., 
2000). These results were corroborated by Bendlin et al. (2010) using more detailed 
diffusion weighted imaging modalities (see 1.3.2.2). White matter alterations are not 
only associated with declining cognition, but serve as indicators of the rate of cognitive 
decline, as the severity of white matter changes detected at the start of a study 
predicted subsequent rate of global functional and cognitive decline (Inzitari et al., 
2009). This was later corroborated by a separate longitudinal study (Boyle et al., 
2016). In consort with a large number of additional studies this strongly suggests that 
white matter alterations drive cognitive decline in ageing and VCI. This is supported 
also by nineteenth century human post mortem analyses that found that focal white 
matter lesions result in impaired cognition (reviewed by Filley and Fields, 2016). 
Chronic cerebral hypoperfusion drives white matter disruption in 
VCI 
Neuroimaging studies demonstrate that areas of white matter intensities exhibit 
reduced CBF (Brickman et al., 2009, Schuff et al., 2009) and that perfusion deficits in 
normal appearing white matter predict future white matter alterations (Promjunyakul 
et al., 2015, Bernbaum et al., 2015). This suggests that cerebral hypoperfusion may 
be an important early driver of white matter disruption. Further in support of this are 
associations identified between impaired cerebral perfusion and cognitive decline 
(Alosco et al., 2013). Reduced CBF precedes clinical dementia (Ruitenberg et al., 
2005) and can, akin to white matter alterations, be used to predict conversion from 
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mild cognitive impairment to dementia (Chao et al., 2010). Furthermore, individuals 
with carotid artery stenosis; narrowing of the carotid arteries as a result of 
atherosclerosis, present with poorer cognition compared to individuals without 
(Balucani et al., 2012) and a longitudinal study found that intracranial arterial stenosis 
increases the risk of patients with mild cognitive impairment developing dementia 
(Zhu et al., 2014). 
Chronic cerebral hypoperfusion can be attributed a range of cerebrovascular 
diseases and risk factors such as atherosclerosis (Barone et al., 2016), small vessel 
disease (Rosenberg et al., 2015), hypertension (Perrotta et al., 2016) and diabetes 
(Novak et al., 2006), as well as progressing age (Aanerud et al., 2012). As such, 
cerebral hypoperfusion may induce common downstream pathophysiological 
mechanisms which can be targeted for therapeutic intervention in a number of 
conditions. There is some conflicting evidence suggesting that reduced perfusion may 
be an effect rather than a cause of white matter alterations as discussed in a recent 
meta-analysis (Shi et al., 2016b). Although, the authors highlight that most perfusion 
measures were either global or from grey matter and, as previously indicated, deep 
white matter structures are more susceptible to reductions in CBF due to the 
arrangement of the cerebrovasculature (Fig 1.1c), possibly accounting for the 
discrepancies. 
Human neuropathology studies also support cerebral hypoperfusion as a possible 
cause of white matter alterations in age and VCI. This conclusion is based on 
immunohistochemical results finding increased hypoxia-inducible factors (HIFs) and 
matrix metalloproteinases (MMPs) in lesioned white matter (Fernando et al., 2006, 
Aboul-Enein et al., 2003). These proteins are both known to be regulated by hypoxia 
and ischaemia and promote vascular inflammation and blood brain barrier 
breakdown. Similarly, Aboul-Enein et al. (2003) demonstrated in post mortem white 
matter lesioned tissue, preferential loss of a protein localised at the innermost part of 
the myelin-sheath; myelin-associated glycoprotein (MAG) (Fig 1.4). MAG is highly 
susceptible to hypoxia and ischaemia, far more so than other myelin proteins such as 
proteolipid protein (PLP) (Barker et al., 2013). The ratio of MAG:PLP is used as a post 
mortem marker of white matter ischaemia, indicative of the previous perfusion status 
of that tissue (Barker et al., 2014). 
Lastly in support of the role of cerebral hypoperfusion in the development of VCI is 
the incidence of dementia in patients who have suffered strokes. Stroke doubles the 
risk of dementia and is so closely associated with VCI that it is categorised as its own 
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sub-type; post-stroke dementia (Smith, 2017). Albeit the reductions in perfusion 
during a stroke far exceeds those resulting from impaired vessel reactivity and 
stenosis in cerebral hypoperfusion, pathophysiological features such as inflammation 
and oxidative stress are observed in both conditions (Raz et al., 2015). 
Figure 1.4 Electron micrograph of a central nervous system axon with 
surrounding myelin. Oligodendrocyte is highlighted in green and myelin sheath can 
be seen surrounding central axon in black. Yellow indicates location of myelin-
associated glycoprotein (MAG) and outside the myelin sheath in red is myelin-
oligodendrocyte glycoprotein (MOG). (adapted from Quarles, 2007) 
1.6 Cerebral hypoperfusion models of VCI 
Rodent models of cerebral hypoperfusion provide an excellent tool for investigating 
flow-related pathophysiological mechanisms involved in white matter disruption 
relevant to VCI. Cerebral blood flow is reduced in rats and mice by occlusion or 
stenosis primarily of the carotid arteries (Fig 1.1, 1.2). Mouse models provide 
advantages as a mammalian system with a genome amenable to genetic modification 
that is also highly analogous with the human genome. 
Bilateral carotid artery stenosis in mice 
Originally developed by Shibata et al. (2004), bilateral carotid artery stenosis 
(BCAS) is achieved by application of microcoils to the carotid arteries, thereby 
reducing their lumen and the flow of blood to the Circle of Willis. Extensive 
characterisation by our group and others show that BCAS in mice induces modest, 
chronic reductions in CBF (20-50%) leading to diffuse evolving white matter pathology 
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and cognitive impairment (Ihara and Tomimoto, 2011, Coltman et al., 2011, McQueen 
et al., 2014, Hattori et al., 2016). At 1 month following BCAS surgery the white matter 
is selectively disrupted as detected by MRI (Holland et al., 2011) and histology or 
immunohistochemistry (Shibata et al., 2004, Coltman et al., 2011). Further, 1 month 
of BCAS induces an impairment in spatial working memory, attributed to disrupted 
frontal-subcortical circuitry, whereas reference memory is still intact (Shibata et al., 
2007, Coltman et al., 2011) consistent with VCI in humans. Longer-term BCAS (3-8 
months) induces additional cerebrovascular disruption including stroke lesions, blood 
brain barrier disruption and microhaemorrhages, resembling small vessel disease 
pathology, which coincide with more extensive cognitive impairment including 
impaired reference memory, (Kitamura et al., 2017, Holland et al., 2015, Nishio et al., 
2010). These studies demonstrate that BCAS-induced chronic cerebral hypoperfusion 
in mice is a relevant and suitable experimental model of VCI. Importantly, CBF 
reductions following BCAS in mice are sub ischaemic (<70%) but induce hypoxic 
conditions in the white matter from 3 days onwards (Duncombe et al., 2017) 
consistent with human neuropathology (Fernando et al., 2006, Aboul-Enein et al., 
2003, Barker et al., 2013). 
1.6.1.1 Considerations for the study of BCAS 
The cerebrovascular arrangement has been shown to differ between mouse 
strains (Yang et al., 1997) and CBF may recover following BCAS, particularly in young 
mice over time due to vascular remodelling (Shibata et al., 2004). Longitudinal CBF 
measurements are therefore important tools for assessing and comparing 
experimental results. This is also of particular importance as the extent of CBF 
reduction following BCAS can vary considerably between animals of same strain and 
age. 
Additionally, criticism of the model is that blood flow reductions following BCAS 
occur acute which is not representative of chronic hypoperfusion in humans which 
arises gradually. An alternative model has been developed using an ameroid 
constrictor device which by absorption of extracellular fluid slowly induces stenosis of 
the carotid arteries. This approach has been employed in rats (Kitamura et al., 2012) 
and mice (Hattori et al., 2015) demonstrating similar results as those seen in the 
BCAS model. In rats the gradual occlusion model resulted in slower and less severe 
reductions in CBF (~30%) and selective disruption of white matter while still producing 
cognitive impairment (Kitamura et al., 2012). In mice, the CBF reduction was induced 
gradually, however, by 28 days the ameroid constrictor device had absorbed enough 
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fluid to completely occlude the carotid artery and the resulting pathology was therefore 
more severe than that produced by BCAS (Hattori et al., 2015). 
 Alternative models of chronic cerebral hypoperfusion 
The two-vessel occlusion model (2VO) in rats was initially established to study VCI 
and did reproduce white matter disruption and cognitive imapairment (Ohta et al., 
1997, Wakita et al., 2002, Farkas et al., 2004). However, acute blood flow reductions 
following 2VO surgery are severe (>70%) and concomitant grey matter damage is 
frequently observed (Tomimoto et al., 1997). Similarly severe reductions in perfusion 
are observed when occluding three or even four arteries (3VO/4VO) (reviewed by 
Jiwa et al., 2010) and occlusion models in rats should therefore be considered models 
of global ischaemia. Results discussed from these models will be clearly stated in the 
text. Occlusion of the carotid arteries in C57Bl/6J mice can only be performed 
transiently, as the lack of collateral blood supply means that permanent occlusion 
results in death (Yang et al., 1997). Unilateral common carotid artery occlusion in mice 
produces reductions in cerebral blood flow more representative of chronic cerebral 
hypoperfusion in humans (Scheff et al., 2016) and selective white matter pathology 
relevant to VCI (Yoshizaki et al., 2008). However, a limitation of this model is that 
perfusion recovers substantially over time and in one study was reported to have 
recovered completely by 15 days (Guo et al., 2011). 
Altogether, the BCAS model in mice is well characterised and induces both 
pathological and behavioural features relevant to human VCI. As such it is the most 
suitable model at present to study pathophysiological mechanisms of chronic cerebral 
hypoperfusion-induced white matter disruption and cognitive impairment. 
1.7 Inflammation and Oxidative stress 
Potential pathophysiological mechanisms underlying white 
matter disruption and cognitive impairment 
 Inflammation 
Inflammation is an endogenous protective response mediated primarily by 
microglia to prevent infection and tissue damage caused by invading pathogens, 
dying cells or debris (Salter and Stevens, 2017). The inflammatory response by 
microglia is commonly referred to as microgliosis. Microglia are capable of 
phagocytosis; engulfment of inflammatory stimuli, and can neutralise immune threats 
by generating an oxidative burst, in which free radicals in large quantities attack and 
destroy pathogens (Mahad et al., 2015). Further, microglia are secretory cells that 
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release a number of pro-inflammatory mediators aimed at recruiting and activating 
additional inflammatory cells (Sasaki, 2016). In the same way, astrocytes can undergo 
reactive astrogliosis in response to inflammatory stimuli, contributing to the secretion 
of inflammatory mediators and free radicals (Sofroniew, 2014b). Inflammation is a 
tightly regulated process, although many disease states are characterised by 
dysregulated and uncontrolled inflammation leading to damage of otherwise healthy 
tissues. 
1.7.1.1 Inflammatory mechanisms detrimental to white matter 
The presence of myelin debris and/or white matter hypoxia may induce gliosis of 
microglia and astrocytes. HIFs released in response to hypoxia enhance activity of 
the pro-inflammatory transcription factor Nuclear Factor κB (NF-κB) by increasing 
signalling and expression of Toll-Like Receptors (TLRs); proteins involved in immune 
cell activation (Eltzschig and Carmeliet, 2011). Further, endothelial cells express 
TLRs and are also activated by hypoxia/ischaemia (Anrather and Iadecola, 2016), 
and have therefore been suggested to induce pro-inflammatory signalling in brain-
endogenous microglia, thereby contributing to a neuroinflammatory response (Liao, 
2013). In addition, hypoxia (Fernando et al., 2006), endothelial cells (Liao, 2013) and 
innate immune cells (Rosenberg, 2017) are all capable of secreting and/or activating 
MMPs. These enzymes are responsible for degradation of the extracellular matrix 
during normal remodelling, but may aberrantly cause BBB opening and/or myelin 
disruption (Rosenberg, 2009), further exacerbating neuroinflammation. 
 Oxidative stress 
Oxidative stress is the result of an imbalance between the production and 
clearance of harmful molecules called free radicals. Free radicals are molecules such 
as reactive oxygen or nitrogen species (ROS/RNS), produced primarily as by-
products of cellular respiration in mitochondria. As previously mentioned, free radicals 
are also produced by inflammatory cells and through enzymes such as nicotinamide 
adenine dinucleotide phosphate oxidases (NAPDH-oxidases/NOXs) (Bennett et al., 
2009) to combat invading pathogens. Free radicals are important cell signalling 
molecules but due to their high reactivity can be detrimental to lipids, proteins and 
DNA (Thannickal and Fanburg, 2000). Under normal conditions, antioxidant 
mechanisms are sufficient to prevent tissue damage by free radicals, but under 
pathological conditions where generation of ROS increases, antioxidant defences 
become overwhelmed and oxidative stress ensues (Bennett et al., 2009). 
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1.7.2.1 Oxidative stress mechanisms detrimental to white matter 
In hypoxic white matter, oxidative stress may result from mitochondrial dysfunction 
which increases the production of free radicals and/or from inhibition of protein 
synthesis which leads to reduced antioxidant production (Liu and Zhang, 2012). As 
previously mentioned, an additional source of free radicals is the NOXs, recognised 
as major contributors to oxidative stress in vascular disease (Drummond et al., 2011). 
Vascular oxidative stress, in addition, disrupts cerebrovascular functions such as 
neurovascular coupling and endothelial-dependent vasodilation (Toth et al., 2017), 
potentially exacerbating hypoxia-inducing cerebral hypoperfusion and creating a 
vicious cycle potentiating further oxidative stress. 
Inflammation and oxidative stress in human VCI 
Neuropathological and neuroimaging studies of human VCI find markers of both 
inflammation (Akiguchi et al., 1997, Rosenberg et al., 2001, Cagnin et al., 2001, 
Olsson et al., 2013) and oxidative stress (Gackowski et al., 2008, Gustaw-Rothenberg 
et al., 2010, Li et al., 2010, Back et al., 2011).  
A post mortem microarray study found that gene expression related to the immune 
response was altered in white matter lesions (Simpson et al., 2009), and microglial 
responses in particular are observed (Akiguchi et al., 1997, Simpson et al., 2007a, 
Simpson et al., 2007b). Rather than reactive astrogliosis, human VCI studies more 
commonly exhibit astrocyte degeneration, referred to as clasmatodendrosis (Akiguchi 
et al., 1997, Simpson et al., 2007a, Chen et al., 2016). This is a process of irreversible 
astrocyte damage thought to result from acidosis and energy failure induced by 
mitochondrial inhibition (Hase et al., 2017). However, studies show that astrogliosis 
occurs in response to ischaemia and in other inflammatory white matter diseases such 
as multiple sclerosis (Sofroniew and Vinters, 2010), and it is possible that 
clasmatodendrosis observed in human VCI post mortem tissue represents end-stage 
of disease. 
Markers of oxidative DNA damage can be detected in CSF of humans with mixed 
VCI/AD (Gackowski et al., 2008) and markers of oxidative lipid damage are higher in 
the plasma of patients with VCI compared to both AD and control (Gustaw-
Rothenberg et al., 2010), perhaps indicating the higher burden of white matter 
disruption. Similarly, low-density lipoprotein cholesterol (LDL) in plasma of VCI 
patients was found to show greater oxidative modification compared to AD and control 
LDL, which was also correlated to the level of cognitive impairment (Li et al., 2010). 
Finally, free radical injury of axonal membranes and myelin measured in post mortem 
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tissue was found to be increased independent of AD (Back et al., 2011), suggesting 
it is a more important mechanism in VCI. 
Evidence from human studies clearly implicate inflammation and oxidative stress 
in VCI suggesting these are potential pathophysiological mechanisms whereby white 
matter disruption occurs. To investigate if these mechanisms are causal or secondary 
to the observed pathology and cognitive impairment, preclinical models of VCI such 
as the BCAS model of cerebral hypoperfusion in mice are invaluable. 
 Inflammation and oxidative stress in the BCAS model of cerebral 
hypoperfusion 
Our group has demonstrated using the BCAS model in mice, that pro-inflammatory 
gene signalling in white matter is increased as early as 3 days post-surgery (Reimer 
et al., 2011), likely in response to the reduced tissue oxygen tension indicative of 
hypoxia (Duncombe et al., 2017). Furthermore, increases in the number of white 
matter microglia can be detected between 7-30 days post-BCAS (Fowler et al., 2017, 
Coltman et al., 2011, McQueen et al., 2014). We find that only microglia are 
significantly increased at 1 month in the corpus callosum, whereas the number of 
astrocytes is unchanged (McQueen et al., 2014). Reactive astrogliosis (density of 
astrocytes) is significant in the corpus callosum at 3 months post-BCAS (Kitamura et 
al., 2017), and in subcortical grey matter at 6 months (Holland et al., 2015). This is in 
contrast to the original study describing the model that found microgliosis paralleled 
by astrogliosis as early as 14 days (Shibata et al., 2004). Microglial changes were 
detected at 7 days when astrocytes were still unchanged suggesting that the 
microglial response occurs initially. Additional studies report increases in both micro- 
and astrogliosis at 7 days (Saggu et al., 2016) and 3 weeks post-BCAS (Dong et al., 
2011) suggesting that both cell types are involved in the inflammatory response when 
CBF is reduced. The discrepancies between our group and others may be due to 
differences in the severity of hypoperfusion or bregma levels studied. 
Studies show that inflammation in the BCAS model can be modulated using MMP 
inhibitors (Nakaji et al., 2006) or hypotensive agents (Washida et al., 2010, Dong et 
al., 2011), as well as generic immunosuppressant approaches (Qin et al., 2017, 
Manso et al., 2017, Fowler et al., 2017). These are associated with improved white 
matter structure and cognitive function and show a reduction in both micro- and 
astrogliosis. This highlights the contribution of inflammation to disease progression, 
and suggests it may play an important role in the induction of pathology. The study by 
Liu et al. (2013) found that absence of complement component 5 (C5); an important 
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inflammatory mediator, abolished white matter disruption and micro- and astrogliosis 
following BCAS. Another study saw that inhibition of the pro-inflammatory 
transcription factor NF-κB in astrocytes greatly reduced white matter disruption, 
microgliosis and cognitive impairment (Saggu et al., 2016). Two separate studies by 
our group find associations between increasing number of white matter microglia and 
reduced white matter structure and function (Manso et al., 2017, Fowler et al., 2017, 
Kitamura et al., 2017). Furthermore, anti-inflammatory pharmacological treatment that 
reduced the number of microglia was associated with improved function (Manso et 
al., 2017, Fowler et al., 2017), suggesting that microglia may drive the progressive 
disruption of white matter function. Astrogliosis was not evaluated in these studies 
though and since microglia and astrocytes both produce and respond to many of the 
same molecular mediators, evaluating cell-specific contributions is difficult. 
Using the BCAS model in mice, Miyamoto et al. (2013) demonstrated that oxidative 
stress induces oligodendrocyte and OPC cell death and inhibits OPC renewal, 
processes which could be inhibited by the radical scavenger Edaravone. In a similar 
study, Dong et al. (2011) showed that oxidative stress could also be reduced by 
inhibition of the renin-angiotensin system using a drug previously approved for the 
treatment of hypertension (Aliskiren). Further, Washida et al. (2010) found that 
another hypotensive drug (Telmisartan) had antioxidative and anti-inflammatory 
effects, but only at non-hypotensive levels. The renin-angiotensin system increases 
expression and activity of the superoxide-producing enzyme NOX2 (Kim et al., 2012), 
and these studies demonstrate that inhibiting oxidative stress is associated with 
reduced white matter damage and gliosis.  
In summary, evidence from both human and animal studies suggest that 
inflammation and oxidative stress may drive white matter disruption and cognitive 
impairment in cerebral hypoperfusion and VCI. The studies in this thesis will build on 
the existing literature and interrogate the role of inflammation and oxidative stress in 
white matter structural and functional disruption using the BCAS model of chronic 
cerebral hypoperfusion, by studying regulatory mechanisms that may inform future 
treatment.  
1.8 Targeting inflammatory and oxidative stress mechanisms 
To prevent the disruption of white matter structure and function 
Inflammation and oxidative stress are interrelated mechanisms that share triggers 
and are involved in many of the same pathologies, ultimately aggravating one another 
and subsequent damage. As such the therapeutic potential of targeting both together 
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may exceed that which has been achieved by previous separate approaches. With 
the development of highly specific transgenic models and pharmacological agents, 
cell-specific contributions to inflammation and oxidative stress in white matter 
disruption can begin to be addressed. 
 Nuclear factor erythroid 2-related factor 2 (Nrf2) 
Both brain and body possess endogenous regulatory mechanisms to prevent 
chronic inflammation and oxidative stress. One such mechanism is mediated via 
Nuclear factor erythroid 2-related factor (Nrf2), also called the master regulator of anti-
inflammatory and antioxidant defences. Nrf2 is a basic leucine zipper transcription 
factor (Moi et al., 1994) consisting of 7 Nrf2-ECH homology domains (Neh) (Itoh et 
al., 1999, Dinkova-Kostova et al., 2018) (Fig 1.5), first isolated and described in the 
early 1990’s (Andrews et al., 1993, Moi et al., 1994). Nrf2 has been shown to regulate 
the expression of over 200 cytoprotective genes (Ishii et al., 2000, Lee et al., 2003), 
and is important not only for cellular protection against oxidants and pro-inflammatory 
molecules, but also to maintain mitochondrial function and protein homeostasis 
(Dinkova-Kostova et al., 2018).  
Figure 1.5 Domain structure of Nrf2. The Neh2 domain binds to Keap1, Neh6 to β-
TrCP and Neh1 binds to ARE on target genes. Adapted from (Dinkova-Kostova et al., 
2018). 
            
Nrf2 acts primarily by binding to the highly conserved antioxidant response element 
(ARE) found in the promoter region of antioxidant, detoxifying and anti-inflammatory 
genes (Rushmore et al., 1991, Venugopal and Jaiswal, 1996, Itoh et al., 1997, 
Piantadosi et al., 2011, reviewed by Raghunath et al., 2018), but has also been shown 
to inhibit the activity of NF-κB (Thimmulappa et al., 2006, Cuadrado et al., 2014), and 
directly inhibit the expression of pro-inflammatory genes in a non-ARE-dependent 
manner (Kobayashi et al., 2016) (Table 1.1).  
1.8.1.1 Molecular basis of the Nrf2 system 
Nrf2 is a cytoplasmic protein which under normal conditions is rapidly turned over 
through proteosomal degradation mediated by the ubiquitin ligase adaptors Keap1 
(Kelch-like ECH-associated protein-1) (Itoh et al., 1999, Itoh et al., 2003) and βTrCP 
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(beta-transducin repeat containing protein), the latter dependent on GSK3β (glycogen 
synthase kinase 3β)-dependent phosphorylation of Nrf2 (Rada et al., 2012) (Fig 1.6). 
In response to cellular stressors such as oxidative stress and inflammation, 
conformational change of cysteine residues on Keap1 or direct inhibition of Nrf2-
binding sites on Keap1 (Yamazaki et al., 2015) or GSK3β (Gameiro et al., 2017) leads 
to the disruption of Nrf2-degradation. As a result, newly synthesised Nrf2 is free to 
translocate to the nucleus where it binds to AREs (mediated by small Maf proteins 
(Itoh et al., 1997)) and thereby activates the transcription of cytoprotective genes (Fig 
1.6) (Table 1.1). As the cellular stress is resolved through antioxidant, detoxifying or 
anti-inflammatory mechanisms, Keap1 and GSK3β/TrCP-dependent degradation 
resumes, completing the negative feedback loop which regulates the Nrf2 system 
(Yamazaki et al., 2015, Cuadrado, 2016). 
Further mechanisms of Nrf2 regulation have been described, including 
phosphorylation of Nrf2 by stress-sensing kinases promoting the dissociation of Nrf2 
from Keap1 and subsequent nuclear translocation (Kobayashi and Yamamoto, 2006) 
as well as epigenetic repression and modification of Nrf2 (Bell et al., 2015, Guo et al., 
2015). Finally, it has also been demonstrated that NF-κB activation induces Nrf2 
activation in a negative feedback loop, and the crosstalk between the two transcription 
factors is considered an important mechanism for regulating inflammation (Cuadrado 
et al., 2014). 
Table 1.1 Subset of Nrf2-regulated genes 
Gene Accession no. 
ARE-
regulated Function Citation 
Induced 
Gclm U95053 Yes Antioxidant/reducing potential (Lee et al., 2003) 
Gclc U85414 Yes Antioxidant/reducing potential (Lee et al., 2003) 
Ho1 X56824 Yes Antioxidant/reducing potential (Lee et al., 2003) 
Trdx X77585 Yes Antioxidant/reducing potential (Lee et al., 2003) 
Gpx4 D87896 Yes Antioxidant/reducing potential (Lee et al., 2003) 
Slc7a11 AI451155 Yes Detoxification (Shi et al., 2016a) 
Nqo-1 U12961 Yes Detoxification (Lee et al., 2003) 
Gsta4 L06047 Yes Detoxification (Lee et al., 2003) 
Gstp1 X53451 Yes Detoxification (Lee et al., 2003) 
Clec4d AF061272 Yes Defense/immune/inflammation (Lee et al., 2003) 
Pla2g7 U34277 Yes Defense/immune/inflammation (Lee et al., 2003) 
Mmp12 M82831 Yes Defense/immune/inflammation (Lee et al., 2003) 
Il10 NP_034678 Yes Defense/immune/inflammation (Piantadosi et al., 2011) 
Inhibited 
Il6 NM_031168 No Pro-inflammatory (Kobayashi et al., 2016) 
Il1β NM_008361 No Pro-inflammatory (Kobayashi et al., 2016) 




Figure 1.6 Molecular basis of the Nrf2-system. In the normal condition, Nrf2 is rapidly 
turned over by proteosomal degradation mediated by ubiquitin ligase adaptors Keap1 
and βTrCP. Oxidative and inflammatory stress disrupts Keap1/ βTrCP-Nrf2 interactions 
which allows newly synthesised Nrf2 to translocate to the nucleus where it binds 
antioxidant response elements (AREs) found in the promoter region of cytoprotective 
genes, inducing their transcription to combat the cellular stress. 
            
1.8.1.2 Nrf2 is highly expressed by astrocytes in the central nervous system 
Astrocytes have been shown to express Nrf2 at levels greatly exceeding that of 
neurons (Zhang et al., 2016), and neuronal antioxidant defences are intrinsically weak 
to permit redox-sensitive signalling necessary during development (Bell et al., 2015). 
In vitro studies demonstrate that astrocytes are necessary for Nrf2-mediated 
neuroprotection against oxidative stress (Lee et al., 2003, Shih et al., 2003, Kraft et 
al., 2004), and are thought to provide the antioxidant support that neurons themselves 
lack. A mouse model overexpressing Nrf2 specifically in astrocytes (GFAP-Nrf2) was 
therefore developed to investigate the therapeutic potential of boosting astrocytic 
Nrf2-signalling in vivo (Vargas et al., 2008). 
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1.8.1.3 Nrf2 in neurodegenerative and white matter disease 
Because inflammation and oxidative stress are characteristic of most 
neurodegenerative diseases, the therapeutic potential of the Nrf2 pathway has been 
under investigation for almost a decade (reviewed by Joshi and Johnson, 2012, 
Cuadrado, 2016, Dinkova-Kostova et al., 2018). Interestingly, Nrf2 expression and 
transcriptional activity declines with age (Ungvari et al., 2011a, Ungvari et al., 2011b, 
Valcarcel-Ares et al., 2012, reviewed bySchmidlin et al., 2019), perhaps explaining 
age-related increased in inflammation and oxidative stress. 
Nrf2 knockout studies demonstrate exacerbation of neurodegenerative 
pathologies in vivo in models of Parkinson’s disease (PD) (Jakel et al., 2007, 
Innamorato et al., 2010, Lastres-Becker et al., 2012), familial amyotrophic lateral 
sclerosis (fALS) (Vargas et al., 2013) and AD (Joshi et al., 2015, Branca et al., 2017, 
Rojo et al., 2017, Rojo et al., 2018). Conversely, pharmacological Nrf2-activators or 
GFAP-Nrf2 mice, has been shown to confer neuroprotection in vivo in models of fALS 
(Vargas et al., 2008), Huntington’s disease (HD) (Calkins et al., 2010), PD (Chen et 
al., 2009, Gan et al., 2012, Ahuja et al., 2016) and AD (Cui et al., 2017). Nrf2-activation 
is also protective against focal ischaemia (Zhao et al., 2006), and interestingly is 
endogenously activated by ischaemic preconditioning thought to underlie the resulting 
neuroprotection to subsequent ischaemic insults, specifically through upregulation of 
glutathione-related genes Gclc, Gclm and Slc7a11 (xCT) (Bell et al., 2011a, Bell et 
al., 2011b) (Table 1). 
Further, Nrf2 knockout mice have been shown to develop vacuolar white matter 
degeneration and widespread astrogliosis with advancing age. The absence of Nrf2 
exacerbates demyelination in a model of the inflammatory white matter disease 
multiple sclerosis (experimental autoimmune encephalomyelitis (EAE)) (Johnson et 
al., 2010), and impairs remyelination in a model of peripheral nerve injury (Zhang et 
al., 2013). Together these studies indicate an important role for Nrf2 in white matter 
maintenance and repair similar to its role of antioxidant support for neurons. 
Comparable to studies activating Nrf2 in neurodegenerative disease models, 
pharmacological activation of Nrf2 in EAE using DMF (dimethyl fumarate) protects 
white matter and improves clinical scores (Linker et al., 2011), and DMF has been 
approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing 
forms of multiple sclerosis (Gopal et al., 2017). Pharmacological activation of Nrf2 
using DMF or an alternative drug sulforaphane, is associated with improved white 
matter structure following experimental hypoperfusion (Fowler et al., 2017, Mao et al., 
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2018). Genetic approaches of modulating the Nrf2-pathway more specifically have 
yet to be applied in cerebral hypoperfusion models and the study of the specific 
contributions of Nrf2-deficiency and astrocytic Nrf2 to white matter pathology in the 
BCAS model is entirely novel. 
 Colony-stimulating factor receptor 1 
As previously mentioned, increased number of microglia is detected in human VCI 
(Akiguchi et al., 1997, Simpson et al., 2007a, Simpson et al., 2007b) and microglial 
proliferation is seen in the BCAS model of cerebral hypoperfusion, which when 
targeted by generic anti-inflammatory agents was associated with improved function 
(Manso et al., 2017, Fowler et al., 2017). However, to effectively interrogate the cell-
specific contribution that microglial proliferation plays in white matter disruption a 
more targeted approach is required.  
Microglial proliferation is dependent on signalling via the colony-stimulating factor 
1 receptor (CSF1R) which is expressed on macrophage lineage cells (Pixley and 
Stanley, 2004). The two known ligands for the CSF1R are the cytokines colony-
stimulating factor 1 (CSF1) and interleukin 34 (IL34) (Chitu et al., 2016), which upon 
binding the CSF1R induce autophosphorylation of the tyrosine kinase and a 
subsequent intracellular signalling cascade which induces gene transcription 
promoting survival, chemotaxis and proliferation (Conway et al., 2005). Some 
available pharmacological agents that target the CSF1R (e.g. PLX3397, PLX5622, 
Plexxikon, Ink) result in complete/partial ablation of the existing microglial population. 
Although studies have shown beneficial effects of ablating microglia on memory in 
models of AD (Dagher et al., 2015, Spangenberg et al., 2016) and on myelin integrity 
in EAE (Nissen et al., 2018), in different disease models such as stroke and ALS, 
microglial ablation is associated with worse outcome (Jin et al., 2017, Spiller et al., 
2018).  
As an alternative, the tyrosine kinase inhibitor GW2580, highly selective for the 
CSF1R, is reported to prevent the expansion of microglia without affecting the stable 
microglial population (Conway et al., 2005, Gomez-Nicola et al., 2013) (Fig 1.7). 
Inhibiting CSF1R using GW2580 treatment has proven advantageous in disease 
models of AD (Olmos-Alonso et al., 2016), prion disease (Gomez-Nicola et al., 2013) 
and multiple sclerosis (Crespo et al., 2011), although the role of CSF1R signalling 
following cerebral hypoperfusion remains to be determined. GW2580 treatment 
provides a cell-specific approach to investigate the effect of CSF1R signalling in 
microglia on white matter disruption and cognitive impairment. 
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Figure 1.7 GW2580 inhibits colony-stimulating factor 1 receptor (CSF1R) 
signalling. Binding of colony-stimulating factor 1 (CSF1) or interleukin 34 (IL34) 
induces proliferation, survival, chemotaxis and gene transcription of microglia. The 
pharmacological agent GW2580 inhibits CSF1R signalling and is reported to inhibit 
microglial proliferation without affecting the stable microglial population (Gomez-Nicola 
et al., 2013). 
1.9 Summary 
Vascular cognitive impairment is a heterogeneous disorder with a tremendous 
unmet need for mechanistic understanding and development of successful therapies. 
Bilateral carotid artery stenosis-induced cerebral hypoperfusion is an experimental 
model of VCI which replicates important aspects of pathology and cognitive 
impairment and as such represents a highly appropriate tool for preclinical studies. 
Inflammation and oxidative stress have been associated with disease progression in 
both VCI and experimental hypoperfusion and this thesis will assess to what extent 
these mechanisms are key drivers of white matter disruption that may be targeted 
therapeutically. The Nrf2 pathway represents a promising therapeutic approach for 
the treatment of VCI with the potential to reduce both inflammation and oxidative 
stress simultaneously to preserve white matter structure and function. Using 
sophisticated genetic tools the studies herein aim to investigate the role of Nrf2 in the 
maintenance of white matter and cognitive function in the bilateral carotid artery 
stenosis model of VCI. Further, increases in microglia is commonly observed in 
human VCI and microglial proliferation is closely associated with white matter 
structural and functional disruption in the animal model. The final aim is therefore to 
investigate whether CSF1R signalling in microglial specifically drive the disruption of 
white matter structure and function in the bilateral carotid artery stenosis model of 
VCI, using highly selective pharmacological inhibition (GW2580). 
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1.10  Hypothesis 
The hypothesis of the present thesis is that oxidative stress and inflammatory 
mechanisms drive structural and functional white matter disruption induced by 
bilateral carotid artery stenosis in mice (Fig 1.8). 
1.11 Aims 
The following aims were investigated to address the above hypothesis (Fig 1.8): 
1. Assess the effect of Nrf2 deficiency on white matter pathology and cognitive 
alterations in the BCAS model in mice. 
2. Assess the effect of astrocytic overexpression of Nrf2 on white matter 
pathology and cognitive alterations in the BCAS model in mice. 
3. Assess the effect of inhibiting CSF1R signalling in microglia on white matter 
pathology and cognitive alterations in the BCAS model in mice. 
Figure 1.8 Hypothesis and aims. Red arrow indicates the prediction that reduced Nrf2 
(Aim 1) will increase inflammation and oxidative stress and result in exacerbated white 
matter disruption and cognitive impairment. The green and purple arrow indicates the 
prediction that increased astrocytic Nrf2 (Aim 2) or inhibition of CSF1R signalling in 
microglial (Aim 3) will reduce inflammation and oxidative stress and result in ameliorated 
white matter disruption and cognitive impairment. 
 
 








Materials & Methods 




All animals were group housed on a 12-hour light/dark cycle with ad libitum access 
to food and water unless otherwise stated due to experimental requirements. All 
experiments were conducted in accordance with the Animal (Scientific Procedures) 
Act 1986 and local ethical approval at the University of Edinburgh, and were 
performed under personal and project licences granted by the Home Office. 
Experimenters were blinded to genotype and surgery status of all animals throughout 
data collection and analysis in accordance with ARRIVE guidelines (Kilkenny et al., 
2010).  
 Nrf2 knock out mice 
The Nrf2 knock out (KO) line was originally developed by Yuet Wai Kan at 
University of California in San Francisco. The Nrf2 gene was knocked out it in 
embryonic stem cells (129X1/SvJ) by homologous recombination and used to derive 
the line, of which homozygotes were found to develop normally and were fertile (Chan 
et al., 1996). Adult male Nrf2 KO mice were obtained from The Jackson Laboratory 
(strain name = B6.129X1-Nfe2l2tm1Ywk/J; backcrossed onto C57Bl/6 mice for at 
least 10 generations) and re-derived in house. Imported homozygous Nrf2-/- mice 
were crossed onto wild type C57Bl/6J and heterozygous progeny was further crossed 
to generate the experimental animals utilised in chapter 3. 
2.1.1.1 Genotyping of Nrf2 knock out mice 
DNA was extracted from tail biopsies using ethanol precipitation. Each biopsy was 
incubated overnight in 20 µl PCR buffer (10X; Tris·Cl, KCl, (NH4)2SO4, 15 mM MgCl2, 
QIAGEN), 4 µl Proteinase K (ThermoFisher) and 164 µl nuclease-free H2O (QIAGEN) 
at 55⁰C followed by heat inactivation at 95°C for 15 min after which samples were 
placed on ice for 10 min. Samples were then vortexed and centrifuged at 18,000 x g 
for 10 min at room temperature and supernatant transferred to a chilled Eppendorf 
tube. The volume was made up to 200 µl with nuclease-free H2O and 20 µl of 3M 
Sodium Acetate (pH 5.2, Sigma-Aldrich) was added and mixed by inverting the tube. 
440 µl of cold (-20°C) absolute ethanol (VWR) was added and the tube inverted 
several times before incubating at -20°C for >3 hours. Samples were then centrifuged 
at 18,000 g for 15 min at 4°C and supernatant carefully discarded leaving the DNA 
pellet at the bottom of the tube. The DNA pellet was washed with 400 µl of cold (-
20°C) 70% Ethanol and vortexed well. A final centrifugation at 18,000 x g for 15 min 
at 4°C was performed before discarding ethanol and allowing the DNA pellet to air 
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dry. DNA was then resuspended in 20 µl nuclease-free H2O and incubated at 37°C 
overnight then stored at -20°C until PCR. 
Polymerase chain reaction (PCR) was performed using QIAGEN HotStarTaq; 10 
µl added to 3.2 µl of each sample along with 5.3 µl PCR grade H2O and 0.5 µl of each 
of three primers (Sigma-Aldrich, Table 2.1) for a final primer concentration of 0.25 µM. 
The PCR program was as follows; 95°C for 15 min followed by 10 cycles of 20 sec at 
94°C, 45 sec at 65°C, 45 sec at 68°C; then 28 cycles of 15 sec at 94°C, 45 sec at 
50°C, 45 sec at 72°C; finished with 2 min at 72°C and 5 min at 10°C.  
Samples were then run (with 4 µl of loading dye (6X, Promega)) on a 3% agarose 
gel (Agarose, Promega; in Tris/Borate/EDTA buffer, Sigma-Aldrich) with 15 µl 
Invitrogen™ SYBR™ Safe stain (ThermoFisher Scientific) at 100 V for 1 hours. Wild 
type animals displayed one band of 262 base pairs (bp; Nrf2), Nrf2+/- animals 
displayed two bands, one at 262 bp and another and 400 bp (mutant band) and Nrf2-
/- one band at 400 bp (no Nrf2 band). 
All animals were re-genotyped at the end of the study to verify genetic status. 
GFAP-Nrf2.2 mice 
GFAP-Nrf2.2 mice were imported from Professor JA Johnson, University of 
Wisconsin, and developed as previously described (Vargas et al., 2008). Briefly, a 
human GFAP-Nrf2 transgene was introduced into mice through pronuclear 
microinjection using fertilised eggs of the FVB/N strain. Imported GFAP-Nrf2 mice 
were crossed with wild type C57Bl/6J mice in-house, and first generation crosses 
(FVB/C57Bl/6J F1) were utilised for experiments in chapter 4. 
2.1.2.1 Genotyping of GFAP-Nrf2 mice 
DNA was extracted from ear clips using 100 µl 50mM sodium hydroxide. Ear clips 
with sodium hydroxide were centrifuged for 90 sec at 12,000 x g. Samples were then 
incubated in a water bath at 100°C for 7 min and then kept on ice for 10 min and were 
then ready for PCR. 
PCR was performed using GoTaq® Green Master Mix (Promega); 12.5 µl added 
to 1 µl of each sample along with 10.5 µl PCR grade H2O and 0.25 µl of each of four 
primers (Sigma-Aldrich, Table 2.1) for a final primer concentration of 25 mM. The PCR 
program was as follows; 95°C for 5 min followed by 35 cycles of 30 sec at 95°C, 30 
sec at 54°C, 30 sec at 72°C; finalised by 5 min at 72°C and held at 4°C. 
Samples were then run on a 3% agarose gel (Agarose, Promega; in 
Tris/Borate/EDTA buffer, Sigma-Aldrich) with 15 µl Invitrogen™ SYBR™ Safe stain 
(ThermoFisher Scientific) at 100 V for 1 hours. Wild type animals displayed one band 
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of 262 bp (Nrf2) and GFAP-Nrf2 animals displayed two bands, one at 262 bp (Nrf2) 
and one at 400 bp (human GFAP). 
All animals were re-genotyped at the end of the study to verify genetic status. 
C57Bl/6J wild type mice 
Wild type C57Bl/6J were purchased from Charles River Laboratories 
(JAXTM- C57BL/6J) and utilised for experiments in chapter 5. 
Table 2.1 Primers used for genotyping 
Nrf2 knock out primers Sequence (5’  3’) 
Common forward (13444) GCC TGA GAG CTG TAG GCC C 
Wild type reverse (13445) GGA ATG GAA AAT AGC TCC TGC C 
Mutant reverse (oIMR8495) GAC AGT ATC GGC CTC AGG AA 
GFAP-Nrf2 primers 
Nrf2 forward GCC TGA GAG CTG TAG GCC C 
Nrf2 reverse GGA ATG GAA AAT AGC TCC TGC C 
GFAP forward CTT CAT AAA GCC CTC GCA TC 
GFAP reverse TCT TGC CTC CAA AGG ATG TC 
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2.2 Chronic cerebral hypoperfusion 
Bilateral carotid artery stenosis (BCAS) surgery (as previously described by 
Coltman et al., 2011, and as developed by Shibata et al., 2004) was used to induce 
chronic cerebral hypoperfusion. In brief, a small cervical midline incision was made 
and the common carotid arteries were exposed by careful dissection and 
displacement of the superficial muscles, surrounding connective tissue and the vagus 
nerve. A 0.16 or 0.18 mm internal diameter microcoil (Sawane Spring Co, Japan. Fig 
2.1b) was placed around one common carotid artery (Fig 2.1a), the animal was 
allowed to recover and was 30 min later re-anesthetised for the placement of the 
second microcoil (0.18 mm). Sham surgery was performed in the same manner 
excluding the placement of the microcoils. The incision was sutured and animals were 
allowed to recover in a heated incubator. All surgical procedures were conducted 
using aseptic techniques while under isoflurane anaesthesia (5% induction, 1.5% 
maintenance), and animals were closely monitored 72 hours post-surgery. Surgeries 
were performed by Prof Karen Horsburgh or Dr Jessica Duncombe (specified in 
relevant chapters).  
Figure 2.1 Bilateral carotid artery stenosis. (a) Schematic diagram of microcoil 
around the common carotid artery below the carotid bifurcation. (b) Schematic diagram 
of the microcoil. (Adapted from Ihara and Tomimoto, 2011)
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2.3 Laser speckle imaging 
Laser speckle imaging is a technique that generates semi-quantitative 
measurements of superficial cortical perfusion through the intact mouse skull. A 
speckle contrast imager with a laser source and a camera is mounted above a 
stereotactic frame. The camera detects the reflected laser light which has a 
characteristic speckle pattern depending on the velocity of the underlying particles 
which is then converts to an arbitrary unit by computer software. 
Superficial cortical perfusion was measured at rest under isoflurane anaesthesia 
prior to, 24 hours and 6 weeks post-BCAS surgery, using a moorFLPI2 speckle 
contrast imager (Moor Instruments, UK). The animal’s head was held in position using 
a stereotactic frame and body temperature was monitored and maintained at 37°C 
using a heated pad. The skull was exposed by a midline incision and 
reflection of the scalp. Water-based gel was evenly spread on the exposed skull and 
a 2 min baseline perfusion recording was acquired. The scalp was then sutured, and 
local analgesic applied to reduce any pain or discomfort to the animals which 
were recovered in a heated incubator. 
Laser speckle image analysis 
An arbitrary flux measure was obtained by manually placing regions of interest in 
the same place on consecutive scans using large vessels as landmarks (moorFLPI-2 
V1.0 software). Due to biological variation, the cortical cerebral blood flow (CBF) of 
each animal was normalised to its own baseline measurement which was obtained 
prior to surgery and data were then expressed as percentage CBF of baseline. 
2.4 Behavioural testing 
Animals were handled extensively, every day for 1-2 weeks, prior to the start of 
each behavioural test to habituate the animals to the experimenters and to facilitate 
the avoidance of anxious behaviour which may influence performance. 
 Radial arm maze 
Spatial working memory in chapter 3 and 4 (Nrf2 studies) was assessed using the 
8-arm radial arm maze. Animals were singly housed and food restricted (maintained
at 85-90% of initial body weight) one week prior to, and throughout the radial arm
maze test, to promote motivation (12-hour light/dark cycle, ad libitum access to water).
Following the last trial animals were provided food ad libitum. The radial arm maze
test was commenced four weeks post-BCAS.
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The radial arm maze comprises a central platform (20 cm in diameter) surrounded 
by 8 arms (47 cm long by 7 cm wide with 20 cm Plexiglas walls) (Fig 2.2a). Each arm 
has a 2 cm deep plastic well for placement of a sugar pellet and all arms can be 
isolated from the central platform by Plexiglas doors (remotely controlled using Any-
Maze software, Stoelting, UK). Large brightly coloured, high contrast spatial cues 
were placed on each of the four walls surrounding the maze, and a camera mounted 
on the ceiling was used for data acquisition connected to Any-Maze tracking software 
(v4.99, Stoelting Europe, Ireland). 
The aim of the radial arm maze is to assess the animals’ ability to remember arms 
entered during each trial in order to retrieval all eight pellets (enter all eight arms) with 
as few revisiting errors as possible. 
2.4.1.1 Acclimatisation phase 
Pre-training is required to acclimatise the animals to the test and environment to 
reduce stress and anxiety. This consisted of one 5 min trial of free exploration with 
sugar pellets scattered at random, and another where each animal was allowed to 
walk down each arm from the central platform to retrieve sugar pellets from the plastic 
wells. These two trials were performed on two consecutive days. 
2.4.1.2 Learning phase 
The behavioural test was carried out on 16 consecutive days (1 trial/day). Each 
arm was baited with a sugar pellet and the animal was placed in the central platform 
at the start of the trial. The animal was confined to the central platform for 5 sec 
between each arm choice and the trial finished when the animal had retrieved all 8 
pellets or when 25 min had elapsed. The number of revisiting errors (visits into 
unbaited arms) during each trial were recorded and analysed as a measure of spatial 
learning and working memory. 
2.4.1.3 Inclusion criteria 
Animals needed to explore more than 75% of the maze during 2 of the first 4 trials 
to be included in the behavioural analysis of the radial arm maze as less implies a 
lack of motivation which results in a skewed learning profile. Details of exclusions are 
described in relevant chapters. 
Y-maze
Animals were placed in the centre of a standard Y-maze (3 arms; 49.5 cm long, 11 
cm wide, walls 10 cm high) (Fig 2.2b) and allowed to freely explore the three arms for 
5 min. The percentage of spontaneous alternation and total number of arm entries 
were recorded and analysed as a measure of innate exploratory behaviour and overall 
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mobility. The Y-maze test was performed after the radial arm maze in the same room 
using the same spatial cues and data acquisition system described in 2.4.1 (Any-
Maze tracking software (v4.99, Stoelting Europe, Ireland)). 
 Barnes maze 
Spatial learning and reference memory in chapter 5 was assessed using the 
Barnes maze (Barnes, 1979). The maze is a simple circular white platform (115 cm 
high x 91.5 cm wide) with 20 “escape holes” evenly situated around the edge (San 
Diego Instruments) (Fig 2.2c). A small, black escape chamber was placed under one 
of the holes; position alternated for consecutive animals to avoid olfactory cues 
influencing behaviour, and a holding cylinder (10.5 cm in diameter) was used to place 
the animals in the maze before each trial. The maze was brightly lit, and an aversive 
noise was played to motivate animals to escape. The same spatial cues and data 
acquisition system described in 2.4.1 were used for animals to navigate the 
environment and to record mouse behaviour (Any-Maze tracking software (v4.99, 
Stoelting Europe, Ireland)). The Barnes maze was commenced four weeks post-
BCAS. 
The aim of the Barnes maze is to assess the animals’ ability to learn and remember 
the location of the escape chamber. Spatial learning was assessed during an initial 
learning phase and reference memory in a 72 hour probe test. Executive function and 
cognitive flexibility were tested in a reversal learning phase and an additional 72 hour 
probe test. 
2.4.3.1 Acclimatisation phase 
In order to prevent stress and anxiety associated with a novel environment, 
animals were acclimatised to the Barnes maze and the behavioural room. During 
acclimatisation there were no bright lights or aversive noise. For two consecutive 
days, animals were placed in the holding cylinder for 10 sec, and then returned to 
their home cage. On the third day, animals were again placed in the holding cylinder 
for 10 sec but this time the cylinder was removed, and the animals were allowed to 
freely explore the maze for 3 min. Following the 3 min, animals were gently guided 
into the escape chamber where they were kept for 1 min before being returned to their 
home cage. 
2.4.3.2 Learning phase 
The day after the acclimatisation phase was the start of the learning phase. 
Animals were trained during two trials every day, with a 1 hour trial interval, over 6 
consecutive days. Briefly, animals were placed in the holding cylinder for 10 sec, the 
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cylinder was removed, and an aversive noise started playing (85db) while animals 
were allowed 3 min to locate and enter the escape chamber. If animals were unable 
to locate the escape chamber during the 3 min they were gently guided to it and kept 
in the chamber for 1 min before being returned to their home cage. As soon as the 
mouse entered the escape chamber the aversive noise ceased. All maze equipment 
was cleaned with 70% ethanol between each animal, and the escape chamber was 
carefully cleaned with ethanol and rinsed with water to avoid aversive alcohol vapours 
building up. Latency to escape was recorded and analysed as a measure of spatial 
learning. 
2.4.3.3 72 hour probe 
Long-term spatial memory was assessed using a probe test 72 hours after the final 
trial of the learning phase. Conditions were kept constant with the learning phase, 
however the escape chamber was removed, and the animals were only allowed to 
explore the maze for 90 sec. Memory was assessed as the proportion of time spent 
in the target quadrant, i.e. where the escape chamber was located during the learning 
phase. Because a large proportion of animals spent some time in the target quadrant 
but then re-commence exploring as there was no escape chamber, the probe test 
analysed the proportion of time spent in the target quadrant during the first 60 sec. 
2.4.3.4 Reminder phase 
Animals were subjected to two additional trials with the escape chamber returned 
to the original position to re-establish the chamber location memory following the 
probe trial. Conditions and trial duration were kept constant with the learning phase. 
2.4.3.5 Reversal learning phase 
To test executive function and cognitive flexibility, the chamber location was shifted 
180° to the opposite side of the maze, with spatial cues remaining in the same 
positions. Conditions and trial duration were kept constant with the learning phase, 
and the reversal learning phase was performed twice a day for 3 days (1 hour trial 
interval). Latency to escape was again recorded and analysed as a measure of re-
learning, i.e. cognitive flexibility. 
2.4.3.6 Reversal 72 hour probe 
Performed exactly like the 72 hour probe, the escape chamber was removed and 
animals were allowed to explore the maze for 90 sec. Similarly, the proportion of time 
spent in the new target quadrant was used to assess long-term memory of the 
reversal learning phase chamber location. Because a large proportion of animals 
spent some time in the target quadrant but then re-commence exploring as there was 
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no escape chamber, the probe test was analysed as a proportion of time spent in the 
target quadrant during the first 60 sec. 
2.4.3.7  Inclusion criteria 
Animals need to be motivated to actively explore the maze in order to locate the 
escape chamber, and they need to learn that the task is to locate and enter the escape 
chamber. Inclusion criteria were therefore as follows; animals must enter a minimum 
of 3 quadrants in 2 of the first 5 learning phase trials and animals must voluntarily 
enter the escape chamber at least 3 out of the final 6 trials to demonstrate that they 
have learned the task objective. Details of exclusions are detailed in the relevant 
chapter.  
Figure 2.2 Schematic diagrams of mazes used for behavioural testing. (a) 8-arm 
radial arm maze with central platform that measures 20 cm in diameter, each of the 8 
arms measures 47 cm by 7 cm and have 20 cm tall Plexiglas walls. The plastic wells at 
the end of each arm are 2 cm deep. (b) Y-maze with 3 arms measuring 49.5cm by 11cm 
with solid white walls 10cm high. (c) Barnes maze sits 115 cm above ground and is 
91.5cm in diameter. 20 escape holes are situated along the edge of the maze, and the 
escape chamber is positioned under one of those holes. The dotted line represents the 
position of the holding cylinder at the start of each trial. 
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2.5 Substance administration 
GW2580 administration 
GW2580 is a pharmacological tyrosine kinase inhibitor for the CSF1 receptor 
(CSF1R) found on macrophage lineage cells including brain resident microglia. 
GW2580 (LC Laboratories, PKC Pharmaceuticals Inc., USA) was administered by 
oral gavage (Chapter 5 acute study) at a concentration of 75mg/kg in 0.5% 
Hypromellose (H3785, Sigma-Aldrich) and 0.1% Tween®80 (P1754, Sigma-Aldrich), 
once daily starting 24 hours post-BCAS. The vehicle solution was prepared with the 
same reagents and administered in an identical manner to drug administration. 
Alternatively GW2580 was administered at 0.1% concentration in diet (LC 
Laboratories, PKC Pharmaceuticals Inc., USA and Test Diet Europe) (Chapter 5 
chronic study) ad libitum starting 24 hours post-BCAS. 
5-Bromo-2’-deoxyuridine (BrdU) administration
5-Bromo-2-‘-deoxyuridine (BrdU, B5002, Sigma-Aldrich) was administered orally
at 50mg/kg for the final three days (of the acute and chronic study in Chapter 5) to 
label actively proliferating cells. For the GW2580-treated animals in the acute study, 
BrdU was added to the GW2580 gavage solution as described in 2.5.1. For all other 
animals, BrdU was prepared in vehicle solution as described in 2.5.1. 
2.6 Tissue collection and processing 
Transcardial perfusion and brain extraction 
Animals from the studies described in chapter 3 and 4 were sacrificed under deep 
anaesthesia (induction at 5% isoflurane, maintenance at 3%) by transcardiac 
perfusion with 40 ml of 0.9% heparinised (0.002%) phosphate buffered saline. The 
heart was exposed through a midline incision, a needle was inserted into the left 
ventricle and the right atrium was opened with scissors. Perfusions were performed 
at 2 ml/min until blood and tissues cleared. 
Brain tissue was then removed and separated into hemi brains down the midline 
using a blade. One hemi brain was snap frozen in liquid nitrogen. The other was fixed 
in 4% paraformaldehyde for 24 hours and further processed automatically for paraffin 
embedding or manually for freezing. 
Brain extraction and white matter dissection 
Animals from the study in chapter 5 were sacrificed by dislocation of the neck by 
Dr Edel Hennessy/Dr Juraj Koudelka. Brains were rapidly removed and transferred to 
ice-cold artificial cerebrospinal fluid. Dr Hennessy/Koudelka sectioned 2 mm of the 
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forebrain from which corpus callosum was isolated under a dissecting microscope 
and snap frozen in liquid nitrogen (by ES). Dr Hennessy/Koudelka sectioned the brain 
further using a vibratome (Hyrax V50) and a 1.6 mm slice was collected at -1.65 mm 
posterior of bregma (according to Paxinos and Franklin, 2001) in a Cellsafe+ Biopsy 
Capsule (Cell Path) for fixation in 4% paraformaldehyde for 24 hours and further 
processed manually for paraffin embedding. 
 Processing for freezing and cryosectioning 
For the study in chapter 3, hemi brains were transferred from 4% 
paraformaldehyde to 30% sucrose for 72 hours, then frozen in isopentane chilled to -
42°C using dry ice. 10 µm coronal sections were collected onto superfrost plus slides 
(VWR International) at -1.70 mm posterior of bregma (according to Paxinos and 
Franklin, 2001) using a cryostat (Leica CM1950), and the rest of the hemi brain cut at 
30 µm coronal sections and stored in cryoprotective medium at -20°C. 
 Automated processing for paraffin embedding  
For the study in chapter 4, hemi brains were transferred from 4% 
paraformaldehyde to phosphate buffered saline and sectioned into two 3 mm coronal 
blocks at either side of bregma using a mouse matrix. Tissue blocks were processed 
on an automated Tissue Tek VIP 2 (Sakura) at the Shared University Research 
Facility as described in Table 2.2 and then manually embedded in paraffin. 
 
  
Table 2.2 Automatic processing schedule for paraffin embedding 
Solution Duration (min) Temperature (°C) 
70% Ethanol 60 35 
90% Ethanol 60 35 
100% Ethanol 60 35 
100% Ethanol 90 35 
100% Ethanol 120 35 
100% Ethanol 60 35 
Xylene 60 35 
Xylene 60 35 
Xylene 60 35 
Paraffin wax 60 60 
Paraffin wax 60 60 
Paraffin wax 60 60 
Paraffin wax 60 60 
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 Manual processing for paraffin embedding 
For the study in chapter 5, fixed brain tissue slices were transferred to phosphate 
buffered saline and maintained in cell sure tissue cassettes throughout manual 
processing as described in Table 2.3 and then embedded in paraffin. 
 
 Microtome sectioning 
Paraffin embedded tissues were cut to 6 µm coronal tissue sections at -1.70 mm 
posterior of bregma (according to Paxinos and Franklin, 2001) (Fig 2.3) using a rotary 
microtome (Leica RM2135, Leica Microsystems, Germany) and mounted on 
superfrost plus slides (VWR International). 
2.7 Histology and immunostaining 
Standard laboratory procedures were utilised for histology and immunostaining. 
Paraffin sections were deparaffinised for 30 min at 60°C followed by 2 x 15 min in 
xylene. Frozen sections were air dried for 30 min, washed in phosphate-buffered 
saline (PBS) then dehydrated through a series of alcohols (70%, 90%, 100%), 
followed by 10 min in xylene. Paraffin and frozen sections were following these initial 
steps treated identically for histology and immunohistochemistry. 
 Immunohistochemistry using DAB 
Sections were returned to 100% ethanol and endogenous peroxidases were then 
quenched using 3% hydrogen peroxide in methanol. Antigen retrieval was carried out 
when required (Iba1 and GFAP). For citric acid retrieval, sections were incubated in 
10 mM citric acid (pH6) and placed in a Decloaking chamber (Biocare Medical), 
heated to 95°C for 10 min. Sections were then washed in PBS and blocked at room 
Table 2.3 Manual processing for paraffin embedding 
Solution Duration (min) Temperature (°C) 
Tap water 30 RT 
70% Ethanol 30 RT 
70% Ethanol 30 RT 
90% Ethanol 30 RT 
90% Ethanol 30 RT 
100% Ethanol 60 RT 
100% Ethanol 90 RT 
Xylene 60 RT 
Xylene 60 RT 
Paraffin wax 60 60 
Paraffin wax 60 60 
Paraffin wax 60 60 
Paraffin wax 60 60 
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temperature for 1 hour with 10% normal serum and 0.5% bovine serum albumin 
before overnight primary antibody incubation at 4°C. Sections were then washed in 
PBS and biotinylated secondary antibodies were applied for 1 hour (room 
temperature) and further amplified using the Vector ABC Elite Kit (Vector Labs, UK) 
before visualisation of peroxidase activity using 3,3’ diaminobenzidine 
tetrahydrochloride (DAB, Vector Labs, UK) for 3 min. Sections were then washed in 
running water and dehydrated through a series of alcohols (70%, 90%, 100%) before 
15 min in xylene and mounting with DPX (Sigma, UK). Primary antibodies and 
concentrations are found in the Table 2.4. 
 Immunofluorescent labelling 
Sections were rehydrated through a series of alcohols (100%, 90%, 70%) and 
rinsed in running water. Antigen retrieval was carried out as described above 
(Methods section 2.6.2). Sections were then washed in PBS and blocked at room 
temperature for 1 hour (10% normal serum, 0.5% bovine serum albumin in PBS) 
before overnight primary incubation at 4°C. Primary antibodies were diluted in 
blocking solution made up in 0.3% Triton-X PBS, concentrations found in Table 2.4. 
On the second day, sections were washed PBS and incubated in biotinylated 
secondary antibodies for 1 hour (room temperature) if amplification was required. This 
was followed by another PBS wash and then application of the fluorescent secondary 
antibodies for 1 hour (room temperature) protected from light. Sections were then 
again washed in PBS, followed by Tris-buffer and then allowed to air dry for 30 min 
before mounting with Vectashield Hardset with DAPI (Vector, UK). 
 Immunostaining controls 
Prior to large immunostaining experiments, antibody conditions and concentrations 
were carefully optimised. To ensure consistency, a section with a known level of 
staining was included as a positive control and closely examined alongside the tissue 
of interest. To ensure antibody specificity, all immunostaining experiments included a 
negative control where the primary antibody was not applied but all other steps were 
kept identical. Antibody staining was only analysed if this negative control was clear, 
and repeated if not. To prevent batch variation, all sections from one study were 
stained for individual proteins in single experiments. 
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Table 2.4 Antibodies used for immunohistochemical and immunofluorescent experiments 
Primary 
antibody Target Dilution Retrieval Supplier Secondary antibody Dilution Supplier 

































95°C Abcam, ab6326 
Biotinylated anti-rat 
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2.8 Image acquisition and analysis 
 Image acquisition 
DAB-labelled sections were imaged using a BX51 microscope (x20, Olympus, UK) 
or an Axio Scan.Z1 slide scanner (x20, Zeiss, Germany) (specified in the relevant 
chapter). Joshua Beverley performed all slide scanner imaging. Immunofluorescent 
labelling for Iba1/BrdU was imaged using a Zeiss 710 confocal microscope (x20, 
Zeiss, Germany), or a Leica TCS SP5 confocal microscope (x20, Leica Microsystems, 
Germany) by Dr Jessica Duncombe, who also delineated the corpus callosum regions 
for Iba1/BrdU analysis. 
 Image analysis 
All image analysis was performed using ImageJ software (v1.46, NIH, Bethesda, 
MD, USA). Iba1/BrdU was manually assessed for cell counts of single and double 
labelled cells in the corpus callosum, using DAPI as a positive cell marker. DAB-
labelled sections were evaluated in the corpus callosum (CC), the internal capsule 
(IC) and the optic tract (OT) or fimbria (FI) which were manually delineated by the 
experimenter (Fig. 2.3). Iba1, GFAP and MAG was analysed by percentage area 
measured after subtracting background and applying a global manual threshold. For 
MAG staining where this was not possible due to increased background, sections 
were instead graded on a scale from 0-3 depending on presence and extent of 
aberrantly accumulated MAG (indicative of axon-glial disruption) (Olympus BX51 
microscope, Olympus, UK), and grades for each side of the brain were summed giving 
a total scale of disruption of 0-6. All analysis was performed on two sections from 
each animal and results averaged to represent a single data point. Details of stains 
and analyses used can be found in relevant chapters. 
 Exclusion criteria 
Due to minor variation in the anatomical level of sections stained, some animals 
had to be excluded from immunohistochemical analysis where particular regions of 
interest were absent. Details of exclusions are specified in relevant chapters. 
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Figure 2.3 Regions of interest for image analysis of immunostained proteins. CC, 
corpus callosum; FI, fimbria; IC, internal capsule; OT, optic tract were manually 
delineated using ImageJ software. Figure 45, Bregma -1.70 mm (Paxinos and Franklin, 
2001) 
2.9 Transcriptomics 
RNA was isolated from optic tract-enriched samples or a slice of whole brain 
dissected from snap-frozen hemi brains, or from freshly dissected white matter as 
described in 2.6.3. 
RNA extraction 
RNA was extracted using the QIAGEN RNeasy Lipid Tissue Mini Kit according to 
manufacturer’s instruction. Briefly, <100mg fresh frozen tissue was homogenised in 
1ml QIAzol® lysis reagent using the Qiagen automated tissue lyser system and metal 
beads. The homogenate was transferred to fresh Rnase/Dnase free tubes and 
incubated for a couple of minutes at room temperature with 200µl chloroform. The 
upper aqueous phase was collected following 15 min centrifugation at 4°C (12,000 x 
g), and RNA was subsequently purified in mini spin columns and washed with a series 
of buffers before it was eluted in Rnase free water. Rnase-free Dnase I (Thermo 
Scientific/QIAGEN) was used to remove genomic DNA according to manufacturer’s 
instruction. 
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 Reverse transcription (RT)-PCR 
cDNA was synthesised from 1-3 µg RNA using the Roche Transcriptor First Strand 
cDNA Synthesis Kit, according to manufacturer’s instruction. Briefly, RNA was added 
to reverse transcriptase reaction mix and cycled through 10 min 25°C; 30 min 55°C; 
5 min 85°C. NoRT control was run alongside and cDNA was diluted to the equivalent 
of 3 ng initial RNA per 15 µl qPCR reaction. 
 Quantitative (q)-PCR 
The CFX96 Real-Time PCR Machine (Bio Rad) was used with the DyNAmo 
ColorFlash SYBR Green qPCR kit according to manufacturer’s instructions (Thermo 
Scientific). cDNA template was mixed with SYBR green master mix, water and 
forward and reverse primer (200 nM each final concentration). Samples were run in 
duplicates alongside no template and no RT negative controls. Primer sequences are 
listed in Table 2.5. The qPCR cycling programme was 7-10 min at 95°C for 
denaturing; 40 cycles of 10 sec at 95°C, primer-specific annealing/extension 
conditions (listed in Table 2.5) with detection of fluorescence; followed by 1 cycle (for 
dissociation curve) at 65°C with a ramp up of 0.5°C every 30 sec at 95°C with 
continuous detection of fluorescence. Data was normalised to Gapdh or 18S 
expression as a reference gene (specified in each graph) and expressed as fold 
change of sham expression. Neither reference gene was significantly altered as a 
result of surgery or genotype. 
 Exclusion criteria 
Samples where reference gene expression was detected >2STD (standard 
deviation) away from the mean were excluded from analysis. Samples were also 
excluded if gene of interest expression was >3 interquartile ranges (IQR) below the 
first quartile or >3 IQR above the third quartile for each group. Details of exclusions 
are specified in relevant chapters. 
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Forward primer sequence Reverse Primer sequence Annealing/extension conditions 
Primer 
efficiency 
Gapdh 5’-GGGTGTAACCACGAGAAAT-3’ 5’-CCTTCCACAATGCCAAAGTT-3’ 
62.5°C 30s 97.4% 
65°C 30s 97.5% 
60°C 40s / 72°C  30s 92.8% 
62.5°C  30s / 72°C  30s 101.1% 
65°C 30s / 72°C 30s 99.2% 
18S 5’- CCCAGTAAGTGCGGGTCAT-3’ 5’- CCGAGGGCCTCACTAAACC-3’ 
62.5°C 30s 96.6% 
65°C 30s 96.8% 
60°C / 72°C 30s 93.8% 
62.5°C 30s / 72°C 30s 102.1 
65°C 30s / 72°C 30s 102.1% 
Nrf2 5’-CAGCTCAAGGGCACAGTGC-3’ 5’-GTGGCCCAAGTCTTGCTCC-3’ 65°C 30s / 72°C 30s 106.3% 
Slc7a11 5’-ATACTCCAGAACACGGGCAG-3’ 5’-AGTTCCACCCAGACTCGAAC-3’ 65°C 30s / 72°C 30s 95.6% 
Gclm 5’-GCACAGCGAGGAGCTTC-3’ 5’-GAGCATGCCATGTCAACTG-3’ 
60°C 30s / 72°C 30s 92% 
60°C 40s / 72°C 30s 92.4% 
C4 5’- ACAACAAGGGAGACCCCCAG-3’ 5’-GCTCAGAGAGCCAGAGTCCTA-3’ 65°C 30s 91.1% 
C1q a 5’- CAAGGACTGAAGGGCGTGAA-3’ 5’- CAAGCGTCATTGGGTTCTGC-3’ 
62.5°C 30s 93% 
62.5°C 30s / 72°C 30s 94.7% 
Ccl3 5’- GCCAGGTGTCATTTTCCTGACT-3’ 5’- TCAGGCATTCAGTTCCAGGTC-3’ 62.5°C 30s 91.5% 
Ccl2 5’- TCCCAAAGAAGCTGTAGTTTTTGTC-3’ 5’- CCCATTCCTTCTTGGGGTCA-3’ 62.5°C 30s / 72°C 30s 90.1% 
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2.10 Statistical analysis 
Statistical analysis was performed using SPSS (v22, IBM Corp.) and Graphpad 
Prism (v5, GraphPad Software Inc, La Jolla, USA). Significance was determined at 
p<0.05. Analysis of variance (ANOVA) was the a priori statistical approach, with 
Bonferroni adjustment for multiple comparisons for post hoc analysis. Where semi-
quantitative data was considered, non-parametric statistical tests were utilised.  
 Repeated measures ANOVA 
Repeated measures ANOVA with Bonferroni adjustment for post hoc analysis and 
Greenhouse-Geisser correction for violation of sphericity was used to investigate the 
effect of BCAS surgery and genotype (between-subjects factors) on cerebral blood 
flow over time (within-subjects factor) (Chapter 3-5), revisiting errors over consecutive 
trials (within-subjects factor) in the radial arm maze (Chapter 3-4) and the effect of 
group (between-subjects factor) and escape latency over consecutive trials (within-
subjects factor) in the learning and reversal phase of the Barnes maze (Chapter 5). 
 Two-way ANOVA 
Two-way ANOVA with Bonferroni adjustment for post hoc analysis was used to 
investigate the effect of BCAS surgery and genotype on spontaneous alternation and 
total entries in the Y-maze and Iba1, GFAP and MAG positive percentage area in 
white matter tracts and gene expression (Chapter 3-4). 
 One-way ANOVA 
One-way ANOVA with Bonferroni adjustment for post hoc analysis was used to 
investigate a group effect on percentage of proliferating Iba1 positive cells, C4 gene 
expression, number and density of Iba1 positive cells, density of GFAP and 
percentage time spent in the target quadrant during Barnes Maze probe tests 
(Chapter 5). 
 One-sample t-test 
One-sample t-test was used to analyse Y-maze spontaneous alternation for each 
group against chance (50%) (Chapter 3-4) and to test each group against chance 
(25%) during probe tests in the Barnes Maze (Chapter 5). 
 Pearson’s correlation 
Pearson’s correlation was used to investigate the relationship between density of 
Iba1 and GFAP (Chapter 5). 
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 Kruskal-Wallis H test (Non-parametric) 
Kruskal-Wallis H test with Dunn’s post hoc test with Bonferroni adjustment for 
multiple comparisons was used to analyse the MAG grade for white matter disruption 
as this data set is semi-quantitative (Chapter 5). 
 Spearman’s correlation (Non-parametric) 
Spearman’s correlation was used to investigate the relationship between density 
of Iba1 and MAG grade in the corpus callosum (Chapter 5). 
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Investigating the effect of chronic cerebral 
hypoperfusion in a mouse model with reduced 
expression of Nrf2 




Vascular risk factors may lead to the development of vascular cognitive impairment 
(VCI) and dementia by promoting cerebral hypoperfusion (de la Torre, 2012). 
Cerebral hypoperfusion is observed before the onset of cognitive decline (Ruitenberg 
et al., 2005) and the severity of hypoperfusion predicts conversion from mild cognitive 
impairment to dementia (Chao et al., 2010, Hirao et al., 2005). One of the primary 
pathological features of VCI and dementia is white matter disruption (Dichgans and 
Leys, 2017) and previous work demonstrates that bilateral carotid artery stenosis 
(BCAS) in mice induces cerebral hypoperfusion which reproduces important features 
of VCI, including white matter disruption and cognitive impairment (Coltman et al., 
2011, Holland et al., 2011, Shibata et al., 2004, Shibata et al., 2007). VCI and 
dementia are both commonly associated with increased levels of inflammation 
(Rosenberg, 2009, Raz et al., 2015) and oxidative stress (Gackowski et al., 2008, 
Bennett et al., 2009), which led to the hypothesis that these are important 
pathophysiological mechanisms whereby white matter structure and function is 
disrupted. To address this hypothesis, this study is investigating the transcription 
factor Nrf2 (Nuclear factor erythroid 2-related factor 2), an important regulator of 
endogenous antioxidant and anti-inflammatory genes. Nrf2 has been shown to play a 
role in maintaining white matter structural integrity under normal physiological 
conditions as Nrf2 knock out mice display age-related white matter disruption (Hubbs 
et al., 2007). In models of white matter disease (sciatic nerve injury and EAE), the 
lack of Nrf2 impairs remyelination and functional recovery (Zhang et al., 2013, 
Johnson et al., 2010) indicating that Nrf2 is also involved in maintaining white matter 
during pathological conditions, and in promoting white matter recovery and repair 
following injury. Hypoperfusion-induced white matter disruption is likewise associated 
with inflammation (Coltman et al., 2011, Reimer et al., 2011, Saggu et al., 2016) and 
oxidative stress (Washida et al., 2010, Dong et al., 2011, Miyamoto et al., 2013) 
however it is currently unknown what role the Nrf2 system plays. By investigating the 
effects of bilateral carotid artery stenosis in transgenic mice with reduced or absent 
expression of Nrf2 this study is interrogating the role of this transcription factor in the 
disruption of white matter structure and function following chronic cerebral 
hypoperfusion.
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Hypothesis 
This study tests the hypothesis that deficiency of the transcription factor Nrf2 
exacerbates white matter disruption and cognitive impairment following BCAS-
induced chronic cerebral hypoperfusion. 
 Aims 
In wild type,Nrf2+/- and Nrf2-/- mice the aims are to: 
1. Assess cerebral blood flow to determine the extent of BCAS-induced cerebral
hypoperfusion
2. Assess the structural integrity of white matter
3. Assess white matter micro- and astrogliosis
4. Assess oxidative stress and inflammatory genes
5. Asses spatial working memory
6. For the above measures determine whether deficiency of Nrf2 exacerbates the
effects of BCAS
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3.2 Materials and Methods 
 Experimental contributions 
The study presented in this chapter was carried out by myself, Dr Martina 
Marangoni, Professor Karen Horsburgh and Dr Jill Fowler. I performed laser speckle 
imaging, behavioural testing, and tissue collection/processing/sectioning with 
assistance from Dr Martina Marangoni. I performed immunostaining and imaging for 
MAG and Iba1, RNA extractions, quantitative PCR and all data analysis presented in 
this chapter. Professor Karen Horsburgh performed BCAS surgery and Dr Jill Fowler 
performed immunostaining and imaging for GFAP. 
 Mice 
Genetic details of Nrf2 knock out (KO) mice are described in 2.1.1. Due to 
difficulties in breeding sufficient numbers of homozygous mice, some measures only 
included data from heterozygotes or combined data from both heterozygotes and 
homozygotes. Wild type littermates were also not generated at sufficient numbers and 
were therefore complemented with separately purchased C57Bl/6J, genetically 
identical to the Nrf2 KO line’s background strain according to supplier. Adult male 
mice, mean age 6 m 17 d (4 to 9 m), weighing on average 33.4 g (25.4-43.8 g) (n=37) 
were randomly assigned surgical intervention as detailed in Table 3.1. The 
experimenters were blinded to genotype and surgery status of animals throughout 
data collection and analysis in accordance with ARRIVE guidelines (Kilkenny et al., 
2010). 
 Chronic cerebral hypoperfusion 
Mice underwent bilateral carotid artery stenosis (BCAS) or sham surgery, as 
described in 2.2. BCAS surgery was performed to induce chronic cerebral 
hypoperfusion, using two 0.18 mm in diameter microcoils. Recovery following surgery 
was closely monitored for 72 hours and animals showing poor recovery were culled. 
Three animals tolerated surgery poorly (two wild type, one Nrf2+/-) and were humanely 
culled by cervical dislocation (see Table 3.1). 
 Laser speckle imaging to measure cortical cerebral blood flow 
Cortical cerebral blood flow (CBF) was measured at rest prior to, 24 hours and 6 
weeks post-BCAS as described in 2.3 in a subset of mice, detailed in Table 3.1 and 
the relevant figure. Because no Nrf2-/- BCAS animals were imaged, data from blood 
flow analysis may only be compared between wild type and Nrf2+/- sham and BCAS 
groups. 
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Behavioural testing 
Animals were singly housed and food restricted for the behavioural tests which 
were performed as described in 2.4.1-2.4.2. Spatial working memory was assessed 
by the 8-arm radial arm maze (2.4.1) and spontaneous alternation and mobility was 
assessed in the Y-maze (2.4.2). Behavioural testing commenced four weeks post-
BCAS. Inclusion criteria described in 2.4.1.3 was applied excluding two animals (one 
wild type BCAS and one Nrf2 KO sham) from behavioural analysis. Due to the limited 
n-numbers of the Nrf2-/- groups all Nrf2 KO animals were grouped together for the
behavioural analysis. Final numbers for each group are detailed in Table 3.1 and
relevant figures.
Tissue collection and processing 
Animals were sacrificed 6 weeks post-BCAS as described in 2.6.1. The tissue was 
further processed for freezing and cryosectioning as described in 2.6.3. 
Immunohistochemistry 
Performed according to 2.7.1. Details of antibodies used (anti-MAG, anti-Iba1, anti-
GFAP) can be found in Table 2.4. Immunohistochemistry was performed on 30 µm 
coronal sections from all animals. 
Image analysis 
Images for MAG and Iba1 were acquired using a BX51 microscope (x20, Olympus, 
UK) and GFAP images were acquired by Dr Jill Fowler using Zeiss Axio Scope.A1 
(x5, Zeiss, UK). Images were analysed for percentage area of MAG, Iba1 and GFAP 
as described in 2.8.2 in the corpus callosum (CC), internal capsule (IC) and optic tract 
(OT) (Fig 2.3). Briefly, ImageJ software (v1.46, NIH, Bethesda, MD, USA) was used 
to apply a global manual threshold followed by quantification of the positive signal 
detected above the selected threshold. Applying exclusion criteria outlined in 2.8.3 
resulted in one animal in the wild type BCAS group and one in the Nrf2+/- BCAS group 
being excluded from the internal capsule and optic tract analysis of Iba1. Similarly, 
one wild type BCAS animal was excluded from GFAP analysis in the internal capsule. 
Final numbers for each region and stain are detailed in Table 3.1 and relevant figures. 
Transcriptomics 
Performed according to 2.9 using optic tract-enriched samples. Details of primers 
used (Gapdh, Nrf2, Slc7a11, Gclm, Ccl3, C1q, C4) can be found in Table 2.5. 
Exclusion criteria outlined in 2.9.4 was applied excluding one wild type sham from 
Gclm and one Nrf2+/- BCAS animal from Slc7a11 analysis. Final numbers detailed in 
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Table 3.1 and the relevant figure also containing reference gene used for each 
experiment. 
  Statistical analysis 
Repeated measures ANOVA was used to analyse cerebral blood flow and 
behaviour as described in 2.10.1. The radial arm maze was analysed separately for 
the first and second half of the test as the first half primarily represents a learning 
phase. Two-way ANOVA was used to investigate the effect of BCAS surgery and 
genotype in the Y-maze and Iba1, GFAP and MAG positive percentage area in white 
matter tracts and gene expression (2.10.2). One-sample t-test was used to analyse 
Y-maze spontaneous alternation (2.10.4). Data are presented as mean ± standard 
error of the mean (SEM). Statistical significance was determined at p<0.05. 
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Table 3.1 Number of mice in each group and experiment with details of exclusion 
BCAS surgery Wild type Nrf2+/- Nrf2-/- 
Sham 7 7 3 
BCAS 8 6 3 
Details of exclusion 
Poor recovery from BCAS surgery 2 (Hypo) 1 (Hypo) 0 
Laser speckle imaging Wild type Nrf2+/- Nrf2-/- 
Sham 4 4 1 
BCAS 5 3 0 
Behavioural testing Wild type Nrf2+/- Nrf2-/- 
Sham 7 7 2 
BCAS 7 6 3 
Details of exclusion 
Initial lack of motivation 1 (Hypo) 0 1 (sham) 
Immunohistochemistry 
(CC, IC, OT) Wild type Nrf2
+/- Nrf2-/- 
MAG 
Sham 7, 7, 7 7, 7, 7 3, 3, 3 
BCAS 8, 8, 8 6, 6, 6 3, 3, 3 
Iba1 
Sham 7, 7, 7 7, 7, 7 3, 3, 3 
BCAS 8, 7, 7 6, 5, 5 3, 3, 3 
Details of exclusion 
Anatomical area missing from slide 0 1 (IC/OT) 0 
GFAP 
Sham 7, 7, 7 7, 7, 7 3, 3, 3 
BCAS 8, 7, 8 6, 6, 6 3, 3, 3 
Details of exclusion 
Anatomical area missing from slide 1 (IC) 0 0 
qPCR 
(Nrf2, Ccl3, C1q, C4, Gclm, Slc7a11) Wild type Nrf2
+/- Nrf2-/- 
Sham 7, 7, 7, 7, 6, 7 7, 7, 7, 7, 7, 7 3, 3, 3, 3, 3, 3 
BCAS 8, 8, 8, 8, 8, 8 6, 6, 6, 6, 6, 5 3, 3, 3, 3, 3, 3 
Details of exclusion 
3IQR<Q1 / 3IQR>Q3 (outlier) 1 (Gclm) 1 (Slc7a11) 0 




 Cortical CBF is significantly reduced post-BCAS 
CBF was evaluated using laser speckle imaging prior to, 24 hours, and 6 weeks 
post-BCAS surgery in a subset of animals to assess the extent of cerebral 
hypoperfusion and to determine if this differed between wild type and Nrf2+/- groups. 
Resting CBF over time was calculated as a percentage of each animal’s baseline flux 
(arbitrary unit). 
BCAS reduced CBF between 40-50%, whereas CBF in sham mice was relatively 
unchanged from baseline (Fig 3.1). There was a significant effect of time (F(2,26)=36.9, 
p<0.0001) and surgery (F(1,13)=22.3, p<0.0001) and a significant interaction between 
time and surgery (F(2,26)=14.7, p<0.0001) (Fig 3.1b). There was no overall effect of 
genotype (F(1,13)=0.72, p=0.41) though post hoc tests found a significant CBF 
reduction in wild type and Nrf2+/- mice at 24 hours (WT; p=0.001, Nrf2+/-, p=0.002) but 
at 6 weeks in the Nrf2+/- only (WT; p=0.18, Nrf2+/-; p=0.02), indicating some CBF 
recovery in wild type mice (Fig 3.1b). 
Since CBF measurements were only performed on a subset of animals which did 
not include Nrf2-/- BCAS, we are unable to determine if the reduction of cerebral blood 
flow following BCAS surgery is more severe when Nrf2 is completely absent. On the 
other hand, the available data show that wild type animals display greater CBF 
recovery (~10%) than Nrf2+/- animals (~5%), although the initial cerebral 
hypoperfusion is comparable. 
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Figure 3.1 Cortical cerebral blood flow is reduced post-BCAS. (a) Representative 
images of laser speckle flowmetry in sham and BCAS, wild type and Nrf2+/- animals at 
baseline, 24 hours and 6 weeks. (b) BCAS surgery reduced CBF at 24 hours to a similar 
extent in both genotypes with some recovery in wild type BCAS at 6 weeks. Mean±SEM. 
**p<0.01 (* indicates post hoc differences between wild type sham and BCAS), #p<0.05, 
##p<0.01 (# indicates post hoc differences between Nrf2+/- sham and BCAS). 
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 White matter disruption is more extensive in Nrf2-/- mice 
compared to wild type and Nrf2+/- post-BCAS 
White matter disruption was evaluated to corroborate previous results in wild type 
mice (Coltman et al., 2011, Holland et al., 2011) and to determine if this was 
exacerbated by a reduction or absence of Nrf2. The initially selective white matter 
disruption observed in the BCAS model is hypothesised to underlie the accompanying 
cognitive impairment. Alterations in immunostaining for myelin associated 
glycoprotein (MAG), present at the axon-glial interface, can be detected as aberrant 
accumulations. 
The percentage area of MAG positive immunostaining was quantified in key white 
matter tracts: corpus callosum (CC), internal capsule (IC) and optic tract (OT). There 
was significant white matter disruption in the corpus callosum post-BCAS (F(1,28)=6.04, 
p=0.02) with an additional effect of genotype (F(2,28)=4.47, p=0.02), but no interaction 
or significant post hoc effects (Fig 3.2a). There was no significant white matter 
disruption in the internal capsule as a result of BCAS surgery or genotype (F(1,28)=2.99, 
p=0.09, F(2,28)=1.89, p=0.17 respectively) (Fig 3.2b). Notably in the optic tract, there 
was prominent white matter disruption post-BCAS (F(1,28)=35.84, p<0.0001) with a 
further effect of genotype (F(2,28)=3.96, p=0.03) and a significant interaction between 
the two variables (F(2,28)=3.87, p=0.03) (Fig 3.2c). Post hoc analysis found significant 
differences between all BCAS groups and their respective sham controls (WT p=0.04, 
Nrf2+/- p=0.004, Nrf2-/- p<0.001). Furthermore, there was significantly greater white 
matter disruption in the Nrf2-/- BCAS group compared to both Nrf2+/- (p=0.02) and wild 
type BCAS (p=0.001) (Fig 3.2c). Collectively, these data show that cerebral 
hypoperfusion induced by BCAS surgery causes white matter disruption in two major 
white matter tracts and that, principally in the optic tract, this disruption is exacerbated 
in the absence of Nrf2. 
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Figure 3.2 White matter disruption is more extensive in Nr2-/- mice compared to 
wild type and Nrf2+/- post-BCAS. (a) White matter disruption was detected post-BCAS 
in the corpus callosum, with a significant effect of genotype (no post hoc differences). 
(b) White matter disruption in the internal capsule was not significant. (c) The optic tract
displayed prominent white matter disruption post-BCAS with a further effect of
genotype, with the Nrf2-/- group displaying the most severe disruption. Mean±SEM. n-
number presented in each bar. *p<0.05, **p<0.01, ***p<0.001 (* indicates post hoc
differences between sham and BCAS), #p<0.05, ##p<0.01 (# indicates post hoc
differences between BCAS groups). (d) Representative images of MAG staining in the
optic tract. Scale bar 50 µm.
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 The density of microglia is increased post-BCAS to a greater 
extent in Nrf2-/- mice compared to wild type and Nrf2+/- 
White matter disruption in the BCAS model has been reported in parallel with acute 
inflammatory signalling (Reimer et al., 2011) and increased density of the 
inflammatory cell microglia (Coltman et al., 2011, McQueen et al., 2014). Similarly, 
Nrf2-/- mice have been reported to have increased number of microglia at baseline 
(Rojo et al., 2010) and an exacerbated microglial response in disease models such 
as Alzheimer’s disease (Joshi et al., 2015, Branca et al., 2017, Rojo et al., 2018). This 
study therefore went on to assess the microglial inflammatory response, to determine 
if this was consistent with previous results and whether it was exacerbated by a 
reduction or absence of Nrf2.  
Immunohistochemistry for ionized calcium binding adapter molecule 1 (Iba1) was 
used and quantified as positive percentage area in key white matter tracts: corpus 
callosum, internal capsule and optic tract. There was a significant increase in density 
of microglia post-BCAS in the corpus callosum (F(1,28)=7.63, p=0.01) with a further 
effect of genotype (F(2,28)=4.25, p=0.02) but no interaction (Fig 3.3a). Post hoc analysis 
identified significantly greater density in the Nrf2-/- BCAS group compared to sham 
controls (p=0.004), and other BCAS groups (Nrf2+/- p=0.005 and wild types p=0.003 
respectively) (Fig 3.3a). The effect of BCAS surgery and genotype narrowly missed 
accepted levels of statistical significance in the internal capsule (F(1,26)=3.66, p=0.07, 
F(2,26)=3.15, p=0.06 respectively) (Fig 3.3b), but similar to the white matter disruption, 
there was a profound microglial response in the optic tract post-BCAS (Fig 3.3c). 
There was a significant effect of both BCAS surgery and genotype (F(1,26)=61.12, 
p<0.0001, (F(2,26)=7.21, p=0.003 respectively), and a significant interaction (F(2,26)=5.8, 
p=0.008). Post hoc analysis found significantly greater density of microglia in all BCAS 
groups compared to their sham controls (WT p=0.005, Nrf2+/- p<0.001, Nrf2-/- p<0.001) 
and in the Nrf2-/- BCAS group compared to both Nrf2+/- (p=0.002) and wild type BCAS 
(p<0.001) (Fig. 3.3c). These data show that cerebral hypoperfusion induced by BCAS 
surgery causes an increased density of microglia in two major white matter tracts 
which exhibit white matter pathology, and that this increase is exacerbated in the 
absence of Nrf2. 
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Figure 3.3 The density of microglia is increased post-BCAS to a greater extent in 
Nrf2-/- mice compared to wild type and Nrf2+/-. (a) There was an effect of BCAS 
surgery and genotype on density of Iba1 in the corpus callosum, with the Nrf2-/- BCAS 
group displaying the highest density. (b) The effect of BCAS and genotype narrowly 
missed accepted levels of statistical significance in the internal capsule. (c) The optic 
tract displayed an increased density of Iba1 post-BCAS, with a further effect of 
genotype, again with the Nrf2-/- BCAS group displaying the highest density. Mean±SEM. 
n-number presented in each bar. **p<0.01, ***p<0.001 (* indicates post hoc differences
between sham and BCAS), #p<0.05, ##p<0.01, ###p<0.001 (# indicates post hoc
differences between BCAS groups). (d) Representative images of Iba1 staining in the
optic tract. Scale bar 50 µm.
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 Astrogliosis in the optic tract is induced to a similar extent in wild 
type and Nrf2 KO mice post-BCAS 
Aged Nrf2 KO mice display widespread astrogliosis in both grey and white matter 
(Hubbs et al., 2007) and astrocytes have been reported to actively contribute to 
chronic neuroinflammation (Sofroniew, 2014a). Previous work by the group find no 
alterations in the number of astrocytes in the corpus callosum at 4 weeks post-BCAS 
in wild type mice (McQueen et al., 2014) although other groups do (Saggu et al., 
2016). To thoroughly evaluate the inflammatory response, glial fibrillary acidic protein 
(GFAP) immunohistochemistry was used to assess astrogliosis. The aim was to 
determine if the current study was consistent with previous results by us or others and 
to investigate if astrogliosis was exacerbated by a reduction or absence of Nrf2, 
similar to the microglial response. 
Reactive astrogliosis was quantified as GFAP positive percentage area in the main 
white matter tracts: corpus callosum, internal capsule and optic tract. BCAS surgery 
did not affect the percentage area of GFAP in the corpus callosum or the internal 
capsule (F(1,28)=1.08, p=0.31; F(1,27)=0.30, p=0.59 respectively) (Fig 3.4a-b). However, 
there was an effect of genotype in the corpus callosum (F(2,28)=3.96, p=0.03) and post 
hoc analysis found that GFAP expression in Nrf2-/- animals was overall higher than 
wild types (p=0.03). This genotype effect was not present in the internal capsule 
(F(2,27)=1.52, p=0.24). Consistent with the white matter disruption and the microglial 
response, there was a significant effect of BCAS surgery in the optic tract 
(F(1,28)=43.61, p<0.0001), although the effect of genotype narrowly missed accepted 
levels of statistical significance (F(2,28)=3.26, p=0.053) (Fig 3.4c). Post hoc analysis 
found significant astrogliosis in all three BCAS groups compared to their sham 
controls (WT p=0.005, Nrf2+/- p<0.001, Nrf2-/- p<0.001). These data show that cerebral 
hypoperfusion induced by BCAS surgery causes astrogliosis in the optic tract and 
there is a trend towards this effect being more pronounced in the absence of Nrf2. 
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Figure 3.4 Astrogliosis in the optic tract is induced to a similar extent in wild type 
and Nrf2 KO mice post-BCAS. (a) There was a significant effect of genotype on % 
Area of GFAP in the corpus callosum but there was no effect of BCAS surgery. (b) % 
Area of GFAP was unchanged in the internal capsule. (c) There was a significant effect 
of BCAS surgery on % area of GFAP in the optic tract but the effect of genotype just 
missed accepted levels of statistical significance. Mean±SEM. **p<0.01, ***p<0.001 (* 
indicates post hoc differences between sham and BCAS), #p<0.05 (# indicates post hoc 
differences between wild type and Nrf2-/-). n-number presented in each bar. (d) 
Representative images of GFAP staining in the optic tract. Scale bar 50 µm. (Stained 
and imaged by Dr Jill Fowler.) 
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 Nrf2 and Nrf2-regulated antioxidant genes are unaltered post-
BCAS but pro-inflammatory gene expression is induced 
The results presented in this chapter thus far demonstrate that BCAS surgery 
induces cerebral hypoperfusion in wild type and Nrf2 KO mice causing white matter 
disruption and increased density of both microglia and astrocytes. Since pathological 
and cellular inflammatory changes are exacerbated in Nrf2-/- mice post-BCAS the next 
aim was to assess antioxidant and inflammatory gene changes to investigate if they 
are altered post-BCAS, and to determine if these are differentially regulated in the 
absence of Nrf2. 
Quantitative PCR analysis was used to assess gene expression levels in optic 
tract-enriched samples as this was the area with most prominent pathology. Nrf2 
levels were significantly reduced to about 50% in Nrf2+/- mice (p<0.001) and nearly 
undetectable in Nrf2-/- compared to wild type mice (p<0.001) (genotype effect; 
F(2,28)=29.6, p<0.0001) (Fig. 3.5a). BCAS surgery did not alter the expression of Nrf2 
(F(1,28)=0.01, p=0.91) (Fig 3.5a) so to further investigate the effect of BCAS surgery on 
Nrf2-mediated signalling two known Nrf2-regulated antioxidant genes involved in 
glutathione synthesis were measured: Slc7a11 (xCT; encoding the glutamate/cystine 
antiporter) and Gclm, (glutamate-cysteine ligase enzyme subunit) (Fig 3.5b-c). These 
genes were selected for investigation as they have previously been reported to 
increase along with Nrf2 following ischaemic preconditioning suggesting the 
glutathione system may be an important for Nrf2-mediated neuroprotection against 
ischaemia and hypoxia (Bell et al., 2011b) as well as oxidative stress (Shih et al., 
2003). 
Contrary to expectations, there was no effect of BCAS surgery or genotype on 
Slc7a11 (F(1,27)=0.23, p=0.63, F(1,27)=2.25, p=0.13 respectively) or Gclm expression 
(F(1,27)=0.39, p=0.54, F(1,27)=0.24 p=0.79 respectively) (Fig 3.5b-c). Instead, as the 
pathological assessment identified inflammatory cell changes, and because 
inflammatory protein and gene changes have been observed in previous 
hypoperfusion studies (Fowler et al., 2017, Reimer et al., 2011), three pro-
inflammatory genes were examined next. Two complement components, C4 and C1q, 
and chemokine ligand 3 (Ccl3) were measured also by qPCR. The expression of Ccl3 
and C1q was increased post-BCAS (F(1,28)=7.96, p=0.009, F(1,28)=4.61, p=0.04 
respectively), whereas the effect of BCAS surgery on C4 expression narrowly missed 
accepted levels of statistical significance (F(1,28)=3.9, p=0.058) (Fig 3.5d-f). Pro-
inflammatory gene expression appears to increase in Nrf2+/-/-/- animals, but no 
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significant effect of genotype was detected for any of the markers (Ccl3-F(2,28)=0.68, 
p=0.52, C1q-F(2,28)=0.28, p=0.76, C4-F(2,28)=0.48, p=0.63) (Fig 3.5d-f), though post 
hoc analysis identified significantly increased expression of Ccl3 in the Nrf2-/- BCAS 
group compared to sham controls (p=0.048) (Fig 3.5c). 
These data show that the expression of Nrf2 is reduced/absent to the expected 
levels in Nrf2+/-/Nrf2-/- animals, with no effect of BCAS surgery. There was no effect of 
BCAS surgery or genotype on Nrf2-regulated antioxidant expression but BCAS-
induced cerebral hypoperfusion minimally, but significantly increased the expression 
of three pro-inflammatory genes in both wild type and Nrf2+/-/-/- animals. 
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◄Figure 3.5 Nrf2 and Nrf2-regulated antioxidant genes in the optic tract are 
unaltered post-BCAS but pro-inflammatory genes are induced. (a) There was an 
effect of genotype on Nrf2 expression but no effect of BCAS surgery. Nrf2 was reduced 
by ~50% in Nrf2+/- mice and almost undetectable in Nrf2-/- mice. (b) There was no effect 
of BCAS surgery or genotype on Slc7a11 (c) or Gclm expression, (d) however, BCAS 
surgery increased the expression of Ccl3 and (e) C1q. (f) The effect of BCAS surgery 
just missed accepted levels of statistical significance for C4 expression and there was 
no genotype effect on any gene. Gene expression was normalised to Gapdh and 
expressed as fold change compared to wild type shams. Mean±SEM. n-number 
presented in each bar. Dashed line indicates WT sham mean. *p<0.05 (* indicates post 
hoc differences between sham and BCAS groups), ##p<0.01, ###p<0.001 (# indicates 
differences between genotypes). 
            
 Spatial working memory is impaired post-BCAS but is not 
exacerbated by deficiency of Nrf2 
As previously mentioned, white matter disruption is hypothesised to underlie 
impairments in cognition. The 8-arm radial arm maze was used in the current study 
to assess spatial working memory as it has previously been demonstrated to be 
sensitive to hypoperfusion-induced disruption of frontocortical circuitry (by us and 
others Coltman et al., 2011, Shibata et al., 2007). Since white matter pathology is 
exacerbated in Nrf2-/- BCAS mice, the next was to determine if this was associated 
with more severe cognitive impairment. Spatial working memory was quantified as 
number of revisiting errors before entry into all 8 arms and cognitively healthy animals 
display a progressive reduction in revisiting errors over consecutive trials as they learn 
the task. Regretfully, due to the low numbers of Nrf2-/- animals they were grouped with 
Nrf2+/- animals for the behavioural analysis, however it is noted that since there was 
no difference in pathology between wild type and Nrf2+/- BCAS groups functional 
effects are likely difficult to detect in this manner. Statistical analysis was performed 
on the first and second half of the test separately because the first half is primarily a 
learning phase (Fig 3.7). 
Spontaneous alternation and total entries in the Y-maze were recorded and 
compared across groups as they represent potential confounds to performance in the 
radial arm maze. Wild type and Nrf2+/-/-/- groups all spontaneously alternated above 
chance level (WT sham p=0.007, WT BCAS p=0.02, Nrf2+/-/-/- sham p=0.02, Nrf2+/-/-/- 
BCAS p=0.02) and there was no effect of BCAS surgery (F(1,28)=0.07, p=0.8) or 
genotype (F(1,28)=1.37, p=0.25) on spontaneous alternation (Fig 3.6a). There was also 
no effect of BCAS surgery (F(1,28)=1.26, p=0.27) or genotype (F(1,28)=1.66, p=0.21) on 
total entries (Fig 3.6b). 
C H A P T E R  3 . 3  R E S U L T S  | 67 
Figure 3.6 Spontaneous alternation and mobility are unaltered post-BCAS in wild 
type and Nrf2+/-/-/- mice. (a) Wild type and Nrf2 KO groups all spontaneously alternated 
above chance level in the Y-maze task, and there was no effect of BCAS surgery or 
genotype. (b) There was no effect of BCAS surgery or genotype on total entries in the 
Y-maze task. Mean±SEM. n-number presented in each bar.
For the radial arm maze, there was a significant effect of trial during both the first 
and second half of the test (F(1,84)=7.03, p<0.0001, F(3,84)=3.62, p=0.02 respectively) 
indicating that mice were able to learn the task successfully (Fig 3.7a-d). The effect 
of BCAS surgery was not significant during the first half of the test (F(1,28)=0.10, 
p=0.76) but was significant during the second half (F(1,28)=4.21, p=0.049) (Fig 3.7a-b). 
This indicates that while both sham and BCAS groups were learning the task initially, 
the BCAS groups’ learning plateaus and they commit significantly more revisiting 
errors than sham groups during the second half of the test. However, there was no 
effect of genotype on spatial working memory (first half, F(1,28)=0.07, p=0.79; second 
half, F(1,28)=0.001, p=0.98) (Fig 3.7c-d), which contests the hypothesis that reductions 
in Nrf2 exacerbates cognitive deficits caused by BCAS-induced cerebral 
hypoperfusion, however due to the low n-number we are unable to determine if the 
absence of Nrf2 has a detrimental effect on spatial working memory post-BCAS.  
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Figure 3.7 Spatial working memory is impaired post-BCAS but is not exacerbated 
by deficiency in Nrf2. There was an effect of trial during both first and second half of 
the test indicating learning over time. During the second half of the test, revisiting errors 
were significantly higher post-BCAS demonstrating impaired spatial working memory. 
However, there was no effect of genotype on revisiting errors during either the first or 
second part of the test. Post hoc analyses identified no further significant differences. 
Mean±SEM. *p<0.05 (* indicates main effect of BCAS surgery during second half of 
test). 
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3.4 Discussion 
Previous studies of the BCAS model in mice demonstrate increased inflammation 
(Coltman et al., 2011, Reimer et al., 2011, Saggu et al., 2016) and oxidative stress 
(Washida et al., 2010, Dong et al., 2011, Miyamoto et al., 2013), indicating these may 
be pathophysiological mechanisms whereby white matter disruption occurs when 
cerebral blood flow is reduced. The current study was designed to test the hypothesis 
that deficiency of the anti-inflammatory/antioxidant regulating transcription factor Nrf2 
exacerbates white matter disruption and cognitive impairment following BCAS-
surgery. The results show that absence but not reduction of Nrf2 aggravates white 
matter disruption and gliosis, but with the available data no conclusion can be drawn 
as to whether this is associated with functional deficits in spatial working memory 
following 6 weeks of mild cerebral hypoperfusion. 
Resting cortical CBF is significantly reduced post-BCAS to a 
similar extent in wild type and Nrf2+/- mice 
The first aim of the study was to examine the extent of CBF reductions post-BCAS. 
The CBF alterations were able to be determined only in a subset of animals and this 
included no hypoperfused Nrf2-/- animals. Using laser speckle imaging, CBF was 
found to be reduced by 40-50% at 24 hours. This is more severe than the original 
characterisation which reported a 25% reduction in CBF at 24 hours (Shibata et al., 
2004). Previous work by the group saw slightly less severe reduction in CBF of 36% 
at 3 days post-BCAS (McQueen et al., 2014). This discrepancy is likely due to CBF 
recovery which has been demonstrated to occur almost immediately following surgery 
(Shibata et al., 2004). Importantly, the extent of CBF reduction seen in the current 
study is not sufficient to induce ischaemia which would elicit a different 
pathophysiological response and while laser speckle imaging is only able to measure 
the superficial cortical circulation previous work by the lab has demonstrated that it is 
reflective of both deep white matter and subcortical perfusion as measured by arterial 
spin labelling MRI (Duncombe et al., 2017). It was noted that CBF recovered slightly 
but persisted at 6 weeks and that CBF recovery was comparably greater in wild types. 
This is consistent with previous studies by us (McQueen et al., 2014) and others 
(Shibata et al., 2004) reporting 10-15% CBF recovery in wild type mice at 1 month. 
The data also suggest that Nrf2 deficiency may impair CBF recovery following BCAS 
surgery. 
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Impaired CBF recovery in Nrf2+/- animals may be explained by studies that have 
found that absence of Nrf2 impairs angiogenic capacity in vitro (Valcarcel-Ares et al., 
2012, Zhao et al., 2016, Gremmels et al., 2017, Huang et al., 2018) and inhibits 
upregulation of angiogenic vascular endothelial growth factor (VEGF) in vivo in a 
model of venous hypertension (Li et al., 2016b). This also suggests that the capacity 
of blood flow recovery following BCAS surgery may be even more inferior in Nrf2-/- 
compared to wild type mice however additional studies would be required to 
determine the effect of BCAS on blood flow in Nrf2-/- mice. With the available data we 
conclude that BCAS surgery reduces CBF chronically and reductions are comparable 
between wild type and Nrf2+/- mice acutely but CBF recovery occurs to a greater extent 
in wild type. 
 White matter disruption is more severe in Nrf2-/- compared to wild 
type and Nrf2+/- mice in response to cerebral hypoperfusion 
The BCAS model has been well-characterised by our group and others and white 
matter pathology has been demonstrated (Coltman et al., 2011, Holland et al., 2011, 
Shibata et al., 2004). In this study white matter disruption was detected in the corpus 
callosum and optic tract following 6 weeks of mild cerebral hypoperfusion, evident by 
increased density of MAG positive debris. MAG is expressed at the axon-glial 
interface and is sensitive to hypoxia-induced injury (Aboul-Enein et al., 2003). Human 
post mortem studies identify loss of MAG, in particular its ratio to the more stable PLP, 
as a measure of white matter ischaemia (Barker et al., 2013). Cerebral hypoperfusion 
in mice exhibits this feature as early as 3 days post-surgery, and at least initially 
affects MAG without influencing other markers of myelin such as myelin basic protein 
and Fluoromyelin (Reimer et al., 2011, McQueen et al., 2014), consistent with 
hypoxia-induced white matter injury in humans (Aboul-Enein et al., 2003). 
The current study saw more prominent white matter disruption in the optic tract 
than in the corpus callosum, areas which in previous studies have been reported 
collectively (Coltman et al., 2011, Holland et al., 2011). These reports have therefore 
not commented on potential reasons for regional susceptibility of different areas; 
which may be due to differences in vascular supply to the two tracts. The ophthalmic 
artery supplying the optic nerve and tract, branches off the internal carotid artery prior 
to it joining the circle of Willis (Ruberte et al., 2017). The corpus callosum in contrast, 
despite being a deep white matter structure, has a slightly better collateral blood 
supply and may therefore benefit from some compensatory redistribution (Ruberte et 
al., 2017). Studies in rats require complete occlusion of both common carotid arteries 
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due to a richer collateral blood supply, however this induces CBF reductions and white 
matter disruption in the optic tract (Wakita et al., 2002, Farkas et al., 2004). Other 
studies using the BCAS model in mice demonstrate more pronounced disruption of 
the corpus callosum compared to the current study (Shibata et al., 2004, Nakaji et al., 
2006, Washida et al., 2010), although utilisation of different markers (commonly used 
histological stain Klüver-Barrera) measured at a different Bregma level (0.50 mm; 
striatum) may account for the observed differences. Because C57Bl/6 mice often 
display an incomplete circle of Willis, the forebrain is expected to exhibit greater 
cerebral hypoperfusion post-BCAS (Yang et al., 1997), potentially explaining greater 
disruption of the corpus callosum at the level of the striatum as opposed to the 
hippocampus. 
Further, it is important to note that MAG only represents a single protein and while 
aberrant accumulations of this indicates a disruption of the axon-glial interface present 
in the white matter suggesting impaired function it does not report on the overall state 
or integrity of the myelin. Some early studies identified disrupted myelin using 
immunostaining for degraded myelin basic protein (dMBP) (Coltman et al., 2011, 
Holland et al., 2011), whereas others found no effect of BCAS on myelin basic protein, 
fluoromyelin or markers of axonal damage (Reimer et al., 2011, McQueen et al., 2014) 
following 1 month of mild cerebral hypoperfusion. Further unpublished data of overall 
myelin basic protein levels as measured using western blotting has led to the 
hypothesis that myelin and axons at least initially remain intact while alterations in 
MAG can be observed, indicating impaired communication which is also relevant to 
changes observed in human VaD (Aboul-Enein et al., 2003). 
As such, the current study finds that cerebral hypoperfusion induces white matter 
axon-glial disruption which is exacerbated in the absence of Nrf2 in both the corpus 
callosum and the optic tract. This supports the hypothesis that Nrf2, present in wild 
type and Nrf2+/- mice, acts to limit whiter matter disruption following hypoperfusion. 
This is consistent with earlier studies investigating the role of Nrf2 in the maintenance 
of white matter integrity. Hubbs et al. (2007) found that the absence of Nrf2 in aged 
mice (>10 months) is associated with vacuolar white matter degeneration, extensive 
astrogliosis and myelin-specific oxidative injury. In the EAE model of multiple 
sclerosis, previous studies show that absence of Nrf2 results in more demyelination 
and worse clinical scores, associated with more extensive microglial and inflammatory 
gene responses compared to wild type controls (Johnson et al., 2010). 
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 Increased microglial density in response to cerebral 
hypoperfusion is exacerbated in Nrf2-/- compared to wild type and 
Nrf2+/- mice 
White matter disruption has previously been shown to be paralleled by cellular 
inflammation primarily characterised by a microglial response (Shibata et al., 2004, 
McQueen et al., 2014, Miki et al., 2009, Saggu et al., 2016). White matter inflammation 
is proposed to contribute to age and disease-related white matter pathology through 
excessive pro-inflammatory signalling, phagocytosis and oxidative stress (Raj et al., 
2017). The data presented in the current study are consistent with previous work 
displaying increased density of microglia in the corpus callosum and optic tract, 
correlating with area and severity of white matter disruption. The results also 
demonstrate that hypoperfusion-induced increases in microglial density are further 
increased in the absence of Nrf2, suggesting that signalling through Nrf2 normally 
acts to limit upregulation of microglia post-BCAS. 
Microglial density was assessed using immunohistochemistry for Iba1. Iba1 is a 
marker common of both microglia and macrophages, although, recently published 
data by our group identified all Iba1 positive cells in the corpus callosum co-labelled 
for the microglia-specific marker TMEM119 (Manso et al., 2017). This indicates that 
there is little to no infiltration of peripheral macrophages following mild cerebral 
hypoperfusion. Further, associations between number of Iba1 positive microglia and 
white matter function suggests microglia may be important contributors to the disease 
process through secretion of cytokines and chemokines (Manso et al., 2017, Fowler 
et al., 2017). It is noted that Iba1 is a pan-marker for microglia/macrophages providing 
no more than morphological information about activation state and sub-population of 
said cells. Utilising alternative markers such as major histocompatibility complex II, 
cluster of differentiation 40 and 68 associated with antigen presentation and 
phagocytosis which are upregulated on the surface of microglia upon activation 
(Simpson et al., 2007b) may increase our understanding of the disease process and 
the involvement of Nrf2. Recent studies have shown that there is tremendous regional 
heterogeneity of naïve microglia which changes with advancing age (Grabert et al., 
2016, Soreq et al., 2017), highlighting the possibility of huge variation in microglial 
responses across the brain and lifespan which may need to be considered in future 
studies. 
Microglia, in white matter, are important for myelin repair both through 
phagocytosis of myelin degradation products which are neurotoxic and prevent 
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recovery if not cleared (Aboul-Enein et al., 2003), and through release of growth 
factors (Lloyd et al., 2017). A study of peripheral nerve crush injury found that Nrf2-/- 
mice had a reduced ability to clear myelin debris (Zhang et al., 2013), a mechanism 
by which white matter disruption may be exacerbated in Nrf2-/- mice also in the current 
study. Additional work suggest that Nrf2 is a regulator of microglial dynamics, for 
example, microglia isolated from Nrf2-/- mice display an exacerbated inflammatory 
response in response to exogenously applied α-synuclein (Lastres-Becker et al., 
2012). In vivo in an experimental model of Parkinson’s disease (chronic MPTP 
injections), authors report increased microglia numbers in Nrf2-/- mice in control 
conditions (saline injection) (Rojo et al., 2010), indicating that Nrf2 may regulate 
microglial number. In contrast, the current study did not detect an increase in 
microglial density in Nrf2-/- animals that were not subjected to BCAS, although this 
may be a result of studying younger animals compared to Rojo et al. (2010). Further, 
Rojo et al. (2010) identified reduced levels of phagocytosis in Nrf2-/- mice in line with 
the study by Zhang et al. (2013) where clearance of myelin debris peripherally was 
impaired. Increased microglial gene (Iba1/cluster of differentiation 11b) and protein 
expression (Iba1) has also been reported in several models of Alzheimer’s disease 
lacking Nrf2 (Joshi et al., 2015, Branca et al., 2017, Rojo et al., 2018), further 
implicating Nrf2 in the regulation of microglial dynamics. 
Cerebral hypoperfusion induces astrogliosis to a similar extent in 
wild type and Nrf2 KO mice in the optic tract 
The next aim of the study was to investigate the extent of astrogliosis to determine 
if this was influenced post-BCAS and altered by Nrf2 deficiency. The data showed 
that there was no effect of cerebral hypoperfusion in the corpus callosum or the 
internal capsule, however astrogliosis was detected post-BCAS in the optic tract, 
reflective of the magnitude of white matter disruption and microgliosis in the same 
area. There was also a trend suggesting that this response was more severe in Nrf2-
/- mice. Previous work by the group in wild type mice detected no alterations in the 
number of GFAP positive astrocytes at 1 month (McQueen et al., 2014) but found 
increased density of GFAP in the corpus callosum and the thalamus at 3 and 6 months 
respectively (Kitamura et al., 2017, Holland et al., 2015), considerably later than the 
microglial response. The results from the current study finds astrogliosis in the optic 
tract at an earlier time point that previously observed, although astrogliosis has not 
been assessed to the same extent as microglia and never in the optic tract. Other 
groups show white matter astrogliosis alongside the microglial response in the corpus 
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callosum and internal capsule (Shibata et al., 2004, Nakaji et al., 2006, Dong et al., 
2011). This suggests that both astrocytes and microglia contribute to the inflammatory 
response triggered by BCAS-induced cerebral hypoperfusion, which may be 
responsible for the disruption of white matter. The results demonstrated in the current 
study are in support of this. 
Interestingly, there was a slight increase in the density of GFAP positive astrocytes 
in both sham and hypoperfused Nrf2-/- mice in the corpus callosum. The report by 
Hubbs et al. (2007) found that aged Nrf2-/- mice display widespread astrogliosis, 
suggesting that Nrf2 contributes to the regulation of astroglial activation state. 
Previous studies using Nrf2-/- mice in models of neurodegeneration show increases in 
GFAP protein (Rojo et al., 2018, Branca et al., 2017), mRNA (Granado et al., 2011) 
or both (Joshi et al., 2015), leading to the prediction that a greater response would be 
seen in the current study. Although, Johnson et al. (2010) report that absence of Nrf2 
in the EAE model of multiple sclerosis resulted in similar levels of astrogliosis 
compared to wild type mice, highlighting that Nrf2 may regulate astrogliosis differently 
in different disease models. Importantly, a lack of significant astrogliosis does not 
inform on the antioxidant and pro/anti-inflammatory capacity of those astrocytes, 
which may differ between genotypes. Transcriptomic analysis of isolated astrocytes 
display a different profile based on the activating insult, suggested to indicate the 
functional phenotype of that population of reactive astrocytes (Zamanian et al., 2012). 
Microarray analysis may therefore provide far more information than 
immunohistochemistry. Similar to the discussion of Iba1 as a marker for microglia, 
GFAP is known to label only a subset of resting astrocytes (Cahoy et al., 2008). During 
reactive astrogliosis GFAP is massively upregulated (Sofroniew, 2014a) making it an 
acceptable marker for astrogliosis but may be inadequate to study the distribution and 
morphology of alternative astrocyte sub-populations. Alternative markers such as 
Aldh1l1 (Aldehyde dehydrogenase 1l1) have been identified, and shown to cover a 
much greater proportion of the entire astrocyte population (Cahoy et al., 2008), albeit 
still not all of it. Again similar to the studies performed on microglia, astrocytes have 
also been shown to display both regional and age-dependent heterogeneity (Morel et 
al., 2017, Boisvert et al., 2018). 
Isolated astrocytes from Nrf2-/- mice do not respond to endogenously applied α-
synuclein (Lastres-Becker et al., 2012) whilst in wild type astrocytes α-synuclein 
induces the expression of Nrf2-regulated antioxidant and detoxifying genes Heme 
oxygenase 1 (Hmox1) and NAD(P)H dehydrogenase 1 (Nqo1). In vitro studies have 
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identified astrocytes as the primary cell type for Nrf2-activation (Shih et al., 2003, Kraft 
et al., 2004) and astrocytes have been shown to mediate neuroprotection through 
increased synthesis of the antioxidant glutathione (Shih et al., 2003). 
Oligodendrocytes, which are highly metabolically active cells also receive antioxidant 
support from astrocytes (Lundgaard et al., 2014), highlighting the possibility that, at 
least initially, a loss of astrocyte antioxidant function rather than pronounced 
astrocyte-mediated inflammation may contribute to white matter disruption following 
hypoperfusion in Nrf2-/- mice. 
Cerebral hypoperfusion does not affect Nrf2 or Nrf2-regulated 
antioxidant gene expression but increases the expression of pro-
inflammatory genes 
As the previous results demonstrate exacerbated white matter disruption in Nrf2-/- 
mice associated with increases in microgliosis the next aim was to investigate the 
gene alterations which may underlie this, as well as determine the expression levels 
of Nrf2 in wild type and transgenic mice. Quantitative PCR (qPCR) analysis was used 
to determine Nrf2 expression of wild type, heterozygous (Nrf2+/-) and homozygous 
Nrf2 (Nrf2-/-) knockout mice used in the current study. There was a 50% reduction of 
Nrf2 in Nrf2+/- mice and Nrf2 expression was nearly undetectable in Nrf2-/- mice 
compared to wild type controls. Contrary to expectations, cerebral hypoperfusion did 
not alter the expression of Nrf2. The prediction was that hypoperfusion would increase 
expression of Nrf2 in wild type mice since previous hypoperfusion studies identify 
increased inflammation (Fowler et al., 2017, Saggu et al., 2016) and oxidative stress 
(Dong et al., 2011, Miyamoto et al., 2013). However, this may be due to previous 
studies inducing more severe reductions in cerebral blood flow, using 0.17 mm 
microcoils (Saggu et al., 2016) or 0.16/0.18 mm microcoils (Fowler et al., 2017), in 
particular as a similar study by our group found that, despite increases in white matter 
disruption and microglial numbers, a battery of pro-inflammatory genes were 
unaltered at 12 weeks following mild hypoperfusion using 0.18 mm microcoils (Manso 
et al., 2017). 
Another possibility is that the Nrf2 expression may have increased acutely 
following the reduction of CBF, such as that observed following middle cerebral artery 
occlusion where Nrf2 peaks between 8 hours (Tanaka et al., 2011) and 24 hours 
(Srivastava et al., 2013) but is reduced again at 72 hours. This response is also 
observed following traumatic brain injury (Miller et al., 2014) and indicates that 
regulatory mechanisms of the Nrf2 system may prevent it from being chronically 
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activated. This suggests that if Nrf2 activation did occur in the following study it is 
likely to have been detectable more acutely following BCAS surgery. A more detailed 
time course study following BCAS surgery would be required to determine if this is 
the case, which could be further strengthened by measuring Nrf2 protein levels and/or 
Nrf2/ARE DNA binding ability assays. Nonetheless, the results show that Nrf2+/-/Nrf2-
/- mice display the expected reductions of Nrf2 compared to wild type mice.  
Two antioxidant genes were assessed next, Slc7a11 and Gclm, as these are 
known to be regulated by Nrf2 and are important for the synthesis of glutathione (Bell 
et al., 2011b). The glutathione system has been shown to be a major pathway 
mediating neuroprotection against oxidative stress by Nrf2 (Shih et al., 2003). 
Gclm/GCLm is decreased in Nrf2-/- compared to wild type mice in a model of 
Parkinson’s disease (Innamorato et al., 2010) and following methamphetamine-
induced axonal damage (Granado et al., 2011). The prediction was that these genes 
would be reduced in Nrf2+/-/Nrf2-/- mice, however there was no effect of genotype nor 
cerebral hypoperfusion. The results suggest that these genes are not constitutively 
downregulated in Nrf2+/-/Nrf2-/- mice, and the lack of a hypoperfusion effect prevents 
conclusions to be drawn as to whether the induction/expression of these genes is 
inferior to wild type mice as seen in other disease models. 
Pro-inflammatory gene signalling has been reported to be exacerbated in Nrf2-/- 
mice in models of Parkinson’s disease (Rojo et al., 2010) and Alzheimer’s disease 
(Rojo et al., 2017). Hypoperfusion studies in mice identify significant increases of the 
chemokine Ccl3 (MIP1α) (Fowler et al., 2017) and increased expression of the pro-
inflammatory complement pathway (Reimer et al., 2011), and so the next aim was to 
measure the expression of Ccl3, complement component 1q (C1q) and 4 (C4). Ccl3 
was significantly increased by cerebral hypoperfusion, although there was no overall 
genotype effect present CCL3 is a pro-inflammatory chemotactic protein involved in 
the recruitment of pro-inflammatory cells (Maurer and von Stebut, 2004), and it has 
also been shown to impair cognition through impairment of hippocampal synaptic 
transmission (Marciniak et al., 2015). Had Ccl3 been significantly increased in all Nrf2-
/- mice following cerebral hypoperfusion this may have been a mechanisms whereby 
microglial density was increased. Hypoperfusion induced a significant increase in 
C1q, C4 expression just missed accepted levels of significance, although there was 
no genotype effect. Activation of the complement pathway has been suggested to 
potentiate chronic inflammation and neurodegeneration (Stevens et al., 2007), and 
C1q specifically has been suggested to mediate astrocyte activation by microglia in 
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conjunction with tumour necrosis factor (TNF) and interleukin 1β (IL1β) (Liddelow et 
al., 2017). Interestingly, the complement cascade has also been shown to be 
activated by myelin-associated products (Johns and Bernard, 1997), suggesting that 
white matter disruption in itself may potentiate inflammatory changes observed 
following cerebral hypoperfusion. 
Considering the exacerbated pathology in Nrf2-/- mice in the current study the 
prediction was reduced antioxidant and/or increased pro-inflammatory gene 
signalling. However, as previously discussed, the Nrf2-regulated response manifests 
differently in different disease models and greater effects may have been detected if 
measuring alternative markers, such as the canonical Nrf2 genes Heme oxygenase 
1 (Hox1) and NAD(P)H dehydrogenase (quinone)-1 (Nqo1) (Dowell and Johnson, 
2013) which are generally not induced in Nrf2-/- mice (Lastres-Becker et al., 2012, 
Rojo et al., 2010). Alternative classical pro-inflammatory markers such as TNFα and 
IL1β are shown to be increased in Nrf2-/- mice (Rojo et al., 2010), however, the 
hypoperfusion model is more subtle than many of the reported models and pro-
inflammatory markers have previously been difficult to detect several weeks after 
surgery (Manso et al., 2017). Another reason gene changes were unaltered in Nrf2-/- 
mice may be due to a lack of sensitivity as a result of analysing white matter 
homogenates containing a collection of different cell types. A recent study identified 
rather striking differences in gene expression in response to peripheral LPS injection 
and in a model of Alzheimer’s disease when comparing whole brain to cell-specific 
populations from the same animal (Swartzlander et al., 2018). Alternatively, due to 
the current mouse model where Nrf2 is globally reduced or absent from the moment 
of conception and throughout development, it is possible that compensatory 
mechanisms are at play. 
Nonetheless, the qPCR results identify an increase in pro-inflammatory genes 
following cerebral hypoperfusion consistent with previous reports (Fowler et al., 2017, 
Reimer et al., 2011), and there is some indication that this is slightly increased in Nrf2-
/- mice. 
Cerebral hypoperfusion causes a subtle impairment in spatial 
working memory in mice which is not exacerbated by absent or 
reduced expression of Nrf2 
Cerebral hypoperfusion has previously been shown to cause an impairment in 
spatial working memory (Shibata et al., 2007, Coltman et al., 2011) attributed to 
disruption of frontal-subcortical circuitry, and because we saw exacerbated white 
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matter pathology in Nrf2-/- mice the next aim was to investigate spatial working 
memory. Consistent with previous reports, the current study demonstrated that 
cerebral hypoperfusion impairs working memory both in wild type and Nrf2 KO mice 
(Nrf2+/-/Nrf2-/-). However, in contrast to the hypothesis and the pathology results, the 
reduction/absence of Nrf2 did not exacerbate this impairment. One possibility is that 
this may be due to technical limitations. The low number of Nrf2-/- mice available for 
the study prevented analysis of Nrf2+/- and Nrf2-/- groups separately as this analysis 
would be underpowered. It is likely that the results from the Nrf2+/- mice are masking 
any effects present in the Nrf2-/- mice, in particular as the pathology revealed that 
Nrf2+/- mice overall displayed similar white matter disruption and gliosis compared to 
wild type mice. Another explanation is that the increased magnitude of white matter 
disruption in Nrf2-/- mice is insufficient to impair spatial working memory further at this 
time point. Longer duration of hypoperfusion would be expected to intensify the 
pathological differences between wild type and Nrf2 deficient animals, and a later time 
point may have identified functional effects of Nrf2-deficiency, in spite of the low n-
numbers. To the best of our knowledge, there are no previous reports on cognitive 
function in Nrf2-deficient mice. With the existing data a conclusion cannot be drawn 
as to whether the absence of Nrf2 exacerbates spatial working memory impairment 
following cerebral hypoperfusion, albeit the pathological data is consistent with similar 
spatial working memory impairment between Nrf2+/- and wild type mice. 
 Potential mechanisms of white matter disruption 
White matter lesions (WML) have been suggested to occur as a result of hypoxia 
as human post mortem studies find associations between WML and hypoxia-inducible 
factors (Fernando et al., 2006), and between the loss of MAG and increased HIF-1α 
(Aboul-Enein et al., 2003). Cerebral hypoperfusion induces white matter hypoxia, as 
demonstrated by reduced tissue oxygen tension in the corpus callosum 3 days post-
surgery, persisting at least 6 weeks (Duncombe et al., 2017). The initial disruption of 
white matter following hypoperfusion is therefore likely caused by hypoxia as loss of 
MAG is detectable at similar time points (Reimer et al., 2011, McQueen et al., 2014). 
Hypoxia leads to disrupted mitochondrial oxidative phosphorylation which in turn 
leads to generation of reactive oxygen species (ROS) and oxidative stress (Toth and 
Warfel, 2017). Oxidative damage is observed in human post mortem tissue with WML 
indicating that oxidative stress is detrimental to the integrity of white matter (Al-
Mashhadi et al., 2015). The primary molecular response to hypoxia is the stabilisation 
of the transcription factor HIF-1, which induces downstream gene changes that 
C H A P T E R  3 . 4  D I S C U S S I O N  | 79 
promote angiogenesis and alterations in cellular metabolism to improve tissue 
oxygenation (Toth and Warfel, 2017). Nrf2 is also activated by hypoxia (Toth and 
Warfel, 2017), and it has been shown that knockdown of Nrf2 inhibits hypoxia-induced 
activation and secretion of HIF-1α (Ji et al., 2014, Zhao et al., 2016, Huang et al., 
2018). This means that hypoxia may be exacerbated in Nrf2-/- mice following 
hypoperfusion, which would be expected to potentiate oxidative stress indirectly, in 
addition to direct effects from potential lack of Nrf2-mediated antioxidant signalling. 
Direct measures of hypoxia or oxidative stress were not included in the current 
study but have been previously reported following hypoperfusion in mice (Duncombe 
et al., 2017), and pharmacological inhibition of oxidative stress is associated with 
improved white matter integrity in the BCAS model in mice (Dong et al., 2011, 
Miyamoto et al., 2013). Unpublished work by our group find free radicals in the brains 
of aged hypoperfused mice, providing support of oxidative stress as a pathological 
feature. However, without direct measures of free radical production or oxidative 
stress from the current study no conclusions can be drawn as to whether this is 
exacerbated in Nrf2-/- mice. Nrf2 deficiency in the context of oxidative stress alongside 
white matter integrity has not been described in the literature, however oxidative 
damage to proteins and lipids is increased in Nrf2-/- mice with both amyloid and 
tauopathy (AT-NRF2-KO) compared to mice with amyloid and tauopathy alone (AT-
NRF2-WT) (Rojo et al., 2017). Oxidative stress may result from increased ROS 
production which was shown by in vitro work to be aggravated in the absence of Nrf2 
through upregulation of the enzyme NOX2 (Kovac et al., 2015), whose activity is also 
shown to increase following hypoperfusion (Dong et al., 2011). In addition, oxidative 
stress is exacerbated by reduced antioxidant support, observed in Nrf2-/- mice in 
response to methamphetamine-induced axonal damage (Granado et al., 2011) and 
in a mouse model of Alzheimer’s disease (AT-NRF2-KO) (Rojo et al., 2017). 
Therefore, hypoxia and oxidative stress are probable mechanisms whereby white 
matter disruption is exacerbated in Nrf2-/- mice in the current study. However, both 
may interact with and potentiate the reported inflammatory response also suggested 
to contribute to white matter disruption (Simpson et al., 2007a, Raj et al., 2017). 
Nrf2 under normal conditions acts to limit inflammation through crosstalk with the 
NF-κB regulated signalling pathway (Cuadrado et al., 2014). Activation of NF-κB 
potentiates pro-inflammatory signalling (Lawrence, 2009) and is followed by activation 
of Nrf2 which acts by way of negative feedback to prevent further activation of NF-κB 
(Cuadrado et al., 2014). It is therefore possible that absence of Nrf2 results in 
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increased microglial number/density through uncontrolled NF-κB activation. Reactive 
oxygen species can also directly activate the NF-κB pathway (Cuadrado et al., 2014) 
and so the absence of Nrf2 may further potentiate inflammation indirectly through 
dysfunctional redox regulation and oxidative stress. Nrf2 furthermore acts to resolve 
inflammation through induction of anti-inflammatory genes (Lee et al., 2003), and 
through direct inhibition of pro-inflammatory genes in a non-ARE dependent manner 
(Kobayashi et al., 2016), which in addition may explain why microglial density is 
increased following hypoperfusion in Nrf2-/- mice. 
 Limitations, conclusion and future directions 
The study would have been improved by an increased number of Nrf2-/- mice to 
adequately interrogate the role of Nrf2 in CBF regulation and cognition following 
hypoperfusion. A major shortcoming of the study is the lack of CBF measurements in 
Nrf2-/- mice, which if different from wild types may underlie the results. 
There are also a number of technical limitations of laser speckle imaging which 
may influence the results. As mentioned previously, this technique only records 
superficial cortical perfusion and while previous data demonstrates that this reflects 
the magnitude of hypoperfusion in subcortical and deep white matter a measured 
using MRI (Duncombe et al., 2017) there is a possibility that this is differentially 
affected in wild type and Nrf2-/- mice. A recently developed alternative approach to 
laser speckle is 3-photon imaging which has recently been reported to allow a depth 
of imaging of 500-1000µm from the surface of the cortex (Wang et al., 2018, Koizumi 
et al., 2018). 
An important factor that affects CBF is blood pressure. While basal blood pressure 
is reported not to differ between wild type and Nrf2-/- mice (Li et al., 2011), one study 
finds that selective inhibition of the Nrf2 gene in the rostral ventrolateral medulla in 
mice induces hypertension (Gao et al., 2017) and another study investigating Nrf2 in 
diabetic mice finds that Nrf2 deficiency exacerbates hypertension in this pre-existing 
condition (Zhao et al., 2018). Together these studies highlight that differences in blood 
pressure between genotypes may arise, in particular perhaps following BCAS 
surgery, however this cannot be commented on as it was not measured in the current 
study. Similar, and relevant to blood pressure and subsequent CBF regulation is blood 
gas content. In particular the partial pressure of CO2 (Payne et al., 2011) which was 
also not recorded during the laser speckle imaging but has a significant impact on 
cerebral autoregulation. Future experiments would be improved by monitoring blood 
pressure and blood gases during CBF laser speckle recordings using an intra-arterial 
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catheter or blood pressure using a tail cuff as a catheter limits the repeatability of the 
experiment. 
Further, wild type animals had to be imported as enough wild type littermates were 
not generated during the in-house breeding, which resulted in an imbalance of ages 
between experimental groups, representing a major limitation for interpretation of the 
results. The wild type groups average ages were 6 months with a few animals as 
young as 4 months old and Nrf2+/- groups average ages were 7 months and Nrf2-/- 8 
months respectively. As Wolf et al., (2017) reports, age impacts not only on cerebral 
blood flow following BCAS, with more severe reductions in aged animals compared 
to young, but also on subsequent white matter disruption and microglial activation. It 
is hence a possibility that the results observed in the current study are influenced by 
age as opposed to or in combination with the reduced expression of Nrf2. Hubbs et 
al., (2007) report that Nrf2-/- animals display white matter pathology and astroglial 
activation with advancing age only, and hence a combinatory effect of both is 
plausible. 
In addition, an understanding of the mechanisms involved in the disruption of white 
matter would have been improved by measures of hypoxia and/or oxidative stress. 
Attempts were made to measure different types of oxidative stress in fixed tissue 
using immunohistochemistry to no avail. Quantitative analysis of hypoxia and 
oxidative stress proteins could be performed using western or dot blot analysis using 
the collected snap frozen tissue. Alternatively, in vivo methods of measuring tissue 
oxygen tension and reactive oxygen species production are available using probes or 
injected fluorescent ligands but are experimentally challenging, particularly in the 
central nervous system. These types of experiments would typically require additional 
cohorts of mice which would greatly increase time and costs. Further, transcriptomic 
analysis of cell-specific populations including more Nrf2-regulated genes would allow 
for a greater understanding of Nrf2 signalling in response to cerebral hypoperfusion. 
Nrf2 signalling in the vasculature has been shown to decline with age (Ungvari et al., 
2011a) and may explain why age is a major risk factor for VCI. However, preserving 
Nrf2 signalling throughout development and adulthood in mice would better model the 
human condition. Inducible, cell-specific transgenic drivers are now available that 
could be used to knock out the Nrf2 gene in an individual cell type at a suitable time. 
This would ensure that compensatory mechanisms that may occur as a result of Nrf2 
being absent during development can be circumvented. 
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Finally, while this model of cerebral hypoperfusion has been demonstrated to 
selectively disrupt white matter initially (4 weeks) (Shibata et al., 2004, Coltman et al., 
2011), progressive damage also to grey matter (3-6 months) (Holland et al., 2015) 
may influence results observed following BCAS in mice. While limited, (Miki et al., 
2009) demonstrate that at 35 days following mild cerebral hypoperfusion there is 
some evidence of neuronal cell loss in the cortex and the hippocampus and at 5-6 
months after BCAS hippocampal atrophy is evident (Nishio et al., 2010). This 
suggests that grey matter damage may be secondary to the observed white matter 
disruption which is likely why it is rarely studied following BCAS in mice. Nonetheless, 
grey matter pathology would be expected to likewise contribute to cognitive 
impairment and in conjunction with white matter disruption resembles pathological 
alterations observed in small vessel disease and further may contribute to worsening 
of other dementias such as Alzheimer’s disease (Snowdon et al., 1997, Iturria-Medina 
et al., 2016, Kapasi et al., 2017, Lin et al., 2018). However, histological analysis of the 
mice from the current study found only minimal ischaemic neuronal pathology (2/17 
hypoperfused animals: 1 wild type, 1 Nrf2-/-) suggesting this is not greatly impacting 
on the results in this chapter although it is worth noting that microglial increases can 
also be observed in the hippocampus, contradicting the reports of a selective white 
matter response to hypoperfusion. 
In conclusion, the current study determined that white matter disruption and 
microgliosis following cerebral hypoperfusion is exacerbated in mice lacking the 
transcription factor Nrf2, in support of the hypothesis. Contrary to the hypothesis there 
was no effect of Nrf2-deficiency on cognitive performance, although this may be due 
to technical limitations of insufficient power. As a final point, the current study 
implicates inflammation and/or oxidative stress as contributors to hypoperfusion-
induced white matter pathology, altered by the absence of Nrf2 signalling.  
Additional hypoperfusion studies utilising Nrf2-/- mice with novel cell-isolation and 
transcriptional experimental approaches could be informative, however the potential 
of exploiting the Nrf2 pathway to reduce or prevent white matter pathology and 
cognitive impairment is of superior value and will therefore be investigated in the next 
chapter of this thesis. 
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Investigating the effect of chronic cerebral 
hypoperfusion in a mouse model with 
increased expression of Nrf2 in astrocytes 




The previous chapter of this thesis demonstrates that lack of the transcription factor 
Nrf2 exacerbates white matter disruption and gliosis compared to wild type mice 
following cerebral hypoperfusion. Another recently published study found that DMF 
treatment, an anti-inflammatory drug thought to act primarily via activation of the Nrf2 
pathway, ameliorates white matter impairment and microgliosis following severe 
cerebral hypoperfusion (Fowler et al., 2017). Further exploration of the involvement 
of Nrf2 in response to hypoperfusion was thus of interest, and in particular, the 
potential of Nrf2 to limit or prevent white matter pathology and cognitive impairment. 
In vitro experiments of neuronal/glial co-cultures show that Nrf2 is expressed several 
fold higher in astrocytes compared to neurons (Shih et al., 2003), and that Nrf2 
activation occurs preferentially in astrocytes (Kraft et al., 2004). Mice overexpressing 
Nrf2 specifically in astrocytes were therefore developed (GFAP-Nrf2 mice, Vargas et 
al., 2008) to investigate the therapeutic potential of boosting Nrf2 signalling in 
neurodegenerative disease (reviewed by Johnson and Johnson, 2015). GFAP-Nrf2 
mice display improved outcomes in models of familial amyotrophic lateral sclerosis, 
Huntington’s and Parkinson’s disease (Vargas et al., 2008, Calkins et al., 2010, Gan 
et al., 2012, Chen et al., 2009). Relevant to the study of cerebrovascular disease and 
vascular cognitive impairment is the ability of Nrf2 to preserve white matter integrity. 
Pharmacological activation of Nrf2 using DMF is now an approved treatment of 
multiple sclerosis (Gopal et al., 2017), and pharmacological Nrf2 activation is 
associated with improved white matter integrity in models of hypoperfusion (Fowler et 
al., 2017, Mao et al., 2018). This study was developed to build on previous work by 
interrogating the effects of increased Nrf2 expression specifically in astrocytes 
following cerebral hypoperfusion. The advantage of this approach is the ability to 
selectively investigate the effect of astrocytic Nrf2 using transgenic GFAP-Nrf2 mice 
(Vargas et al., 2008), unlike previous studies which have used pharmacological 
approaches to indirectly assess the effect of Nrf2-activation of white matter structure 
and function (Jin et al., 2014, Liu et al., 2015, Zhang et al., 2017, Fowler et al., 2017, 
Mao et al., 2018). 
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Hypothesis 
This study tests the hypothesis that increased expression of Nrf2 in astrocytes 
prevents white matter disruption and cognitive impairment following BCAS-induced 
chronic cerebral hypoperfusion. 
 Aims 
In wild type and GFAP-Nrf2 mice the aims are to: 
1. Assess cerebral blood flow to determine the extent of BCAS-induced cerebral
hypoperfusion
2. Assess spatial working memory
3. Assess the structural integrity of white matter
4. Assess white matter micro- and astrogliosis
5. Assess oxidative stress and inflammatory genes
6. For the above measures determine whether astrocytic overexpression of Nrf2
ameliorates the effects of BCAS
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4.2 Materials and Methods 
 Experimental contribution 
The study presented in this chapter was carried out by myself, Dr Martina 
Marangoni and Professor Karen Horsburgh. I performed laser speckle imaging, 
behavioural testing, and tissue collection/processing/sectioning with assistance from 
Dr Martina Marangoni. I performed immunostaining and imaging for MAG, Iba1 and 
GFAP, RNA extractions, quantitative PCR and all data analysis presented in this 
chapter. Professor Karen Horsburgh performed BCAS surgery. 
 Mice 
Genetic details of GFAP-Nrf2 mice are described in 2.1.2. Adult male GFAP-Nrf2 
and wild type littermates, mean age 4 m 23 d (4 to 5 m), weighing on average 35.4 g 
(27.6-41.4 g), were used for the following experiments. Animals (n=40) were randomly 
assigned surgical intervention as detailed in Table 4.1. The experimenters were 
blinded to genotype and surgery status of animals throughout data collection and 
analysis throughout data collection and analysis in accordance with ARRIVE 
guidelines (Kilkenny et al., 2010). 
 Chronic cerebral hypoperfusion 
Mice underwent bilateral carotid artery stenosis (BCAS) or sham surgery, as 
described in 2.2. BCAS surgery was performed to induce chronic cerebral 
hypoperfusion, using two 0.18 mm in diameter microcoils. Recovery following surgery 
is closely monitored for 72 hours and animals showing poor recovery are culled. Four 
animals tolerated surgery poorly (two wild types and two GFAP-Nrf2 mice) and were 
humanely culled by cervical dislocation (see Table 4.1). 
 Laser speckle imaging to measure cortical cerebral blood flow 
Cortical cerebral blood flow (CBF) was measured at rest prior to, 24 hours and 6 
weeks post-BCAS as described in 2.3. Laser speckle imaging was performed on all 
animals. 
 Behavioural testing 
Animals were singly housed and food restricted for the behavioural tests which 
were performed as described in 2.4.1-2.4.2. Spatial working memory was assessed 
by the 8-arm radial arm maze (2.4.1) and spontaneous alternation and mobility was 
assessed in the Y-maze (2.4.2). Behavioural testing commenced four weeks post-
BCAS. Inclusion criteria described in 2.4.1.3 was applied excluding six animals (three 
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wild type shams, two wild type BCAS and one GFAP-Nrf2 BCAS animal) from 
behavioural analysis. Final numbers for each group are detailed in Table 4.1 and 
relevant figures. 
Tissue collection and processing 
Animals were sacrificed 6 weeks post-BCAS as described in 2.6.1. The tissue was 
further automatically processed for paraffin embedding as described in 2.6.4 and 
Table 2.2 and sectioned as described in 2.6.6. 
Immunohistochemistry 
Performed according to 2.7.1. Details of antibodies used (anti-MAG, anti-Iba1, anti-
GFAP) can be found in Table 2.4. Immunohistochemistry was performed on 6µm 
coronal sections from all animals. 
Image analysis 
Images were acquired using a BX51 microscope (x20, Olympus, UK). Images were 
analysed for percentage area of MAG, Iba1 and GFAP as described in 2.8.2 in the 
CC, IC and OT (Fig 2.3). Briefly, ImageJ software (v1.46, NIH, Bethesda, MD, USA) 
was used to apply a global manual threshold followed by quantification of the positive 
signal detected above the selected threshold. Applying exclusion criteria outlined in 
2.8.3 resulted in one GFAP-Nrf2 sham animal being excluded from the optic tract 
analysis of MAG. Final numbers for each region and stain are detailed in Table 4.1 
and relevant figures. 
Transcriptomics 
Performed according to 2.9 using whole brain and optic tract-enriched samples. 
Details of primers used (Gapdh, 18s, Nrf2, Slc7a11, Gclm, Ccl3, Ccl2, C1q, C4) can 
be found in Table 2.5. Exclusion criteria were applied as described in 2.9.4, resulting 
in no exclusion from whole brain samples but from optic tract-enriched samples 
exclusion of one wild type sham animal from Gclm analysis, one wild type sham, one 
wild type BCAS and one GFAP-Nrf2 BCAS animal from Ccl3 analysis and one wild 
type BCAS animals from Ccl2 analysis. Final numbers are detailed in Table 4.1 and 
the relevant figure also containing reference gene used for each experiment. 
 Statistical analysis 
Repeated measures ANOVA was used to analyse cerebral blood flow and 
behaviour as described in 2.10.1. The radial arm maze was analysed separately for 
the first and second half of the test as the first half primarily represents a learning 
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phase. Two-way ANOVA was used to investigate the effect of BCAS surgery and 
genotype in the Y-maze and Iba1, GFAP and MAG positive percentage area in white 
matter tracts and gene expression (2.10.2). One-sample t-test was used to analyse 
Y-maze spontaneous alternation (2.10.4). Unpaired one-tailed t-test was used to 
investigate the fold change of white matter disruption (2.10.5). Data is presented as 
mean ± standard error of the mean (SEM). Statistical significance was determined at 
p<0.05. 
C H A P T E R  4 . 2  M A T E R I A L S  &  M E T H O D S  | 89 
Table 4.1 Number of mice in each group and experiment with details of exclusion 
BCAS surgery Wild type GFAP-Nrf2 
Sham 8 10 
BCAS 8 10 
Details of exclusion 
Poor recovery from BCAS surgery 2 (Hypo) 2 (Hypo) 
Laser speckle imaging Wild type GFAP-Nrf2 
Sham 8 10 
BCAS 8 10 
Behavioural testing Wild type GFAP-Nrf2 
Sham 5 10 
BCAS 6 9 
Details of exclusion 
Initial lack of motivation 5 1 
Immunohistochemistry 
(CC, IC, OT) Wild type GFAP-Nrf2 
MAG 
Sham 8, 8, 8 10, 10, 9 
BCAS 8, 8, 8 10, 10, 10 
Details of exclusion 
Anatomical area missing from slide 0 1 (OT) 
Iba1 
Sham 8, 8, 8 10, 10, 10 
BCAS 8, 8, 8 10, 10, 10 
GFAP 
Sham 8, 8, 8 10, 10, 10 
BCAS 8, 8, 8 10, 10, 10 
qPCR whole brain 
(Nrf2, Slc7a11, Gclm) Wild type GFAP-Nrf2 
Sham 8, 8, 8 10, 10, 10 
BCAS 8, 8, 8 10, 10, 10 
qPCR optic tract 
(Nrf2, Gclm, C4, C1q, Ccl3, Ccl2) Wild type GFAP-Nrf2 
Sham 8, 7, 8, 8, 7, 8 10, 10, 10, 10, 10, 10 
BCAS 8, 8, 8, 8, 7, 7 10, 10, 10, 10, 9, 10 
Details of exclusion 
3IQR<Q1 / 3IQR>Q3 (outlier) 2 (Ccl3, Ccl2) 1 (Ccl3) 
Reference gene >2STD from mean 2 (Gclm, Ccl3) 0 




 Cortical cerebral blood flow is significantly reduced post-BCAS 
CBF was evaluated using laser speckle imaging prior to, 24 hours and 6 weeks 
post-BCAS surgery to determine the extent of cerebral hypoperfusion and to 
determine if this differed between genotypes. Resting CBF over time was calculated 
as a percentage of each animal’s baseline flux (arbitrary unit). 
BCAS surgery induced reductions in CBF between 30-40%, whereas CBF in the 
sham group remained relatively stable over time (Fig 4.1). There was a significant 
effect of time (F(2,64)=57.02, p<0.0001) and BCAS surgery (F(1,32)=55.2, p<0.0001) and 
a significant interaction between time and surgery (F(2,64)=32.63, p<0.0001) (Fig. 
4.1b). Post hoc tests found that BCAS surgery reduced CBF in wild type and GFAP-
Nrf2 groups at 24 hours (p<0.001) and 6 weeks (WT; p<0.001, GFAP-Nrf2 p=0.03). 
No effect of genotype was detected (F(1,32)=0.03, p=0.86), indicating that 
overexpression of Nrf2 does not affect resting CBF in sham or BCAS groups (Fig 
4.1a-b). 
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◄Figure 4.1 Cortical cerebral blood flow is reduced post-BCAS. (a) Representative
images of laser speckle flowmetry in sham and BCAS, wild type and GFAP-Nrf2 animals
at baseline, 24 hours and 6 weeks. (b) BCAS surgery reduced CBF to a similar extent
in both genotypes. Mean±SEM. ***p<0.001 (* indicates post hoc differences between
wild type sham and BCAS), #p<0.05, ###p<0.001 (# indicates post hoc differences
between GFAP-Nrf2 sham and BCAS.
Spatial working memory is impaired post-BCAS but is less 
pronounced in GFAP-Nrf2 mice compared to wild type 
The previous chapter of this thesis demonstrates that even though the absence of 
Nrf2 exacerbates white matter pathology and gliosis, the cognitive impairment was 
comparable between wild type and Nrf2 KO mice. Because the overarching 
hypothesis is that oxidative stress and inflammation drive both structural and 
functional white matter disruption in the current study we next sought to determine if 
astrocytic overexpression of Nrf2 protects against BCAS-induced cognitive 
impairment before assessing structural alterations. The 8-arm radial arm maze was 
used to assess spatial working memory as described in the previous chapter (3.3.6) 
and published work (Coltman et al., 2011), to corroborate previous results in wild type 
mice and to determine if there was a difference between genotypes. Due to 
differences in the learning profile of wild type and GFAP-Nrf2 sham groups (Fig 4.3a), 
the effect of BCAS surgery was initially investigated for each genotype separately, 
and similar to the previous chapter, because the first half of the test represents a 
learning phase, statistical analysis was performed on the first and second half of the 
test separately (Fig 4.3b-c). 
 Again, as a control measure, spontaneous alternation and total entries in the Y-
maze were recorded and compared across groups (potential confounds to 
performance in the radial arm maze). Wild type and GFAP-Nrf2 groups all 
spontaneously alternated above chance level (WT sham p=0.047, WT BCAS p=0.03, 
GFAP-Nrf2 sham p<0.001, GFAP-Nrf2 BCAS p=0.0002), and there was no effect of 
BCAS surgery (F(1,26)=0.88, p=0.36) or genotype (F(1,26)=2.37, p=0.14) on 
spontaneous alternation (Fig 4.2a). There was also no effect of BCAS surgery 
(F(1,26)=3.96, p=0.06) or genotype (F(1,26)=2.57, p=0.12) on total entries (Fig 4.2b). 




Figure 4.2 Spontaneous alternation and mobility are unaltered in wild type and 
GFAP-Nrf2 mice. (a) Wild type and GFAP-Nrf2 groups all spontaneously alternated 
above chance level in the Y-maze task, and there was no effect of BCAS surgery or 
genotype. (b) There was also no effect of BCAS surgery or genotype on total entries in 
the Y-maze task. Mean±SEM. n-number presented in each bar. 
            
For the radial arm maze, there was an overall effect of trial for both wild type 
(F(2.9,25.9)=3.39, p=0.04) and GFAP-Nrf2 mice (F(4,68.3)=9.47, p<0.0001) (Fig 4.3b-c), 
indicative of learning. There was no difference in revisiting errors between wild type 
sham and BCAS groups in the first half of the test (F(1,9)=1.51, p=0.25) but in the 
second half the wild type BCAS group made significantly more revisiting errors than 
sham controls (F(1,9)=6.56, p=0.03) indicative of impaired spatial working memory (Fig 
4.3b). Post hoc analysis found significant differences at block 5, 6 and 7 (p=0.01, 0.04, 
0.04 respectively). In contrast, the GFAP-Nrf2 sham group was not significantly 
different from BCAS in the first half of the test (F(1,17)=0.33, p=0.57) and in the second 
half the effect of BCAS surgery missed the accepted levels of statistical significance 
(F(1,17)=3.81, p=0.07) indicating only a trend of impaired spatial working memory in the 
GFAP-Nrf2 BCAS group (Fig 4.3c). To investigate whether there may be a genotype 
difference, the fold change of revisiting errors of BCAS groups compared to respective 
sham controls was calculated as a measure of magnitude of cognitive impairment. 
There was an overall genotype effect (F(1,13)=4.79, p=0.048), a significant effect of trial 
(F(2.5,32.4)=8.70, p<0.0001) and a significant interaction between trial and genotype 
(F(2.5,32.4)=3.36, p=0.04) (Fig 4.3d). Post hoc analysis identified significant differences 
between wild type and GFAP-Nrf2 groups at blocks 4, 5 and 6 (p=0.046, 0.02, 0.03 
respectively) (Fig 4.3d). Overall these data suggest a modest protective effect of 
astrocytic Nrf2 overexpression on spatial working memory impairment caused by 
BCAS-induced hypoperfusion. 
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Figure 4.3 Cerebral hypoperfusion causes an impairment in spatial working 
memory which is less pronounced in GFAP-Nrf2 mice. (a) The learning profile for 
wild type and GFAP-Nrf2 sham groups displayed a different pattern, however was not 
significantly different from each other. (b) The wild type BCAS group committed 
significantly more revisiting errors than wild type shams during the second half of the 
test. (c) The GFAP-Nrf2 BCAS group trended towards committing more revisiting errors 
than GFAP-Nrf2 shams. (d) The magnitude of cognitive impairment was greater in wild 
types compared to GFAP-Nrf2. Mean±SEM. *p<0.05 (* indicates post hoc differences 
between groups), #p<0.05 (# indicates main effect of BCAS surgery during second half 
of test). 
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 White matter disruption in the optic tract is less extensive in 
GFAP-Nrf2 mice compared to wild type post-BCAS 
Behavioural performance in the radial arm maze is dependent on the integrity of 
myelinated axons within the white matter for efficient communication. Alterations in 
immunostaining for myelin associated glycoprotein (MAG) was used to assess white 
matter disruption as previously described in Chapter 3 (3.3.2) to evaluate the 
pathological response to BCAS compared to the previous chapter and studies and to 
determine if this differed between genotypes. 
The percentage area of MAG positive immunostaining was quantified in key white 
matter tracts: corpus callosum, internal capsule and optic tract. There was no 
significant white matter disruption post-BCAS in the corpus callosum (F(1,32)=2.63, 
p=0.12) or the internal capsule (F(1,32)=0.08, p=0.78), and no effect of genotype 
(F(1,32)=0.82, p=0.37; F(1,32)=0.17, p=0.68 respectively) (Fig 4.4a-b). Similar to the 
study presented in chapter 3, there was a prominent white matter disruption post-
BCAS in the optic tract (F(1,31)=13.57, p=0.001) albeit no significant effect of genotype 
(F(1,32)=0.6, p=0.44) (Fig 4.4c). Post hoc analysis of the effect of BCAS revealed 
significant white matter disruption in the wild type BCAS group compared to sham 
controls (p=0.004), but the difference between GFAP-Nrf2 BCAS and sham controls 
missed accepted levels of statistical significance (p=0.054) (Fig. 4.4c). To investigate 
whether the magnitude of white matter disruption in the optic tract differs between 
genotypes, the fold difference of MAG positive percentage area compared to controls 
was calculated and compared between wild type and GFAP-Nrf2 mice (Fig. 4.4d). 
There was a significantly higher magnitude of white matter disruption in wild type mice 
(p=0.03) (Fig 4.4d), indicating a modest protective effect of Nrf2 overexpression on 
optic tract white matter integrity following BCAS-induced cerebral hypoperfusion. 
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Figure 4.4 White matter disruption in the optic tract is less extensive in GFAP-
Nrf2 mice compared to wild type post-BCAS. (a) There was no effect of BCAS 
surgery or genotype in the corpus callosum, (b) nor in the internal capsule. (c) In the 
optic tract, there was an effect of BCAS albeit no overall effect of genotype. (d) Fold 
change of white matter disruption compared to respective sham controls in the optic 
tract was significantly increased in wild type animals. Mean±SEM. n-number presented 
in each bar. *p<0.05, **p<0.01. (e) Representative images of MAG staining in the optic 
tract. Scale bar 50 µm. 
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 The density of microglia is increased post-BCAS in the optic tract 
To assess the inflammatory response associated with white matter disruption as 
observed in the previous chapter and studies (Coltman et al., 2011, McQueen et al., 
2014), immunohistochemistry for ionized calcium binding adapter molecule 1 (Iba1) 
was used as previously described in Chapter 3 (3.3.3). Further, Iba1 positive 
percentage area was used to determine if astrocytic overexpression of Nrf2 influences 
the inflammatory response of microglia post-BCAS. 
Iba1 was evaluated in key white matter tracts: corpus callosum, internal capsule 
and optic tract. Consistent with the absence of white matter disruption, there was no 
significant increase in density of microglia post-BCAS in the corpus callosum 
(F(1,32)=2.41, p=0.13) nor in the internal capsule (F(1,32)=2.75, p=0.11), and there was 
no effect of genotype (F(1,32)=3.12, p=0.09; F(1,32)=2.23, p=0.14 respectively) (Fig 4.5a-
b). The white matter disruption in the optic tract was paralleled by an increased density 
of microglia post-BCAS (F(1,32)=14.74, p=0.001), and post hoc analysis detected 
significantly higher densities in wild type and GFAP-Nrf2 BCAS groups compared to 
their sham controls (p=0.007, p=0.02 respectively) (Fig 4.5c). There was no effect of 
genotype on microglial density (F(1,32)=0.29, p=0.59) (Fig 4.5c). These data show that 
cerebral hypoperfusion induced by BCAS surgery causes an increased density of 
microglia in the optic tract which also exhibits white matter pathology, but that this is 
not reduced by astrocytic overexpression of Nrf2. 
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Figure 4.5 The density of microglia is increased post-BCAS in the optic tract. (a) 
There was no effect of BCAS or genotype on % area of Iba1 in the corpus callosum (b) 
nor the internal capsule. (c) There was an effect of BCAS in the optic tract, with no 
further effect of genotype. Mean±SEM. n-number presented in each bar. *p<0.05, 
**p<0.01. (d) Representative images of Iba1 staining in the optic tract. Scale bar 50 µm. 
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 Astrogliosis in the optic tract is less in GFAP-Nrf2 mice 
compared to wild type post-BCAS 
Despite seeing no genotype effect on the microglial inflammatory response post-
BCAS, the next aim was to assess astrogliosis since Nrf2 is specifically 
overexpressed in astrocytes, and because the previous chapter of this thesis detected 
significant astrogliosis in both wild type and Nrf2 KO animals post-BCAS (3.3.4).  
Glial fibrillary acidic protein (GFAP) immunohistochemistry: quantified as GFAP 
positive percentage area was evaluated in the main white matter tracts: corpus 
callosum, internal capsule and optic tract. BCAS surgery induced reactive astrogliosis 
in the optic tract (F(1,32)=38.87, p<0.0001) (Fig 4.6c) but, similar to Iba1 expression 
and white matter disruption, not in the corpus callosum or the internal capsule 
(F(1,32)=1.43, p=0.24, F(1,32)=2.01, p=0.17 respectively) (Fig 4.6a-b). There was also no 
effect of genotype in these regions (F(1,32)=1.95, p=0.17, F(1,32)=3.34, p=0.08 
respectively) (Fig 4.6a-b). However, there was a significant effect of genotype in the 
optic tract (F(1,32)=7.45, p=0.01) and a significant interaction between BCAS surgery 
and genotype (F(1,32)=7.05, p=0.01). Post hoc tests identified significant reactive 
astrogliosis in wild type (p<0.001) and GFAP-Nrf2 BCAS groups (p=0.01), but also a 
significant reduction in the GFAP-Nrf2 BCAS group compared to wild type BCAS 
(p=0.001) (Fig 4.6c). These data illustrate that cerebral hypoperfusion induced by 
BCAS surgery causes reactive astrogliosis in the optic tract, and that the extent of 
astrogliosis is reduced by astrocytic overexpression of Nrf2. 
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Figure 4.6 Astrogliosis in the optic tract is less in GFAP-Nrf2 mice compared to 
wild type post-BCAS. (a) % Area of GFAP in the corpus callosum and (b) internal 
capsule was unchanged post-BCAS with no effect of genotype.  (c) % Area of GFAP in 
the optic tract was increased post-BCAS with a significant effect of genotype and the 
GFAP-Nrf2 BCAS group displayed less astrogliosis compared to wild type BCAS. 
Mean±SEM. n-number presented in each bar. *p<0.05, ***p<0.001 (* indicates post hoc 
differences between sham and BCAS), ##p<0.01 (# indicates post hoc differences 
between BCAS groups). (d) Representative images of GFAP staining in the optic tract. 
Scale bar 50µm. 
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 Pro-inflammatory genes are induced post-BCAS in the optic tract 
and the level of complement component 4 is reduced in GFAP-
Nrf2 mice compared to wild type 
The results presented in this chapter demonstrate that BCAS surgery induces 
cerebral hypoperfusion in wild type and GFAP-Nrf2 mice which causes white matter 
disruption and increased density of both microglia and astrocytes in parallel with 
impaired spatial working memory. The data indicates that GFAP-Nrf2 provides 
modest protection of white matter structure and function and reduces the astroglial 
response post-BCAS. We therefore went on to assess antioxidant and inflammatory 
gene changes as described in the previous chapter (3.3.5), to determine if there were 
differences between wild type and GFAP-Nrf2 mice that underlie the protective effects 
observed. 
Relative gene expression of Nrf2, Scl7a11 (xCT; encoding the glutamate/cystine 
antiporter) and Gclm, (glutamate-cysteine ligase enzyme subunit), two Nrf2-regulated 
genes involved in glutathione synthesis were initially measured in a whole brain slice 
corresponding to the level of pathological assessment using qPCR and compared 
across groups (Fig 4.7-a-c). There was a 3.5-fold increase in Nrf2 and an 
accompanied 2-fold increase in Slc7a11 and Gclm (F(1,32)=298, p<0.0001, 
F(1,32)=74.05, p<0.0001, F(1,32)=737.5, p<0.0001 respectively), however there was no 




Figure 4.7 Nrf2, Slc7a11 and Gclm relative gene expression in whole brain is 
higher in GFAP-Nrf2 animals with no effect of BCAS surgery. (a) Nrf2, (b) Slc7a11 
and (c) Gclm expression was significantly higher in GFAP-Nrf2 animals but this was not 
altered post-BCAS. Gene expression was normalised to Gapdh and expressed relative 
to WT sham. Mean±SEM. n-number presented in each bar. Dashed line indicates WT 
sham mean.  
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Alterations in gene expression were further investigated instead in optic tract 
enriched samples since the previous results demonstrate disruption and glial 
alterations in this region. Nrf2 expression in the optic tract was similar to that of the 
whole brain sample with a 4-fold increase in GFAP-Nrf2 animals compared to wild 
type (F(1,32)=116.4, p<0.0001) and no further effect of BCAS surgery (F(1,32)=0.47, 
p=0.5) (Fig 4.8a). To investigate the involvement of the glutathione antioxidant system 
Gclm expression was measured in optic tract enriched samples, but similarly found 
an effect of genotype (F(1,31)=49.83, p<0.0001) but not BCAS surgery (F(1,31)=0.22, 
p=0.65) (Fig 4.8b). Collectively the results suggest that antioxidant gene alterations 
cannot explain the white matter protection conferred in the GFAP-Nrf2 BCAS group 
at this time. Instead, the inflammatory milieu beyond the cellular responses was 
explored as an alternative mechanism whereby Nrf2 may confer protection following 
BCAS-induced hypoperfusion. Gene expression of complement component 4 and 1q 
(C4, C1q) and two chemokines; Ccl3 (Mip-1α) and Ccl2 (Mcp-1), which have 
previously been detected in the BCAS-model (Fowler et al., 2017, Reimer et al., 2011) 
were measured. 
BCAS surgery significantly increased the expression of C4, C1q, and Ccl3 
expression (F(1,32)=8.07, p=0.008, F(1,32)=7.92, p=0.008, F(1,29)=8.68, p=0.006; 
respectively) (Fig 4.8c-e), whereas Ccl2 expression was reduced (F(1,31)=6.09, 
p=0.02) (Fig 4.8f). C4 expression was also significantly different in GFAP-Nrf2 
animals (F(1,32)=5.66, p=0.02) and post hoc analysis found significant upregulation in 
the wild type BCAS (p=0.005) but not the GFAP-Nrf2 BCAS group (p=0.39), and 
further that C4 expression was significantly lower in GFAP-Nrf2 BCAS compared to 
the wild type BCAS group (p=0.007) (Fig 4.8c). C1q expression followed a similar 
pattern, however there was no overall genotype effect (F(1,32)=0.05, p=0.83). Post hoc 
tests found a significant increase of C1q in wild type BCAS compared to shams 
(p=0.02) but found no significant difference between GFAP-Nrf2 groups (p=0.13) (Fig 
4.8d). No effect of genotype was detected on Ccl3 and Ccl2 expression (F(1,29)=0.12, 
p=0.73, F(1,31)=1.62, p=0.21; respectively), and post hoc analysis identified significant 
differences between GFAP-Nrf2 groups (p=0.03, p=0.01; respectively), but not 
between wild type groups (p=0.07, p=0.35; respectively) (Fig 4.8e-f). Together the 
data indicates that BCAS-induced cerebral hypoperfusion increases the expression 
of specific pro-inflammatory genes and that Nrf2-overexpression in astrocytes may 
protect white matter integrity and behavioural performance by selectively suppressing 
aspects of this inflammatory response. 




Figure 4.8 Pro-inflammatory genes are induced post-BCAS in the optic tract and 
the level of C4 is reduced in GFAP-Nrf2 mice. (a) Nrf2 and (b) Gclm expression in 
the optic tract was increased in GFAP-Nrf2 animals, but was not altered post-BCAS. (c) 
C4 expression in the optic tract was increased post-BCAS with an effect of genotype 
and the GFAP-Nrf2 BCAS group displaying levels of expression similar to both sham 
groups.  (d) BCAS surgery increased C1q and (e) Ccl3 expression in the optic tract, but 
reduced the expression of Ccl2. There was no effect of genotype on the expression of 
C1q, Ccl3 or Ccl2. Gene expression was normalised to Gapdh or 18S and expressed 
relative to WT sham. Mean±SEM. n-number presented in each bar. Dashed line 
indicates WT sham mean. *p<0.05, **p<0.01 (* indicates post hoc differences between 
sham and BCAS), ##p<0.01 (# indicates post hoc differences between BCAS groups. 
 
C H A P T E R  4 . 4  D I S C U S S I O N  | 103 
4.4 Discussion 
The present study was designed to test the hypothesis that overexpression of the 
transcription factor Nrf2 specifically in astrocytes limits cerebral hypoperfusion-
induced white matter disruption and spatial working memory impairment. The results 
demonstrate that white matter disruption and astrogliosis was alleviated in the optic 
tract, in parallel with modestly improved spatial working memory. These protective 
effects appear to be mediated via repression of specific inflammatory genes. 
Resting cortical cerebral blood flow is significantly reduced 
following bilateral carotid artery stenosis to a similar extent in 
wild type and GFAP-Nrf2 mice 
In agreement with previous work, this study finds that bilateral carotid artery 
stenosis induces mild, sustained cerebral hypoperfusion in wild type mice, which is 
similar in Nrf2-overexpressing mice. The extent of CBF reduction (~30-40% at 24 
hours) and modest restoration at 6 weeks (~5%) is comparable to those previously 
published (McQueen et al., 2014, Shibata et al., 2004, Nishio et al., 2010, Maki et al., 
2011). Importantly, no difference was found in the extent of CBF reduction between 
wild type and GFAP-Nrf2 mice. As discussed in the previous chapter, absence of Nrf2 
has previously been shown to have vascular related effects acting to impair 
angiogenic capacity in vitro (Valcarcel-Ares et al., 2012, Gremmels et al., 2017, Zhao 
et al., 2016) and inhibits the upregulation of VEGF in an in vivo model of venous 
hypertension (Li et al., 2016b). The prediction may therefore have been to observe 
greater recovery of CBF in GFAP-Nrf2 mice, in particular because increased VEGFα 
expression and other angiogenic genes are detected 3 days following hypoperfusion 
(Reimer et al., 2011). Promoting these endogenous processes to improve CBF is 
currently explored in models of hypoperfusion to establish its potential in the treatment 
of vascular dementia (as discussed in Du et al., 2016). Nevertheless, the current study 
found that overexpression of Nrf2 in astrocytes does not alter CBF responses 
following BCAS surgery, which therefore allowed the effects of Nrf2 to be investigated 
without confounding flow-related differences. 
Cerebral hypoperfusion causes an impairment in spatial working 
memory which is ameliorated in GFAP-Nrf2 mice 
Consistent with the previous chapter and published studies, the results 
demonstrate that hypoperfusion induces impairments in spatial working memory in 
wild type mice as measured by the radial arm maze (Coltman et al., 2011, Shibata et 
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al., 2007). Wild type and GFAP-Nrf2 sham mice were able to learn the task with 
increasing trial duration but the hypoperfused mice in both cohorts were impaired 
compared to their controls. It was noted that the baseline learning pattern was 
different in the wild type and GFAP-Nrf2 sham mice. To the best of our knowledge no 
previously published studies using this transgenic mouse line have investigated 
cognitive changes, and no reports of altered cognition at baseline in models of Nrf2-
overexpression/activation have been identified. One potential explanation may be a 
disruption in redox balance. Reactive oxygen species (ROS), albeit detrimental in 
excess, are cell signalling molecules (Thannickal and Fanburg, 2000) important for 
synaptic plasticity (Massaad and Klann, 2011, De Pasquale et al., 2014), and it is 
possible that Nrf2-overexpression affects spatial behaviour by excessive ROS 
depletion. Despite this different baseline learning pattern, GFAP-Nrf2 sham mice 
successfully learned the task by trial block 8 and the extent of impairment in spatial 
working memory in GFAP-Nrf2 hypoperfused mice was modestly, but significantly 
less pronounced as compared to wild type mice. Thus the data supports the 
hypothesis that increased expression of Nrf2 may protect against hypoperfusion 
induced functional impairment. 
 White matter disruption in the optic tract is less severe in GFAP-
Nrf2 compared to wild type mice in response to cerebral 
hypoperfusion 
Since the impairment in spatial working memory was less pronounced in 
hypoperfused GFAP-Nrf2 mice this suggested that there may be fewer pathological 
alterations. The previous chapter of this thesis and earlier studies demonstrate that 
white matter is particularly vulnerable to cerebral hypoperfusion (3.3.2, Coltman et al., 
2011, Holland et al., 2011, Shibata et al., 2004, Ihara and Tomimoto, 2011), similar to 
ischaemic and hypoxic white matter damage in human VCI (Barker et al., 2013, Aboul-
Enein et al., 2003). The current study agrees with previous findings of hypoperfusion-
induced white matter disruption, however only in the optic tract where the extent of 
pathology is more severe than previously reported, with the exception of the previous 
chapter of this thesis. As discussed, the vascular supply to the two tracts differs and 
may account for this optic tract vulnerability. An alternative explanation is that this 
study utilised mice on a different background strain compared to previous studies 
(FVB/C57Bl/6J F1 mice in this study compared to pure C57Bl/6J in previous studies). 
It is reported that the cerebral vasculature of different strains is differently organised 
and may therefore present with different spatial distribution and severity of 
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hypoperfusion (Yang et al., 1997). There is also a possibility that the optic tract in 
FVB/C57Bl/6J F1 mice is more vulnerable to hypoperfusion than C57Bl/6J mice due 
to genetic differences, as pure FVB/N mice are known to be visually impaired from an 
early age due to a mutation causing retinal degeneration (Brown and Wong, 2007). 
However, it is unlikely that the mice were visually impaired since our FVB/C57 first 
generation cross successfully learned the visual-dependent radial arm maze task and 
we observed no altered behaviour indicating visual impairment in any of the mice and 
because the previous chapter displayed a similar pattern of pathology. However, with 
the available data, we cannot discount that disruption of the optic tract in 
hypoperfused mice resulted in impaired visual acuity underlying the impaired 
performance on the radial arm maze task. 
Even so, the results indicate that astrocyte-specific overexpression of Nrf2 
modestly reduces white matter disruption in the optic tract. GFAP-Nrf2 mice, to the 
best of our knowledge, have not previously been studied in the context of white matter 
injury and repair, but, overexpression of astrocytic Nrf2 by GFAP-specific Keap1-
deletion reduced demyelination and oligodendrocyte cell loss in the cuprizone model 
of multiple sclerosis (Draheim et al., 2016). Similarly, Nrf2-activating pharmacological 
compounds have been reported to protect white matter both in models of multiple 
sclerosis (Linker et al., 2011) and cerebral hypoperfusion (Fowler et al., 2017, Mao et 
al., 2018). The compound DMF was recently approved for the treatment of multiple 
sclerosis in humans (Gopal et al., 2017), and although one study using Nrf2-/- mice 
indicates that DMF can be beneficial in the absence of Nrf2 (Schulze-Topphoff et al., 
2016), there is a large body of evidence highlighting downstream activation of the Nrf2 
signalling pathway as a mechanisms of action (Linker et al., 2011, Ahuja et al., 2016, 
Gopal et al., 2017). The subtle pathology observed in this study, compared to 
previously published hypoperfusion studies (Reimer et al., 2011, Coltman et al., 2011, 
Holland et al., 2011, McQueen et al., 2014) and models of multiple sclerosis, may 
have limited the ability to investigate the effect of Nrf2-overexpression completely. 
There is also a possibility that mechanisms other than hypoxia, oxidative stress and 
inflammation contribute to white matter disruption, such as reduced trophic support or 
increased blood brain barrier permeability (Iadecola, 2013), which Nrf2-
overexpression may not influence. Nevertheless, the subtle reduction in the severity 
of white matter disruption in Nrf2-overexpressing mice was associated with modest 
improvements in spatial working memory compared to wild type mice, in agreement 
with the hypothesis. 
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 Microglial and astrocyte density is increased in the optic tract in 
response to cerebral hypoperfusion but only astrogliosis is less 
severe in GFAP-Nrf2 mice 
As previously introduced, earlier reports indicate that microgliosis precedes 
significant increases in astrogliosis following cerebral hypoperfusion, and 
associations between microgliosis and impaired white matter function suggest that 
microglia are important contributors to the disease process (Fowler et al., 2017, 
Manso et al., 2017). However, in the studies reported in this thesis, both microglial 
and astrocyte density in the optic tract were increased after 6 weeks of mild 
hypoperfusion. Other studies have identified associations between astrogliosis and 
impaired white matter integrity following cerebral hypoperfusion in mice (Saggu et al., 
2016) and astrogliosis and impaired spatial working memory following 2VO in rats 
(Vicente et al., 2009). Similar to the proposed microglial contribution this is suggested 
to occur through increased inflammation (Saggu et al., 2016) but may also result from 
astrocyte dysfunction such as reduced astroglial glutamate uptake resulting in 
excitotoxicity (Vicente et al., 2009). 
The current study found that overexpression of Nrf2 in astrocytes reduced the 
extent of astrogliosis but did not have an effect on microglial density after 
hypoperfusion. This was somewhat unexpected as GFAP-Nrf2 mice have previously 
been demonstrated to have reduced astro- and microgliosis in models of Parkinson’s 
Disease (Gan et al., 2012, Chen et al., 2009), and as discussed in the previous 
chapter (3.4.3), considering the role Nrf2 is suggested to play in regulating microglial 
dynamics (Rojo et al., 2010, Joshi et al., 2015, Branca et al., 2017, Rojo et al., 2018). 
However, there is some conflicting evidence of the effect of Nrf2 on gliosis, for 
example in a transgenic mouse model of Alzheimer’s disease (APP/PS1). One study 
found that only astrogliosis was reduced by increasing Nrf2 (Kanninen et al., 2009), 
while another found that both astro- and microgliosis were affected (Fragoulis et al., 
2017), though both were associated with improved cognition. These differences may 
be accounted for by different means of Nrf2-activation; lentiviral-Nrf2 hippocampal 
injection (Kanninen et al., 2009), oral administration of the Nrf2-activating compound 
methysticin (Fragoulis et al., 2017) or transgenic overexpression of Nrf2 in astrocytes 
(Gan et al., 2012, Chen et al., 2009). The contrasting results from previous studies in 
GFAP-Nrf2 mice may be explained by different experimental models, and perhaps 
particularly by the comparably more subtle pathology in the current study. Together, 
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these studies highlight the complexity of glial responses in different disease models 
and suggest that the benefit of Nrf2-activation may be context-dependent. 
Despite the above discrepancies, the study by Saggu et al. (2016) implicates 
astrocyte-specific activation of pro-inflammatory NF-κB in the disruption of white 
matter structure and function following cerebral hypoperfusion in mice. It is possible 
that GFAP-Nrf2 mice in the current study, Nrf2 being a negative regulator of NF-κB, 
downregulate pro-inflammatory signalling specifically in astrocytes, without 
significantly affecting microgliosis. It is worth noting that the immunohistochemical 
results presented in this study are merely morphological and do not reveal anything 
about the inflammatory state of individual cells or the overall inflammatory milieu. 
Nonetheless, these results demonstrate that increased Nrf2 expression in astrocytes 
alone can have downstream beneficial effects on optic tract white matter integrity and 
spatial working memory. 
Cerebral hypoperfusion induces pro-inflammatory gene 
expression in the optic tract and complement component 4 is 
downregulated in GFAP-Nrf2 mice 
To probe mechanisms by which Nrf2 overexpression in astrocytes mediates these 
protective effects, the levels of two glutathione-related genes; Slc7a11 (xCT) and 
Gclm were measured in a whole brain sample. As previously mentioned, the 
glutathione system forms an important part of cellular antioxidant capacity (Dringen, 
2000) and has been shown previously to be upregulated by ischaemic preconditioning 
in an Nrf2-dependent manner (Bell et al., 2011b), as well as in GFAP-Nrf2 mice in 
several models of neurodegenerative disease (Vargas et al., 2008, Calkins et al., 
2010, Gan et al., 2012). We found an increase in both Slc7a11 and Gclm in GFAP-
Nrf2 compared to wild type mice, however contrary to expectations there were no 
further increases in expression of these genes with hypoperfusion. Given that 
hypoperfusion induces oxidative damage (Dong et al., 2011, Miyamoto et al., 2013), 
the prediction was that antioxidant gene expression would be increased also in wild 
type hypoperfused animals indicative of Nrf2 pathway activation. Instead, antioxidant 
enzymes were increased only in GFAP-Nrf2 animals; in line with a study in a 
transgenic model of Parkinson’s disease (Gan et al., 2012). The current results, 
consistent with those reported in the previous chapter, suggest that hypoperfusion in 
wild type mice may be insufficient to induce Nrf2 expression and activation directly 
but, considering the current experimental design, it is impossible to rule out acute 
changes that may have occurred following hypoperfusion surgery. It would be 
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plausible to assume that transient activation of antioxidant genes induced by 
hypoperfusion would be superior in GFAP-Nrf2 compared to wild type mice although 
a time-course study would be required to verify this assumption. On a similar note, 
the constitutively higher glutathione-related gene expression in the GFAP-Nrf2 
animals may indicate a higher capacity of glutathione synthesis perhaps providing 
some protection to white matter following hypoperfusion, however, direct measures 
of glutathione would be required to draw that conclusion. A model of Alexander 
disease, a white matter disease caused by aberrant accumulation of GFAP, found 
glutathione-independent protective effects of GFAP-Nrf2 expression (LaPash Daniels 
et al., 2012). Similarly, a proteomic study of Nrf2-overexpressing astrocytes found 
important roles of detoxifying and anti-inflammatory enzymes catalase, peroxiredoxin-
6 and prostaglandin reductase 1 (Dowell and Johnson, 2013) which could 
alternatively be implicated following hypoperfusion. 
The speculation was that since no alterations in glutathione-related genes were 
observed, the protective effect seen in the study could be mediated by modulation of 
the inflammatory environment rather than by antioxidant mechanisms. This was 
investigated by further qPCR analysis of optic tract-enriched samples of pro-
inflammatory genes; C4 and C1q; complement component 4 and 1q, and Ccl3 (MIP-
1α) and Ccl2 (MCP-1); chemokine (C-C motif) ligand 3 and 2. The complement 
system is an important part of the innate immune system, aiding early responses to 
infection or injury. It also contributes to the adaptive immune system by interacting 
with antigen/antibody complexes eliciting a cascade of proteolytic events which 
ultimately boost phagocytosis and inflammation by the recruitment of more 
inflammatory cells (Janeway et al., 2001). Ccl3/Ccl2 encode pro-inflammatory 
chemokines involved in the recruitment of microglia and astrocytes as well as 
peripheral monocytes and macrophages (Bose and Cho, 2013, Maurer and von 
Stebut, 2004). Increased expression of complement components as well as pro-
inflammatory chemokines has long been recognised as an indication of chronic 
inflammation for example in Alzheimer’s disease (Bennett et al., 2009, Eikelenboom 
and Stam, 1982, Azizi et al., 2014). Previous work finds increased expression of C4 
and a putative receptor for C1q in white matter at 72 hours post-hypoperfusion 
(Reimer et al., 2011) and in whole brain at 4 weeks following mild hypoperfusion in 
wild type mice (unpublished obeservations) using microarray analysis, as well as 
increased protein levels of Ccl3 and Ccl2 following severe hypoperfusion (Fowler et 
al., 2017). The previous chapter reports increased Ccl3 and C1q (and C4 trend) with 
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cerebral hypoperfusion. In the current study, an increase in C4, C1q and Ccl3 
expression following hypoperfusion was determined in wild type mice, indicative of 
ongoing inflammation. In contrast to previous work where Ccl2 protein was increased 
at 1 week after severe hypoperfusion (Fowler et al., 2017) and 2 weeks after mild 
hypoperfusion (Yuan et al., 2017), Ccl2 expression was determined to be 
downregulated in the current study. The discrepancy may be due to differences in 
anatomical areas sampled and/or different extent of hypoperfusion. Overall, the 
differential change in inflammatory gene expression likely reflects the spatial and 
temporal heterogeneity of inflammatory responses to hypoperfusion which is likely 
highly dynamic. 
In Nrf2 overexpressing mice the increase in complement related genes was 
dampened. Complement activation has been suggested to potentiate chronic 
inflammation and neurodegeneration (Liddelow et al., 2017, Stevens et al., 2007), and 
has been demonstrated to trigger neuroinflammation following traumatic brain injury 
(Alawieh et al., 2018). Since direct inhibition of complement has been neuroprotective 
in mouse models of Alzheimer’s disease (Shi et al., 2017) and cerebral ischaemia 
(Yang et al., 2013, Ducruet et al., 2012), reduced complement activation may be a 
mechanism whereby Nrf2 overexpression is protective following hypoperfusion. 
Recent evidence has also demonstrated that Nrf2 not only induces the expression of 
cytoprotective genes but is also able to suppress expression of pro-inflammatory 
genes directly (Kobayashi et al., 2016). Since the Nrf2 overexpression is selectively 
in astrocytes, one possibility is that these are more resistant to microglia-driven pro-
inflammatory signalling. Isolation and transcriptomic analysis of astrocytes and 
microglia separately would have allowed more detailed information regarding the 
protective mechanisms involved. And as previously mentioned, recent work has 
highlighted how transcriptomic analysis of mixed cell populations may be misleading 
as gene signalling is differentially regulated in different cell types (Swartzlander et al., 
2018). Nevertheless, the results demonstrate that astrocyte-specific overexpression 
of Nrf2 alters the inflammatory milieu by dampening aspects of the pro-inflammatory 
response following cerebral hypoperfusion. 
Alternative mechanisms of Nrf2 pathway activation 
Despite the experimental evidence of astrocytes role in antioxidant and anti-
inflammatory defence, GFAP-Nrf2 mice may not be the most efficient method to boost 
Nrf2 activity. It is unknown if the molecular mechanisms controlling Nrf2 become 
altered by the constitutively increased expression of Nrf2 throughout development 
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and adulthood. An alternative approach is transgenic mouse models which instead 
downregulate Keap1, the main repressor of Nrf2, that have been shown to efficiently 
increase Nrf2 signalling (Draheim et al., 2016). Cell-specific downregulation of Keap1 
combined with a diet-inducible transgenic driver would provide a highly specific model 
to investigate the therapeutic potential of boosting Nrf2 in disease without confounds 
of it being upregulated throughout development. Further, this represents a highly 
plausible therapeutic approach where pharmacological inhibition of Keap1 may boost 
Nrf2 as and when required. 
Alternatively, pharmacological activation of Nrf2 can be utilised to achieve a more 
global response, and of course represents a more clinically relevant approach. 
Compounds such as Sulforaphane, Methysticin, Curcumin and Resveratrol are 
naturally occurring Nrf2-activators (Liddell, 2017). Further, synthetic Nrf2 activators 
such as tert-butyl-hydro-quinone (tBHQ) are available, with Dimethyl fumarate (DMF) 
approved for treatment of relapsing form of MS (Dinkova-Kostova et al., 2018) and 
Edaravone for the treatment of ALS (Liddell, 2017). The precise mechanisms of how 
these compounds activate Nrf2 is not completely known, but they are thought to 
disrupt Keap1 or Keap1/Nrf2 interactions (Dinkova-Kostova et al., 2018). Further, 
compounds inhibiting GSK3β are able to activate Nrf2 and may be beneficial in 
treatment of mixed dementias since GSK3β is an important contributor to the 
hyperphosphorylation of tau, responsible for forming neurofibrillary tangles, one of the 
characteristic AD hallmarks (Gameiro et al., 2017). 
Relevant to the study of hypoperfusion/ischaemia, a recent study utilising the 2VO 
model in rats, find that Nrf2 activation using Sulforaphane ameliorates but, similar to 
the results in the current study, does not completely rescue cognitive impairment and 
white matter disruption (Mao et al., 2018). Similar cognitive results are seen in a 2VO 
study instead using Edaravone, although white matter integrity was not assessed 
(Zhang et al., 2017). Previous work in the BCAS model in mice, find that Nrf2 
activation using DMF improves white matter function, however without significantly 
improving white matter structure (Fowler et al., 2017). The specificity of these 
compounds for activation of Nrf2 has been disputed, and the development of more 
specific and effective pharmacological activators may prove more favourable. 
Although, the greater beneficial effects of already available Nrf2 activators in other 
disease models, such as Sulforaphane reducing infarct volume in experimental stroke 
(Zhao et al., 2006), or DMF in MS (Linker et al., 2011), suggests that alternative 
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therapeutic approaches should perhaps be explored in the context of cerebral 
hypoperfusion and VCI. 
Limitations, conclusion and future directions 
A limitation of the current study is the comparably more subtle pathology observed 
compared to previous studies and other models. To overcome this, carotid artery 
stenosis could be induced with one of the microcoils having a smaller diameter, hence 
producing slightly more severe reductions in cerebral blood flow. Alternatively, as the 
BCAS model is progressive, extending the time course would exacerbate pathology 
and perhaps reveal greater differences between wild type and GFAP-Nrf2 animals.  
Further, and as discussed in the previous chapter, transcriptomic analysis of mixed 
cell populations, albeit white matter-enriched samples, could be masking subtle and 
cell-specific changes (Swartzlander et al., 2018). Cell-isolation studies and more 
detailed analyses of a greater number of genes would provide more information than 
the current approach. A relatively recent approach called translating ribosome affinity 
purification (TRAP), utilises cell-specific ribosomal tags to isolate translating mRNA 
and thereby getting as close to a functional readout as currently possible using 
transcriptomic analysis (Heiman et al., 2014). Crossing these mice with mice 
overexpressing Nrf2 or repressing Keap1 could be used to investigate Nrf2 signalling 
following cerebral hypoperfusion in much greater detail.  
An additional consideration is whether GFAP is an appropriate promoter of Nrf2 in 
astrocytes. A novel astrocyte marker Aldh1l1 has been identified (Cahoy et al., 2008), 
frequently used as it is expressed by a much larger proportion of the astrocyte 
population. Aldh1l1 has already been used for astrocyte-specific targeting of the 
TRAP transgene described above (Morel et al., 2017) and may provide a better target 
for transgenic overexpression of Nrf2. Alternatively, Nrf2 despite being expressed at 
low levels in neurons, is abundant not only in astrocytes but endothelial cells and 
microglia too (Zhang et al., 2014), and global overexpression/activation of Nrf2 may 
result in increased protection of white matter and cognitive function when cerebral 
blood flow is reduced. 
Of further interest, both in terms of cerebral hypoperfusion and in particular as Nrf2 
is overexpressed specifically in astrocytes is the effect on astrocyte-blood vessel 
signalling. As previously introduced, astrocytes are considered essential to relay 
information about increased neuronal activity to the blood vessels to mediate activity-
depend increases in blood flow, also called neurovascular coupling (Iadecola and 
Nedergaard, 2007). Our group has previously demonstrated that age-related deficits 
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in neurovascular coupling can be detected using Laser speckle imaging during 
whisker stimulation (Duncombe et al., 2016) and unpublished data show that this can 
also be detected following 3 months of cerebral hypoperfusion. This technique was 
employed also in the current study but is technically very challenging and did not 
identify a difference in neurovascular function between groups. Hypoperfusion is 
hypothesised to induce vascular dysfunction via mechanisms of oxidative stress, as 
reactive oxygen species can reduce the bioavailability of the vascular tone regulator 
nitric oxide, as well as impair its function and ability to be produced (Pierini and Bryan, 
2015). Increased antioxidant and anti-inflammatory potential of astrocytes through 
increased Nrf2-signalling is therefore subsequently hypothesised to protect against 
hypoperfusion-induced neurovascular coupling deficits and future studies should aim 
to incorporate and refine this technique. 
Additionally worth noting, as briefly discussed in the previous chapter, is the 
potential influence of grey matter damage or neuronal dysfunction. Similar to the 
previous chapter, minimal ischaemic neuronal damage was observed in the 
hypoperfused animals (3/18: 2 wild type, 1 GFAP-Nrf2), however that does not reflect 
neuronal function such as synaptic plasticity, which to the best of our knowledge has 
not been investigated in mice following BCAS. However in rats it was recently reported 
that synaptic plasticity is perturbed by hypoperfusion (2VO) as measured by 
electrophysiology (long-term potentiation) and western blotting of synaptic proteins 
(Yao et al., 2019), indicating that this is a measure worth studied in the future. 
In conclusion, the results indicate that Nrf2 overexpression in astrocytes dampens 
hypoperfusion-induced astrogliosis and pro-inflammatory signalling in the optic tract 
and modestly reduces white matter disruption and cognitive impairment. This 
supports the hypothesis that astrocytic Nrf2 reduces pathology and subsequent 
cognitive impairment following cerebral hypoperfusion, however, since the effects of 
hypoperfusion aren’t completely abolished, additional mechanisms must be involved. 
Hypoperfusion studies find associations between increasing numbers of microglia and 
impaired white matter function and cognition (Fowler et al., 2017, Manso et al., 2017, 
Kitamura et al., 2017). Since these represent early changes there is a possibility that 
microglial proliferation drives white matter pathology when cerebral blood flow is 
compromised. The final chapter of this thesis will hence go on to investigate this 
hypothesis and the therapeutic potential of inhibiting microglial proliferation to improve 
white matter structure and cognitive function following BCAS-induced cerebral 
hypoperfusion. 
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Investigating the effect of inhibiting microglial 
proliferation in a mouse model of chronic 
cerebral hypoperfusion 




The studies in chapter 3-4 highlight that inflammation and oxidative stress 
contribute to the loss of white matter integrity and cognitive impairment following 
BCAS-induced cerebral hypoperfusion, as altered expression of the antioxidant and 
anti-inflammatory transcription factor Nrf2 impacted on structural and functional 
outcome. It would be of interest to next investigate the role of Nrf2 in microglia, as this 
cell type is largely implicated in the inflammatory response following BCAS. However, 
due to the lack of an available mouse model this thesis instead goes on to interrogate 
the role of microglial colony-stimulating factor 1 receptor (CSF1R) signalling to 
determine if modulating the microglial inflammatory response impacts on disease 
progression. 
Microglial numbers increase progressively following cerebral hypoperfusion, 
resulting from proliferation rather than migration or infiltration of peripheral 
macrophages (Manso et al., 2017). The extent of white matter dysfunction (as 
measured by electrophysiology) is closely associated with increasing microglial 
numbers, and white matter function is improved when the numbers of microglia are 
reduced (Manso et al., 2017, Fowler et al., 2017). Further, increasing number of 
microglia have also been associated with cognitive impairment following mild 
hypoperfusion (Kitamura et al., 2017). This suggests that microglia may drive the 
progressive disruption and dysfunction of myelinated axons following hypoperfusion, 
ultimately leading to cognitive impairment. Previous studies have used non-specific 
pharmacological anti-inflammatory approaches (minocycline (Manso et al., 2017) and 
DMF (Fowler et al., 2017)), but in order to specifically test the hypothesis that 
microglia drive the pathological changes more specific inhibition of microglia is 
required. The drug GW2580 is a kinase inhibitor which is highly selective for CSF1R, 
which when bound by its ligands stimulates survival, differentiation and proliferation 
of microglia (Conway et al., 2005). This drug is advantageous as it is reported not to 
affect the stable microglial population but inhibits its expansion (Gomez-Nicola et al., 
2013). GW2580 treatment has been shown to improve/slow down both grey and white 
matter degenerative diseases such as prion disease (Gomez-Nicola et al., 2013), 
Alzheimer’s disease (Olmos-Alonso et al., 2016) and multiple sclerosis (Crespo et al., 
2011), however it has yet to be investigated in the context of chronic cerebral 
hypoperfusion. 
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Hypothesis 
This study tests the hypothesis that microglial CSF1R signalling causes white 
matter disruption and cognitive impairment following BCAS-induced chronic cerebral 
hypoperfusion. 
 Aims 
In wild type mice treated with vehicle or GW2580 the aims are to: 
1. Assess cerebral blood flow to determine the extent of BCAS-induced cerebral
hypoperfusion
2. Assess white matter microglial proliferation and pro-inflammatory signalling one
week post-BCAS and determine whether GW2580-treatment inhibits these
3. Assess white matter microglia and astrogliosis 6 weeks post-BCAS
4. Assess white matter disruption 6 weeks post-BCAS
5. Assess spatial learning and memory 6 weeks post-BCAS
6. For the above measures determine whether chronic GW2580-treatment reduces
the effects of BCAS
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5.2 Materials and Methods 
 Experimental contributions 
The studies presented in this chapter were carried out by myself, Dr Jessica 
Duncombe and Joshua Beverley, Dr Edel Hennessey and Dr Juraj Koudelka. I 
performed laser speckle imaging, behavioural testing, white matter dissections, tissue 
processing/sectioning, immunostaining for GFAP and MAG, RNA extractions, 
quantitative PCR and all data analysis presented in this chapter. Dr Jessica 
Duncombe performed BCAS surgery, administered oral gavages, processed tissue, 
stained tissue from the chronic study for Iba1/BrdU and imaged all fluorescently 
stained sections. Joshua Beverley performed laser speckle imaging, behavioural 
testing, tissue sectioning, immunostaining for Iba1, slide scanner imaging and 
assisted with RNA extractions. Dr Edel Hennessey administered oral gavages, 
collected and processed tissue and stained tissue from the acute study for Iba1/BrdU. 
Dr Juraj Koudelka collected tissue for the chronic study. 
 Mice 
Wild type mice (C57Bl6/J) (n=106) were purchased from Charles River 
Laboratories (JAXTM- C57BL/6J) and randomly assigned surgical intervention as 
detailed in Table 5.1. Mean age 3 m 9 d (3 m 2d to 3 m 23 d), weighing on average 
29 g (23.1 – 33.8 g). Mice were studied acutely (1 week) and chronically (6 weeks) 
following BCAS or sham surgery. 
 Chronic cerebral hypoperfusion 
Mice underwent bilateral carotid artery stenosis (BCAS) or sham surgery, as 
described in 2.2. BCAS surgery was performed to induce chronic cerebral 
hypoperfusion, using one 0.16 mm and one 0.18 mm in diameter microcoil. Recovery 
following surgery is closely monitored for 72 hours and animals showing poor recovery 
are culled. Six animals in the first study and seven animals in the second study 
tolerated surgery poorly and were humanely culled by cervical dislocation (see Table 
5.1) 
 Laser speckle imaging to measure cortical cerebral blood flow 
Cortical cerebral blood flow (CBF) was measured at baseline, 24 hours and 6 days 
post-BCAS for the acute study and baseline, 24 hours and 6 weeks post-BCAS for 
the chronic study as described in 2.3. Laser speckle imaging was performed on all 
animals. 
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Study inclusion criteria and group assignment 
Laser speckle imaging was analysed after the second imaging session (baseline 
and 24 hour measurements) as described in 2.3.1, and animals displaying an average 
CBF reduction exceeding 35% from baseline were included in the final study. This 
excluded twelve animals from the acute study and nine animals from the chronic 
study. BCAS animals were then randomly assigned experimental treatment, balanced 
for magnitude of 24 hour CBF reduction as detailed in Table 5.1 and relevant figures. 
GW2580 administration 
GW2580 (LC Laboratories, PKC Pharmaceuticals Inc., USA) was administered by 
oral gavage or in diet as described in 2.5.1. For the chronic study where GW2580 was 
administered in diet, food intake was monitored and determined not to be different 
between treatment groups. 
5-Bromo-2’-deoxyuridine (BrdU) administration
5-Bromo-2‘-deoxyuridine (BrdU, B5002, Sigma-Aldrich) was administered by oral
gavage during the final three days as described in 2.5.2. 
Behavioural testing 
The Barnes maze was used to assess spatial learning and memory in the chronic 
study as described in 2.4.3. Behavioural testing commenced four weeks post-BCAS. 
Inclusion criteria described in 2.4.3.7 was applied highlighting one sham animal that 
was subsequently excluded from the study (Final numbers in Table 5.1 and relevant 
figure). 
Tissue collection and processing 
Animals were sacrificed by cervical dislocation and white matter was isolated as 
described in 2.6.2. The tissue was further processed manually for paraffin embedding 
as described in 2.6.5 and Table 2.3 and sectioned as described in 2.6.6. 
 Immunohistochemistry 
Performed according to 2.7.1-2.7.2. Details of antibodies used (anti-MAG, anti-
Iba1, anti-GFAP, anti-BrdU) can be found in Table 2.4. Immunohistochemistry was 
performed on 6µm coronal sections from all animals as detailed in Table 5.1 and 
relevant figures. 
 Image analysis 
DAB-stained sections (Iba1/GFAP) were imaged using an Axio Scan.Z1 slide 
scanner (x20, Zeiss, Germany). Fluorescently stained sections were as described in 
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2.8.1 and analysed by manual counting as described in 2.8.2. DAB-labelled images 
were analysed for percentage area of Iba1 and GFAP, and MAG was analysed by 
manual grading as described in 2.8.2 in the CC, IC and FI (Fig 2.3). Briefly, ImageJ 
software (v1.46, NIH, Bethesda, MD, USA) was used to apply a global manual 
threshold followed by quantification of the positive signal detected above the selected 
threshold. Applying exclusion criteria outlined in 2.8.3 resulted in no exclusions. Final 
numbers for each region and stain are detailed in Table 5.1 and relevant figures. 
  Transcriptomics 
Quantitative-PCR was performed on animals from the acute study (see Table 5.1). 
RNA extraction was performed as described in 2.9.1 using white matter enriched 
samples and RT-PCR and qPCR experiments as described in 2.9.2-2.9.3. Details of 
primers used (18s, C4) can be found in Table 2.5. Animal numbers and reference 
gene used are specified in the relevant figure. 
  Statistical analysis 
Repeated measures ANOVA was used to investigate group effects on CBF and 
escape latency in the learning and reversal phase of the Barnes maze (2.10.1). One-
sample t-test was used to test each group against chance (25%) during probe tests 
(2.10.4) and one-way ANOVA was used to investigate a group effect in all other data 
sets apart from MAG grade (2.10.3). Pearson’s correlation was used to investigate 
the relationship between Iba1 and GFAP (2.10.5). Kruskal-Wallis H test was used to 
analyse the MAG grade for white matter disruption (2.10.6). Spearman’s correlation 
was used to investigate the relationship between Iba1 and MAG (2.10.7). Data are 
presented as mean ± standard error of the mean (SEM) or as median with errors bars 
representing interquartile range (IQR) where non-parametric statistical analysis was 
used (specified in relevant figure legend). Statistical significance was determined at 
p<0.05. 
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Table 5.1 Number of mice in each group and experiment with details of exclusion 
BCAS Surgery Acute (1 week) Chronic (6 weeks) 
Sham 13 10 
BCAS 45 38 
Final group assignments 
Sham (Vehicle) 13 10 
BCAS vehicle 14 12 
BCAS GW2580 13 10 
Details of exclusion 
Poor recovery from BCAS surgery 6 (3 veh/3 GW) 7 (veh) 
<35% CBF reduction 12 (6 veh/6 GW) 9 (4 veh/5 GW) 
Behavioural testing Chronic (6 weeks) 
Sham (Vehicle) 9 
BCAS vehicle 12 
BCAS GW2580 10 
Details of exclusion 
Non-completion of task >50%/trials 1 
Immunohistochemistry 
All stains/regions Acute (1 week) Chronic (6 weeks) 
Sham (Vehicle) 13 9 
BCAS vehicle 14 12 
BCAS GW2580 13 10 
qPCR Acute (1 week) 
Sham (Vehicle) 13 
BCAS vehicle 14 
BCAS GW2580 13 




 GW2580-treatment dampens white matter microglial proliferation 
and pro-inflammatory signalling one week post-BCAS 
The first aim of the study was to assess the extent of microglial proliferation and to 
determine if GW2580 could alter this response one week post-BCAS. Initially CBF 
was measured using laser speckle imaging prior to, 24 hours and 6 days post-BCAS 
as previously described (3.3.1/4.3.1), to ensure that the extent of reduction was 
sufficient (>35%) to model cerebral hypoperfusion. 
BCAS surgery using one 0.18 and one 0.16 mm microcoil induced reductions in 
CBF of ~60%, whereas sham mice displayed relatively stable CBF over time (Fig 5.1). 
There was a significant effect of time (F(2,74)=217.6, p<0.0001) and group 
(F(2,74)=37.66, p<0.0001) and a significant interaction (F(2,74)=42.87, p<0.0001) (Fig 
5.1b). Post hoc tests found that BCAS reduced CBF in vehicle- and GW2580-treated 
animals both at 24 hours (p<0.001) and at 6 days (p<0.001) and there was no 
difference between groups at any time (p=1.00) (Fig 5.1b). This demonstrates that 
treatment with GW2580 does not influence resting CBF one week post-BCAS and 
that the effect of drug treatment can be assessed without confounding flow-related 
differences between groups. 
Immunofluorescent labelling of Iba1 and BrdU was used to assess the percentage 
of proliferating microglia in the corpus callosum one week post-BCAS (Fig 5.2a). The 
results show that the percentage of proliferating microglia was significantly different 
between the groups (F(2,37)=5.08, p=0.01), and post hoc analysis found that the BCAS 
vehicle group has significantly more proliferating microglia compared to shams 
(p=0.02). In contrast, the proportion of microglia proliferating in the BCAS GW2580 
group compared to shams missed accepted levels of statistical significance (p=0.06) 
(Fig 5.2b). The data indicate that GW2580-treatment reduces but does not completely 
inhibit microglial proliferation following one week of BCAS-induced cerebral 
hypoperfusion. 
Furthermore, because previous studies using GW2580 has reported a shift in 
inflammatory profiles following drug treatment (Gomez-Nicola et al., 2013, Olmos-
Alonso et al., 2016), we next measured the expression of the pro-inflammatory marker 
complement component 4 (C4), as this was demonstrated to increase following 
BCAS-surgery in the previous chapter of this thesis (see Results 4.3.6, Fig. 4.8). 
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Figure 5.1 Cortical cerebral blood flow is reduced post-BCAS. (a) Representative 
images of laser speckle flowmetry in sham, BCAS vehicle and BCAS GW2580 animals 
at baseline, 24 hours and 6 days. (b) BCAS surgery reduced CBF to a similar extent in 
both vehicle and GW2580 groups. Mean±SEM. ***p<0.001 (* indicates post hoc 
differences between sham and BCAS vehicle), ###p<0.001 (# indicates post hoc 
differences between sham and BCAS GW2580). 
C4 was shown to be significantly different between groups (F(2,37)=5.65, p=0.007) 
and post hoc analysis found significantly increased C4 in the BCAS vehicle group 
compared to shams (p=0.005) but not between the BCAS GW2580 group and shams 
(p=0.38) (Fig 5.2c). Together these data indicate that GW2580-treatment reduces 
microglial proliferation, and modestly dampens pro-inflammatory signalling compared 
to vehicle-treatment one week following moderate cerebral hypoperfusion. 
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◄Figure 5.2 GW2580 treatment dampens white matter microglial proliferation and
pro-inflammatory signalling one week post-BCAS. (a) Representative images of
Iba1/BrdU positive staining. Arrow represents Iba1 positive cells and arrowhead
represents Iba1/BrdU double positive cells. Scale bar 50 µm. (b) Percentage of
proliferating Iba1 positive cells in the corpus callosum is increased in the BCAS vehicle
group compared to shams whereas the BCAS GW2580 group missed accepted levels
of statistical significance. (c) Pro-inflammatory marker C4 is increased in the BCAS
vehicle group compared to shams but not in the BCAS GW2580 group. Dashed line
indicated WT sham mean. Mean±SEM. *p<0.05, **p<0.01.
Resting cortical cerebral blood flow is chronically reduced 
following bilateral carotid artery stenosis to a similar extent in 
GW2580- and vehicle-treated animals 
The acute study demonstrated that microglial proliferation and pro-inflammatory 
signalling was modestly modulated one week following moderate hypoperfusion using 
GW2580-treatment. The next aim was to undertake a chronic study over 6 weeks to 
investigate the long-term pathological and cognitive changes following moderate 
hypoperfusion and the ability to modulate these using GW2580 in diet. The extent of 
cerebral hypoperfusion was evaluated using laser speckle flowmetry prior to, 24 hours 
and 6 weeks following BCAS surgery as previously described (3.3.1/4.3.1). BCAS 
surgery (0.18 mm/0.16 mm microcoils) reduced CBF by ~50%, and sham mice 
displayed stable CBF over time (Fig 5.3). There was a significant effect of time 
(F(1.56,43.6)=164.85, p<0.0001) and group (F(2,28)=110.15, p<0.0001) and a significant 
interaction (F(3.11,43.6)=32.51, p<0.0001) (Fig 5.3b). Post hoc tests found that BCAS 
surgery reduced CBF in vehicle- and GW2580-treated animals at 24 hours (p<0.001) 
and at 6 weeks (p<0.001) post-surgery, but there was no difference between these 
groups (24 hours p=1.00, 6 weeks p=0.77) (Fig 5.3b). This demonstrates that 
treatment with GW2580 does not influence resting CBF following BCAS either acutely 
or chronically, and that the following results can be interpreted without confounding 
flow-related differences between groups. 




Figure 5.3 Cortical cerebral blood flow is reduced post-BCAS. (a) Representative 
images of laser speckle flowmetry in sham, BCAS vehicle and BCAS GW2580 animals 
at baseline, 24 hours and 6 days. (b) BCAS surgery reduced CBF to a similar extent in 
both vehicle and GW2580 groups. Mean±SEM. ***p<0.001 (* indicates post hoc 
differences between sham and BCAS vehicle), ###p<0.001 (# indicates post hoc 
differences between sham and BCAS GW2580). 
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GW2580-treatment prevents increases in white matter microglia 6 
weeks post-BCAS 
To determine whether GW2580-treatment was effectively inhibiting increases in 
white matter microglia, immunofluorescent and DAB staining of Iba1 was evaluated 
in the corpus callosum, fimbria and the internal capsule. Immunofluorescent staining 
was used to quantify the number of microglia/0.1mm2 as these could be corroborated 
by the nuclear DAPI label and DAB staining was quantified as percentage area 
(density) to include more information about activation state as activated microglia are 
reported to occupy a larger area than quiescent ones (Nayak et al., 2014). 
There was an overall group effect on the number of Iba1 positive cells/0.1mm2 in 
the corpus callosum (F(2,28)=5.19, p=0.01) and post hoc analysis identified a significant 
increase in microglia in the BCAS vehicle group compared to BCAS GW250 (p=0.01) 
(Fig 5.4a). Similarly, there was an overall group effect on the density of microglia in 
the corpus callosum (F(2,28)=5.42, p=0.01) and post hoc analysis found a significant 
increase in the BCAS vehicle group compared to both sham (p=0.03) and BCAS 
GW2580 groups (p=0.03) (Fig 5.4b). The density of microglia in the fimbria and 
internal capsule was not significantly altered in any group (F(2,28)=2.28, p=0.12, 
F(2,28)=1.74, p=0.19 respectively) (Fig 5.4c-d). These results demonstrate that 
microglia in the corpus callosum are increased in response to BCAS-induced chronic 
cerebral hypoperfusion, and that GW2580-treatment successfully prevents this 
upregulation. 




Figure 5.4 GW2580-treatment prevents increases in white matter microglia 6 
weeks post-BCAS. (a) Iba1/0.1mm2 in the corpus callosum is increased in the BCAS 
vehicle group but not the BCAS GW2580 group. (b) Iba1 percentage area in the corpus 
callosum in the BCAS vehicle group is increase compared to both sham and BCAS 
GW2580 (c)(d) Iba1 percentage area is not significantly altered in the fimbria and the 
internal capsule. Mean±SEM. *p<0.05. (e) Representative images of fluorescent 
Iba1/DAPI in the corpus callosum (f) Representative images of DAB Iba1 in the corpus 
callosum. Scale bar 50 µm. Dashed line indicates boundary of the corpus callosum. 
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GW2580-treatment inhibits white matter astrogliosis 6 weeks 
post-BCAS 
Glial fibrillary acidic protein (GFAP) was used to determine if inhibiting increases 
in microglia altered the extent of astrogliosis; quantified as percentage area in the 
corpus callosum, fimbria and internal capsule. There was a significant effect of group 
in the corpus callosum (F(2,28)=6.09, p=0.006) and post hoc tests found that the BCAS 
vehicle group displays significant astrogliosis compared to shams (p=0.01) and the 
BCAS GW2580 group (p=0.04) (Fig 5.5a). Similar to the microglial response, there 
was no significant difference between groups in the fimbria or the internal capsule 
(F(2,28)=1.81, p=0.18, F(2,28)=0.68, p=0.52 respectively) (Fig 5.5b-c). 
Figure 5.5 GW2580-treatment prevents white matter astrogliosis 6 weeks post-
BCAS. (a) Astrogliosis was increased in the BCAS vehicle group compared to shams 
and the BCAS GW2580 group. (b)(c) Astrogliosis is not significantly altered in the 
fimbria and the internal capsule.  Mean±SEM. *p<0.05. (d) Representative images of 
GFAP in the corpus callosum. Scale bar 50 µm. 
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In addition, the extent of astrogliosis in the corpus callosum had a strong positive 
correlation with increasing density of microglia in the same area (r=0.88, n=31, 
p<0.0001) (Fig 5.6). Together, these data demonstrate that BCAS-induced 
hypoperfusion causes astrogliosis in the corpus callosum, associated with increases 
in microglia, and that treatment with GW2580 successfully inhibits both. 
Figure 5.6 The extent of astrogliosis in the corpus callosum is positively 
correlated with increased density of microglia. The extent of astrogliosis 
(percentage area of GFAP) is positively correlated with increased density of microglia 
(percentage area of Iba1) in the corpus callosum. Mean, n=31. 
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GW2580-treatment protects against white matter disruption 6 
weeks post-BCAS 
Myelin associated glycoprotein (MAG) was used to asses white matter disruption 
as previously described in Chapter 3 (3.3.2) but due to increased background the 
severity of white matter disruption was quantified by a grading score between 0-3 
(none to extensive aberrantly accumulated MAG) for each side of the brain and 
summed to get a total scale of 0-6 for the corpus callosum, the fimbria and the internal 
capsule. There was a significant effect of group in the corpus callosum (X2(2)=8.62, 
p=0.01) and post hoc test found that the BCAS vehicle group displayed significant 
white matter disruption compared to shams (p=0.02) which was not detected between 
BCAS GW2580 and shams (p=0.72) (Fig 5.7a). Similarly, there was a significant 
effect of group in the fimbria (X2(2)=9.05, p=0.01) and post hoc tests found significant 
white matter disruption in the BCAS vehicle group compared to shams (p=0.04) and 
the BCAS GW2580 group (p=0.03) (Fig 5.7b). There was also a group effect in the 
internal capsule (X2(2)=7.98, p=0.02) where post hoc test again found significant 
white matter disruption in the BCAS vehicle group compared to shams (p=0.03) 
(5.7c).  
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◄Figure 5.7 GW2580-treament protects against white matter disruption 6 weeks 
post-BCAS. (a) White matter disruption in the corpus callosum was evident in the BCAS 
vehicle group. (b) The fimbria was similarly disrupted in the BCAS vehicle group as well 
as the (c) the internal capsule. There was no white matter disruption in the BCAS 
GW2580 group in any region. Median, bars represent IQR. *p<0.05. (d) 
Representative images of MAG in the corpus callosum. Scale bar 50 µm. 
            
Further, the extent of white matter disruption in the corpus callosum was positively 
correlated with increased density of microglia in the same area (r=55, n=31, p=0.001) 
(Fig 5.8). Collectively, these results demonstrate that treatment with GW2580 protects 
against white matter disruption resulting from BCAS-induced hypoperfusion, and that 
the extent of disruption is associated with increased density of microglia. 
 
Figure 5.8 The severity of white matter disruption in the corpus callosum is 
positively correlated with increased density of microglia. The severity of white 
matter disruption (MAG grade) is positively correlated with increased density of 
microglia (percentage area of Iba1) in the corpus callosum. Mean, n=31. 
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GW2580-treatment protects against chronic hypoperfusion-
induced impairment in spatial learning 
Spatial learning and memory and cognitive flexibility was assessed using the 
Barnes maze after four weeks of cerebral hypoperfusion. Spatial learning was 
quantified as the time taken for the animal to find the correct hole and enter the escape 
chamber, i.e. escape latency, and plotted over consecutive trials. There was a 
significant effect of time (F(3.34,93.51)=65.08, p<0.0001) indicative of learning (Fig 5.9a). 
There was also an overall significant effect of group (F(2,28)=13.12, p<0.0001) and post 
hoc tests identified overall significantly greater escape latency in the BCAS vehicle 
group compared to shams (p<0.001) (Fig 5.9a) demonstrating an impairment in 
spatial learning induced by hypoperfusion. Remarkably, the BCAS GW2580 group 
displayed very similar escape latency compared to shams, which was significantly 
lower than the BCAS vehicle group (p=0.001) (Fig 5.9a), indicating that GW2580 
protects against hypoperfusion-induced impairment in spatial learning.  
Spatial reference memory was quantified as proportion of time spent in the 
quadrant where the escape chamber was previously located (probe test). The sham 
group spent significantly more time than chance in the target quadrant (p<0.001), 
whereas the BCAS vehicle group narrowly missed accepted levels of statistical 
significance (p=0.06) (Fig 5.9b), indicating a trend of impairment in spatial memory. 
The BCAS GW2580 group spent significantly more time than chance in the target 
quadrant (p=0.049), however performance was similar between both BCAS groups 
and there was no overall difference between any of the groups (F(2,28)=2.41, p=0.11) 
(Fig 5.9b). 
Cognitive flexibility was assessed similar to spatial learning and memory with 
reversed location of the escape chamber (180º), training animals for an additional 3 
days (2 trials/day). There was a significant effect of time (F(2,56)=31.98, p<0.0001) 
during the reversal phase indicative of learning (Fig 5.9c). The BCAS vehicle group 
appears to perform worse than sham and BCAS GW2580 groups, however the effect 
of group narrowly misses accepted level of statistical significance (F(2,28)=3.28, 
p=0.053) (Fig 5.9c). During the reversal probe only the sham group spend significantly 
more time than chance in the target quadrant (p=0.02, BCAS vehicle p=0.08, BCAS 
GW2580 p=0.18) (Fig 5.9d), although performance of the sham group compared to 
the initial probe is worse, indicating the increased complexity of the reversal task. 
There was no overall difference between groups in the reversal probe (F(2,28)=0.49, 
p=0.62). Collectively the results demonstrate that GW2580-treatment effectively 
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protects against hypoperfusion-induced impairment in spatial learning, whereas 
spatial reference memory was similar between vehicle and GW2580-treated groups. 
There are indications that cognitive flexibility is improved by GW2580 treatment but 
there was no effect of the drug on reference memory following the reversal phase.  
 
Figure 5.9 GW2580-treatment protects against hypoperfusion-induced 
impairment in spatial learning. (a) There was an overall effect of time indicating 
learning and the BCAS vehicle group had increased escape latency compared to shams 
indicating impaired spatial learning. Escape latency was similar between BCAS 
GW2580 and shams indicating that GW2580 protects against spatial learning 
impairment. (b) Sham and BCAS GW2580 groups spent more time than chance in the 
target quadrant whereas the BCAS vehicle group missed accepted levels of statistical 
significance. There was no overall difference between groups. (c) There was an overall 
effect of time on escape latency during the reversal phase but no group effect. (d) Only 
the sham group spent more time than chance in target quadrant during the reversal 
probe test and there was no overall difference between the groups. Dashed line 
indicates chance level (25%). Mean±SEM. ***p<0.001 (* indicates post hoc differences 
between BCAS vehicle and sham groups), ##p<0.01 (# indicates post hoc differences 
between BCAS vehicle and BCAS GW2580 groups), $p<0.05, $$$p<0.001 ($ indicates 
difference between each group and chance level). 
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5.4 Discussion 
The current study was designed to investigate whether microglial CSF1R signalling 
contributes to white matter disruption and cognitive impairment following cerebral 
hypoperfusion. The results demonstrate that treatment with GW2580 following BCAS 
acutely reduced microglial proliferation and pro-inflammatory signalling modestly and 
chronically inhibited increases in white matter microglia and astrogliosis, preserved 
white matter structure and protected against hypoperfusion-induced impairment in 
spatial learning. 
Resting cortical cerebral blood flow is acutely and chronically 
reduced following bilateral carotid artery stenosis to a similar 
extent in GW2580- and vehicle-treated animals 
The overarching aim of the study was to assess the effect of inhibiting microglial 
CSF1R signalling on white matter disease progression and cognition. In order to test 
this a robust increase in microglia was warranted. To ensure this, the BCAS model 
was modified (compared to chapter 3/4) to utilise a mixed coil strategy (0.16/0.18 mm) 
and strict inclusion criteria of >35% CBF reduction at 24 hours post-BCAS. Consistent 
with previous reports (Fowler et al., 2017, Miki et al., 2009), this produced a reduction 
in CBF of 50-60% at 24 hours which persisted over the one and the six week time 
points measured. Importantly, the results demonstrate comparable CBF reduction 
between GW2580- and vehicle-treated BCAS groups indicating that GW2580 
treatment does not affect the CBF response to BCAS surgery and hence allowing 
subsequent results to be assessed without confounding flow-related differences. 
GW2580-treatment dampens microglial proliferation and pro-
inflammatory signalling one week following bilateral carotid 
artery stenosis 
After BCAS had been determined to induce sufficient reductions in CBF the next 
aim was to evaluate the microglial response and whether GW2580 treatment inhibited 
microglial proliferation. Consistent with previous studies (Fowler et al., 2017), the 
current study saw an increase in white matter microglia in the corpus callosum one 
week post-BCAS, and to determine the effect of GW2580 treatment on microglial 
proliferation, BrdU was administered during the final 3 days (incorporates into DNA of 
actively proliferating cells). 
The data demonstrates that treatment with GW2580 does not inhibit microglial 
proliferation in the corpus callosum one week post-BCAS in all animals, however there 
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was statistically no difference between the sham and GW2580-treated group. These 
results suggest that treatment with GW2580 in the current study induced an all-or-
nothing inhibitory response on microglial proliferation. This is in contrast with previous 
studies administering GW2580 where microglial proliferation was reduced by ~50% 
in models of prion disease (Gomez-Nicola et al., 2013) and AD (Olmos-Alonso et al., 
2016) using the same dose (75mg/kg), although only mean±SEM was reported 
without individual data points and hence the distribution of this response across the 
group is impossible to interpret. 
Further, these studies demonstrate that GW2580 shifts the overall inflammatory 
profile from pro- to anti-inflammatory (Gomez-Nicola et al., 2013, Olmos-Alonso et al., 
2016) and the pro-inflammatory marker C4 was therefore measured using qPCR. 
While C4 was significantly upregulated only in the vehicle-treated hypoperfused group 
compared to the sham this result was driven by a small number of animals with 
considerably higher expression. Additional inflammatory markers would need to be 
investigated to determine if the GW2580 at one week following moderate 
hypoperfusion alters the inflammatory profile consistent with the published literature. 
Nonetheless, it was determined that since GW2580 inhibited microglial proliferation 
in a subset of animals, the effect of GW2580 would be studied longer term (6 weeks) 
to interrogate the effect of chronic CSF1R inhibition on white matter pathology and 
cognition post-BCAS. 
 GW2580-treatment prevents chronic hypoperfusion-induced 
increases in white matter microglia 
Consistent with previous studies of acute severe (Fowler et al., 2017) and chronic 
mild cerebral hypoperfusion (Manso et al., 2017, Kitamura et al., 2017) there was a 
significant increase in microglia in the corpus callosum in vehicle-treated animals 6 
weeks post-BCAS. The next aim was therefore to determine the efficacy of GW2580 
administration in diet over the same period. Similar to the acute study, BrdU was 
administered during the last 3 days but there was no evidence of proliferating 
microglia at this time in any group, suggesting that the rate of proliferation is higher 
acutely following BCAS surgery. Instead number and density of Iba1 positive cells in 
the corpus callosum was assessed, and density of Iba1 positive cells in the fimbria 
and internal capsule. Remarkably, chronic treatment with GW2580 completely 
inhibited hypoperfusion-induced increases in both microglial number and density in 
the corpus callosum. 
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Compared to previous studies administering GW2580 chronically (1-3 months) at 
the same doses, either by daily oral gavage (75mg/kg) or ad libitum in chow (0.1%), 
the results in the current study demonstrate more successful inhibition of microglial 
upregulation, however without further experiments this cannot be attributed to an 
inhibition of proliferation. In models of prion disease, AD, ALS and spinal cord injury 
(SCI), GW2580 treatment reduced microglial proliferation by ~50% but was compared 
to wild type controls still elevated (about 2-fold), shown using BrdU/ErdU (Gomez-
Nicola et al., 2013, Olmos-Alonso et al., 2016, Martinez-Muriana et al., 2016, Gerber 
et al., 2018). It was also noted that the extent of inhibition following GW2580-treatment 
in the current study was more effective chronically vs acute. There may be 
explanations for this. 
Firstly, the models that GW2580 has been previously studied in are all far more 
severe than chronic cerebral hypoperfusion. That would be expected to induce a 
greater release of inflammatory molecules such as CSF1 and IL34 which bind to 
CSF1R to induce proliferation of microglia. GW2580 acts as a competitive inhibitor at 
the ATP pocket of CSF1R and as many tyrosine kinases have similar structure it is 
possible that it would show nonspecific kinase inhibition, however, (Conway et al., 
2005) showed that at least in vitro GW2580 was inactive against 26 kinases. One 
possibility is that the bioavailability of GW2580 following the current treatment 
paradigms is insufficient to completely inhibit the binding of CSF1/IL34 to its receptor 
due to its action as a competitive antagonist. In the cerebral hypoperfusion model, a 
large initial microglial proliferative event may be necessary to perpetuate the chronic 
inflammation which in turn is detrimental to white matter structure and function. In 
contrast, prions, amyloid, SOD1 (superoxide dismutase) deficiency and SCI may by 
different means induce continuous production of inflammatory mediators that 
compete with GW2580. That would explain why GW2580 is unable to completely 
inhibit microglial proliferation in these models as well as acutely following BCAS, but 
that by 6 weeks post-BCAS GW2580-treated animals display levels of microglia 
similar to wild type controls. Experimental evidence in support of this includes early 
detectably increases in a battery of pro-inflammatory genes in white matter in the 
hypoperfusion model (72 hours post-BCAS) (Reimer et al., 2011), which are 
demonstrably more difficult to detect at later time points (6 weeks) (Manso et al., 
2017). In contrast, the prion model displays robust increases in pro-inflammatory 
genes such as IL1β, CSF1 and IL34 at 18 weeks post-inoculation (Gomez-Nicola et 
al., 2013), similarly observed in 9 month old AD mice (Olmos-Alonso et al., 2016). 
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However, of note, the levels of CSF1 and IL34 have not been measured following 
BCAS which would be required before this explanation can be verified. 
Secondly, an alternative explanation may be that microglial apoptosis in the 
GW2580-treated group accounts for the apparent greater efficacy in the chronic 
compared to the acute study. It was recently shown that the microglial population self-
renews by coupled proliferation and apoptosis at a rate estimated to replace the entire 
population in about 3 months (Askew et al., 2017). An experiment administering 
GW2580 to wild type animals for 3 months found reduced number of microglia (Askew 
et al., 2017) suggesting that CSF1R is involved in this homeostatic proliferative 
mechanism. The proliferation/apoptosis dynamics of the microglial population 
following cerebral hypoperfusion has not been investigated, and there may be 
hypoperfusion-driven alterations in the rate of apoptosis which go undetected by 
comparably greater rates of proliferation. This could be tested by a time course study 
employing BrdU administration and a TUNEL assay. 
Even so, the data demonstrates successful inhibition of the hypoperfusion-induced 
white matter microglial response using GW2580, and so the next aim was to assess 
the effect of this inhibition on the wider inflammatory response and on white matter 
disruption and cognition. 
 GW2580-treatment inhibits chronic hypoperfusion-induced white 
matter astrogliosis 
Because the previous chapters of this thesis detects significant astrogliosis 
following mild chronic hypoperfusion the effect of inhibiting CSF1R signalling in 
microglia on white matter astrocytes was interrogated post-BCAS. The results 
demonstrate that astrogliosis is increased in the corpus callosum post-BCAS and that 
this is inhibited by treatment with GW2580, and that this response is positively 
correlated with increasing density of microglia. Following treatment with GW2580, 
only one previous study reported the effects on astrocytes. Gerber et al. (2018) found 
reduced astrocytosis in several parts of the spinal cord following GW2580 
administration in SCI, however due to lack of uninjured controls it is impossible to say 
if this reduction was comparable to that observed in the current study. 
These data, and the fact that astrocytes have been shown not to express CSF1R 
(Gomez-Nicola et al., 2013), indicates that CSF1R-mediated microglial upregulation 
likely resulting from proliferation following cerebral hypoperfusion may be required to 
induce reactive astrogliosis. This would be consistent with a recent study by Liddelow 
et al. (2017) that proposes that secreted microglial factors are responsible for the 
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induction of astrogliosis. Interestingly they argue that the type of stimuli that induces 
the microgliosis (e.g. ischaemia/systemic inflammation) determines if the reactive 
astrocytes will assume a harmful or protective phenotype (Liddelow et al., 2017, 
Zamanian et al., 2012). Alternatively, in the current study, the effect on astrogliosis 
may be indirectly mediated via an overall reduction in pro-inflammatory signalling 
since astrocytes, similar to microglia, are known to be dynamic responders to their 
environment (Sofroniew and Vinters, 2010). Teasing out the specific cell-to-cell 
interactions is difficult with the current experimental paradigm but could be addressed 
using cell isolation studies and transcriptomics as previously discussed. The 
inflammatory response of both cell types is incredibly complex as they respond to and 
produce many of the same molecules (Sofroniew, 2014b), however recent studies are 
beginning to shed some light on signals mediating microglia/astrocyte crosstalk 
(Rothhammer et al., 2018, Liddelow et al., 2017, Yun et al., 2018). The converse of 
the current experiment would be to specifically inhibit astrogliosis and study the effect 
on microglia. However, because astrocyte reactivity can be induced by such a vast 
number of triggers; pro-inflammatory molecules (TNFα, IL1β), cell damage, death and 
ischaemia (ATP, ROS, RNS) and neuronal hyperactivity (Glutamate) (Sofroniew and 
Vinters, 2010), finding one such agent may prove problematic. 
Regardless, the data demonstrate that inhibiting increases in white matter 
microglia following BCAS using a microglia-specific drug efficiently inhibits increases 
in white matter astrogliosis, ultimately blocking the cellular inflammatory response 
observed when cerebral perfusion is reduced. The next question is what effect does 
this have on white matter pathology and cognition. 
GW2580-treatment protects against chronic hypoperfusion-
induced white matter disruption 
The next aim was to determine the effect of GW280 on white matter disruption 
post-BCAS. Consistent with previous studies (Coltman et al., 2011, Holland et al., 
2011, Reimer et al., 2011, McQueen et al., 2014, Kitamura et al., 2017), BCAS 
induced white matter disruption in the corpus callosum, fimbria and internal capsule 
and treatment with GW2580 protected against hypoperfusion-induced white matter 
disruption in all regions studied. Increasing density of microglia in the corpus callosum 
was positively correlated with progressive white matter disruption in the same area. 
This indicates that upregulation and activation of white matter microglia is actively 
contributing to the pathological disruption of myelinated axons following chronic 
hypoperfusion. This is consistent with previous work that find close associations 
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between number of microglia and impaired white matter structure and function 
(Manso et al., 2017, Fowler et al., 2017, Kitamura et al., 2017). This is the first line of 
evidence demonstrating the direct contribution of microglia to white matter disruption 
following chronic cerebral hypoperfusion using highly selective pharmacological 
inhibition of microglial proliferation. 
The study by Fowler et al. (2017) reported that treatment with the Nrf2-activating 
compound DMF following severe hypoperfusion reduced microglial number and 
improved white matter function (measured by electrophysiology) but surprisingly did 
not reduce white matter disruption. This may be because white matter microglia were 
not restored to sham levels as observed in the current study. Manso et al. (2017) 
demonstrated that increasing numbers of microglia following mild hypoperfusion was 
associated with increasing white matter disruption, reduced axonal node length and 
impaired white matter function. Using the generic anti-inflammatory drug Minocycline, 
microglial proliferation was reduced (almost to sham levels) and white matter function 
was restored to sham levels, however white matter structure following drug treatment 
was not assessed. 
Microglia are thought to be detrimental to white matter and oligodendrocytes by 
releasing cytokines and free radicals, and by sustaining inflammation through antigen-
presentation (Howell et al., 2010). Treatment with the drug fingolimod which shifts 
microglia toward an anti-inflammatory phenotype saw partially improved spatial 
working memory and white matter structure following hypoperfusion (Qin et al., 2017), 
suggesting pro-inflammatory signalling by microglia contributes to white matter 
disruption. GW2580 treatment has similarly been demonstrated to shift microglia from 
a pro- to an anti-inflammatory phenotype in models of prion disease and AD (Gomez-
Nicola et al., 2013, Olmos-Alonso et al., 2016). Proteomic or transcriptomic analysis 
of the inflammatory milieu in the current study could be used to investigate if GW2580 
is similarly shifting microglial phenotype in addition to inhibiting their upregulation. 
There are a number of mechanisms whereby inhibiting microglial upregulation 
using GW2580 may protect white matter following cerebral hypoperfusion. The 
current study went on to assess the effect of microglial CSF1R signalling on cognition. 
 GW2580-treatment protects against chronic hypoperfusion-
induced impairment in spatial learning 
Because white matter disruption is thought to underlie cognitive impairment the 
next aim was to assess spatial learning and memory, to determine the effect of 
microglial CSF1R signalling on cognition. The data demonstrate that cerebral 
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hypoperfusion induced an impairment in spatial learning and reference memory. This 
is firstly consistent with the impairment in spatial working memory detected in the first 
two chapters of this thesis and previous studies using the radial arm maze (Shibata 
et al., 2007, Coltman et al., 2011). Secondly, impairments in reference memory 
following mild cerebral hypoperfusion has previously not been detected until 5-6 
months post-BCAS (Holland et al., 2015, Nishio et al., 2010). This suggests that by 
increasing the severity of cerebral hypoperfusion this also induces progressively more 
severe cognitive deficits, however different behavioural tests were utilised and as 
such cannot be reliably compared. 
In agreement with the hypothesis, treatment with GW2580 protected against 
hypoperfusion-induced impaired spatial learning, but only displayed modest 
protection of spatial reference memory. The advantage of using the Barnes maze is 
that spatial learning, also referred to as learning working memory, could be assessed 
alongside spatial reference memory (Sharma et al., 2010). The observed protection 
is likely a result of the preservation of white matter structure as spatial learning and 
working memory is dependent on the integrity of the white matter circuitry to ensure 
efficient communication between different brain regions (Shibata et al., 2007, Coltman 
et al., 2011). Spatial reference memory on the other hand is suggested to be more 
hippocampal-dependent (Nishio et al., 2010, Sharma et al., 2010). The hippocampus, 
being connected via myelinated axons, is also dependent on good white matter 
integrity but there may be alternative mechanisms influencing cognition in this study, 
for example neuronal functions required for memory. As discussed in previous 
chapters, longer term hypoperfusion results in hippocampal neuronal damage and 
atrophy and it is a possibility that neuronal alterations that influence memory are 
changing alongside the detected white matter disruption. For example, if synaptic 
plasticity is impaired such as in rats following 2VO (Yao et al., 2019), this would be 
expected to influence the ability to remember the position of the escape chamber 
during the probe test and it may be possible that treatment with GW2580 preserves 
white matter structure more efficiently than neuronal function. Olmos-Alonso et al., 
(2016) found using a T-maze that short term memory, very similar to spatial learning 
(learning working memory) in this context, was improved following treatment of 
GW2580 in APP/PS1 mice, which is consistent with the current results. Further, Luo 
et al. (2013) report expression of CSF1R on a small subset of hippocampal and 
cortical neurons, and find that activation of the receptor is associated with protection 
against excitotoxic insult and increased neuronal survival. GW2580-treatment 
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following cerebral hypoperfusion may therefore inhibit CSF1R signalling on 
hippocampal neurons causing dysfunction and/or damage. Minimal neuronal damage 
was observed using haematoxylin and eosin (5/22 hypoperfused animals), but 
interestingly only occurred in vehicle-treated animals. This suggests that GW2580 
may be neuroprotective following BCAS although the results from the probe test 
suggests that this may not have subsequently protected function. However, it does 
highlight the importance of considering potential non-microglial effects of inhibiting the 
activity of CSF1R using GW2580. Future studies incorporating electrophysiology to 
measure long-term potentiation may shed more light on the role of synaptic 
plasticity/neuronal function following spatial learning and memory following BCAS 
with and without GW2580 treatment. 
A similar pattern of performance was observed during the reversal phase which 
tests cognitive flexibility and executive function (O'Leary and Brown, 2013). There 
was an indication that hypoperfusion induced an impairment in learning the new 
position of the escape chamber, whereas drug-treated animals performed similar to 
shams. Only shams displayed intact memory of the new position, possibly indicating 
more beneficial effects of the drug on learning rather than memory.  
Selective protection of spatial learning as opposed to reference memory may be of 
clinical importance. VCI is characterised by impairments in cognitive function 
depending on good white matter integrity, e.g. such as speed of processing (de Groot 
et al., 2000), however as the disease progresses memory is also known to be 
impaired (Skrobot et al., 2017). It is therefore important to understand how inhibiting 
microglial upregulation via CSF1R may influence cognition early versus late in the 
disease progression and if there are mechanisms involved in memory impairment in 
VCI beyond the disruption of white matter a combination of treatments may be 
required. 
Nonetheless, the data demonstrate complete protection against hypoperfusion-
induced spatial learning impairment, consistent with the preservation of white matter 
structure and relevant to human VCI. This is in support of the hypothesis that 
microglial upregulation via CSF1R signalling causes white matter disruption and 
cognitive impairment following BCAS-induced chronic cerebral hypoperfusion. 
 Potential mechanisms 
Excessive phagocytosis of white matter components may directly contribute to 
white matter disruption in age and following hypoperfusion (Raj et al., 2017), but 
reduced phagocytosis may also be detrimental to white matter integrity indirectly via 
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increased burden of neurotoxic products such as myelin debris which may exacerbate 
further inflammation (Chitu et al., 2016). GW2580 has previously been reported to be 
beneficial in models of multiple sclerosis (Crespo et al., 2011, Borjini et al., 2016). 
While both studies saw improved clinical scores with the drug treatment, and Crespo 
et al. (2011) attributed this to reduced macrophage infiltration and proinflammatory 
signalling, neither quantified the extent of white matter disruption nor investigated 
mechanisms beyond the inflammatory response. It is currently unknown how 
GW2580 affects alternative microglial functions such as phagocytosis, though in vitro 
application of CSF1 stimulates phagocytosis of amyloid by primary human microglia 
(Chitu et al., 2016) suggesting that inhibiting CSF1 receptor kinase activity through 
GW2580 may reduce phagocytosis. Assessing phagocytic activity of microglia in the 
current study could be carried out using immunohistochemical approaches; for 
example Lysosome-associated membrane protein 2, or in future studies by isolating 
microglia for in vitro functional assays or transcriptomic analysis such as single-cell 
RNA sequencing. The latter would provide a tremendous amount of information 
regarding the microglial response to cerebral hypoperfusion and treatment of 
GW2580, aiding our understanding of the pathophysiological mechanisms involved in 
the disruption of white matter. Microglial responses to hypoperfusion are exacerbated 
in aged mice, associated with worse cognitive performance and white matter integrity 
(Wolf et al., 2017), demonstrating that age and cerebrovascular disease 
synergistically contribute to VCI. It would be of interest to study the effect of GW2580 
post-BCAS in aged mice, to interrogate if white matter disruption and spatial learning 
could be similarly protected. Raj et al. (2017) studied white matter microglia from aged 
mice and reported increases not only in pro-inflammatory gene signalling but also 
phagocytosis-associated genes and alterations in genes associated with lipid 
homeostasis.  
In addition and as previously discussed, white matter hypoxia evident following 
cerebral hypoperfusion (Duncombe et al., 2017) enhances inflammation through 
increased NF-κB signalling (Eltzschig and Carmeliet, 2011). Since inflammation in 
turn exacerbates hypoxia by monopolising available resources (Eltzschig and 
Carmeliet, 2011), it is possible that inhibiting microglial proliferation via CSF1R may 
reduce hypoxia and contribute to the preservation of white matter and spatial learning 
following cerebral hypoperfusion. Early axon-glial disruption (Reimer et al., 2011) and 
reduced number of oligodendrocytes are evident post-BCAS, however since 
oligodendrocyte pools are demonstrated to have restorative potential (McQueen et 
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al., 2014) it is possible that GW2580 treatment by reducing inflammation allows for 
this response to enable white matter regeneration and prevent further damage. 
 Limitations, conclusion and future directions 
The current study, while presenting encouraging results, is limited by the lack of 
mechanistic insight.  
Firstly, as a result of our experimental design we were unable to detect microglial 
proliferation in either BCAS group and hence cannot conclude that GW2580 
specifically inhibits or reduces microglial proliferation as reported by other groups 
(Gomez-Nicola et al., 2013, Olmos-Alonso et al., 2016, Martinez-Muriana et al., 2016, 
Gerber et al., 2018). In order to determine that this is the case also following cerebral 
hypoperfusion an alternative BrdU treatment regime would need to be employed. 
Nonetheless, we are able to conclude that microglial upregulation via CSF1R is a 
driver of white matter pathology and cognitive impairment following cerebral 
hypoperfusion, as treatment with GW2580 successfully inhibits this increase in white 
matter microglia. However, whether this is driven by modulation of the inflammatory 
milieu, phagocytic activity or white matter hypoxia remains to be determined. 
Additionally, elucidating cell-to-cell interactions between microglia and astrocytes and 
other cell types of the neuro-gliovascular unit is essential to fully understand the 
pathophysiological mechanisms involving white matter disruption following cerebral 
hypoperfusion. Recent studies suggest that both microglia and astrocytes constitute 
diverse, heterogeneous populations (Grabert et al., 2016, John Lin et al., 2017, Morel 
et al., 2017), which display distinct ageing phenotypes such as increased 
inflammatory gene expression (Soreq et al., 2017, Boisvert et al., 2018). This 
highlights the need to study the therapeutic potential of inhibiting microglial 
proliferation in older animals, and to better characterise sub-cellular populations 
responsible for detrimental or protective pathophysiological processes. Employing 
newly developed cell-isolation techniques such as concurrent brain cell type 
acquisition (Swartzlander et al., 2018) and highly sophisticated transcriptomic and 
phenotypic analyses will be critical to increase our understanding of the mechanisms 
involved. 
Tyrosine kinase inhibitors have been extensively used for the treatment of cancers 
which is promising for the use of GW2580 in a clinical setting, however as these are 
sometimes associated with adverse effect including liver injury, thought to result from 
inhibited oxidative metabolism and glycolysis (Mingard et al., 2018), careful study of 
the potential ‘off-targets’ will need to be included in future investigations. 
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All in all the data presented here forms a scientific basis for the use of CSF1 
receptor tyrosine kinase inhibitors that target microglial proliferation as a potential 
treatment of chronic inflammation and white matter disruption in cerebrovascular 
disease and dementia. 
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General discussion
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6.1 Implications for future research 
In summary, the work herein demonstrates that cerebral hypoperfusion induced by 
bilateral carotid artery stenosis in mice increases microglial numbers and astrogliosis, 
disrupts white matter and impairs cognition (Fig 6.1). 
The first two chapters of this thesis utilised genetic approaches to investigate the 
contribution of the Nrf2 pathway in white matter pathology and cognitive impairment 
when cerebral blood flow is reduced. The results demonstrate that Nrf2 signalling is 
involved in the pathophysiological response following cerebral hypoperfusion, as 
white matter pathology and microgliosis are exacerbated in Nrf2-/- mice compared to 
wild types (Table 6.1). Further, astrocyte-specific overexpression of Nrf2 is associated 
with protection of white matter and cognitive function which is associated with reduced 
pro-inflammatory signalling (Table 6.1). However, the reduced/absent expression of 
Nrf2 did not result in a further functional impairment despite exacerbated pathology 
Figure 6.1 Diagram of alterations observed following reductions in cerebral blood 
flow. Following blood flow reductions microglial numbers increase and astrocytes become 
activated in the white matter leading to white matter disruption and cognitive impairment. 
(Diagram created with BioRender.com)  
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and microgliosis, and the magnitude of protection resulting from astrocytic Nrf2 
overexpression was modest. A few conclusions can be drawn from these results. One, 
the Nrf2 KO study was underpowered in regard to homozygous knock out mice which 
resulted in the failure to determine if knocking Nrf2 out had a functional outcome. Two, 
superior models to GFAP-Nrf2 mice may be more efficient for evaluating the 
therapeutic potential of Nrf2. Or three, additional/alternative mechanisms of 
inflammation/oxidative stress are contributing to the disruption of white matter 
structure and function. Additional studies comparing a larger number of Nrf2-/- mice to 
wild type mice and alternative models of activating/overexpressing Nrf2 would need 
to be carried out to address conclusion one and two. However, the third conclusion 
was explored in the final chapter of this thesis. 
Table 6.1 Summary of results of BCAS and BCAS + experimental intervention 
BCAS BCAS + Nrf2-/- BCAS + GFAP-Nrf2 BCAS + GW2580 
WHITE MATTER MICROGLIOSIS + + + + - - 
WHITE MATTER ASTROGLIOSIS + + - - -
WHITE MATTER DISRUPTION + + + - - - 
COGNITIVE IMPAIRMENT + + - - 
The final chapter details an investigation of the hypothesis that increases in 
microglia, a characteristic both of human VCI and cerebral hypoperfusion in mice, via 
CSF1R-signalling is an early driver of white matter pathology which causes 
subsequent cognitive impairment. In support of this hypothesis, pharmacological 
inhibition of CSF1R signalling using the tyrosine kinase inhibitor GW2580 protected 
against white matter disruption and preserved spatial learning following cerebral 
hypoperfusion (Table 6.1). Inhibiting the upregulation of microglia was further 
associated with reduced white matter astrogliosis suggesting that the overall 
inflammatory response was prevented. These results are encouraging as they provide 
robust evidence of an inflammatory mechanism involved in the disruption of white 
matter structure and function by cerebral hypoperfusion, which is amenable to 
modulation. A large number of questions remain as to how microglial increases lead 
to disruption of white matter, for example which specific microglial functions are 
responsible and what the effect and contribution of other cell types is. Cell-isolation 
studies should aid in answering these. One of the most important questions that needs 
to be answered is what the therapeutic potential of inhibiting microglial CSF1R-
148 | C H A P T E R  6  G E N E R A L  D I S C U S S I O N  
 
 
signalling is when an inflammatory response is already established, as would be 
expected in the human condition. Further, all studies reported in this thesis were 
carried out using adult mice, and as previously discussed, profound changes to 
microglia/astrocyte transcriptomes (Grabert et al., 2016, Soreq et al., 2017, Boisvert 
et al., 2018) and reductions in cell-signalling such as Nrf2 (Ungvari et al., 2011a) occur 
with age which renders the brain more vulnerable to damage and dysfunction. It is 
therefore essential that future studies are carried out in older animals, especially as 
these have already been observed to show a more severe inflammatory response to 
cerebral hypoperfusion (Wolf et al., 2017). 
It is also imperative to acknowledge that the results from this thesis and other 
cerebral hypoperfusion studies reflect only one aspect of VCI, which is in an incredible 
complex and heterogeneous condition. Pathological changes with are not 
incorporated in the model at the time points studied are blood brain barrier disruption 
and microhaemorrhages, both suggested to contribute to chronic inflammation and 
whit matter disruption. Longer-term chronic cerebral hypoperfusion lead to these 
changes (Holland et al., 2015), however, other mechanisms can cause this type of 
damage, such as hypertension or atherosclerosis which are also risk factors of VCI 
(Smith, 2017). Atherosclerosis for example, is associated with cerebral hypoperfusion 
and vascular cognitive impairment (de la Torre, 2012, Kalback et al., 2004), and 
inflammation is a central aspect of its pathophysiology (Geovanini and Libby, 2018). 
An in vitro study found that inflammation mediated by CSF1 promotes a 
proatherogenic environment which could be reduced by GW2580 (Irvine et al., 2009). 
Further, animal models incorporating multiple aspects of VCI are being developed, for 
example bilateral carotid artery stenosis in spontaneously hypertensive rats can be 
used to explore hypertensive and hypoperfusion mechanisms simultaneously (Choi 
et al., 2015). Clearly, further studies in additional experimental models should be 
carried out to assess the effect of GW2580 to ultimately determine its potential in the 
treatment of cerebrovascular disease (CVD) and VCI.
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6.2 Clinical relevance 
At present, available dementia treatments alleviate symptoms only and are short-
lived in a subset of patients. As such, there is a desperate need for disease-modifying 
treatments of CVD and dementia. Pharmacological activators of the Nrf2 system are 
used to treat relapsing forms of MS (DMF) (Gopal et al., 2017), and ALS (Edaravone) 
(Hardiman and van den Berg, 2017, Liddell, 2017), both devastating fatal central 
nervous system disorders. Similarly, Nrf2 has been demonstrated to play an important 
role in preclinical models of Parkinson’s disease (Chen et al., 2009), Huntington’s 
disease (Calkins et al., 2010) and ischaemic stroke (Zhao et al., 2006). While a large 
body of work indicate a huge therapeutic potential of Nrf2 activation for the treatment 
of neurodegenerative disease, the evidence presented in this thesis and the available 
literature does not strongly support the use of Nrf2-activators for the treatment of 
hypoperfusion-induced CVD and cognitive impairment. 
In contrast, results presented in this thesis suggest that the inhibition of microglial 
proliferation through CSF1R signalling could be an effective future treatment. While 
the beneficial effect of this approach was profound in a mouse model of cerebral 
hypoperfusion, a large amount of work will need to be carried out before it can be 
considered in a human setting. As mentioned in the previous section, further studies 
in additional experimental models of VCI need to be carried out. Due to the 
heterogeneity of VCI accumulating evidence from several different experimental 
models will be necessary. Building up a body of evidence in preclinical studies will 
determine whether GW2580 should be taken into a clinical trial. Previous clinical trials 
have been hampered by the lack of translatability between rodent models and actual 
human diseases. Part of this may be attributed to deficient reproducibility and 
robustness of results from preclinical studies using animal models, issues that could 
be overcome by improved study and statistical design as well as improved reporting 
standards (Snyder et al., 2016). 
Considerations for targeting CSF1R signalling in humans 
It is worth noting that mutations of the CSF1R in humans results in a white matter 
disease referred to as hereditary diffuse leukoencephalopathy with spheroids (HDLS) 
which is associated with behavioural and cognitive deficits including dementia 
(Rademakers et al., 2011). A recent study in zebrafish found that haploinsufficiency 
of CSF1R, resembling adult-onset leukoencephalopathy with axonal spheroids and 
pigmented glia (ALSP) resulted in partial depletion of microglia (Oosterhof et al., 
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2018), leading the authors to urge caution before employing therapeutic strategies 
which target the receptor.  
Importantly, and in consideration of this, treatment with GW2580 does not 
drastically deplete the existing microglial population, even at higher doses (Olmos-
Alonso et al., 2016), but acts to inhibit its expansion, at least in mice. As a therapeutic 
agent this should in theory allow for treatment of the chronic inflammatory response 
which is detrimental to white matter integrity while preserving the established 
population microglial and its homeostatic function. Although further studies are 
warranted to ensure that GW2580 does not influence microglial phenotype, or other 
cell types such as neurons, in a manner which would be detrimental in the long term. 
Considering this investigating the effect of GW2580 on human cells may be vital. 
Advances in techniques to induce pluripotent stem cells (iPSCs)(Hung et al., 2017) 
and complex in vitro systems that model the neuro-gliovascular unit including 
simulated perfusion (Alcendor et al., 2013) means that potential drug treatments for 
VCI and neurodegenerative disease can now be tested on human cells. While these 
models will not be able to recapitulate the human setting completely as there is no 
white matter present, toxicity and molecular mechanisms of the drug treatment can 
be investigated. Non-human primates represent an additional model which much 
better reflects humans, in particular for the study of VCI as primate brains contain 
similar proportions of white matter (Hainsworth et al., 2017). However, these studies 
are complicated by comparably greater life span and ethical regulations relating to 
primates compared to rodents. 
All things considered, the road from the bench to the clinic is long and 
cumbersome. Nonetheless, the results presented in this thesis provide a good 
scientific basis for further exploration of the contribution of microglial proliferation to 
the disruption of white matter structure and function, and highlights the potential of 
inhibiting this response for the treatment of cerebrovascular disease and vascular 
cognitive impairment. 
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Astrocyte-specific overexpression 
of Nrf2 protects against optic 
tract damage and behavioural 
alterations in a mouse model of 
cerebral hypoperfusion
Emma Sigfridsson1, Martina Marangoni1,8, Jeffrey A. Johnson2,3,4,5, Giles E. Hardingham1,6,7, 
Jill H. Fowler1 & Karen Horsburgh1
Mouse models have shown that cerebral hypoperfusion causes white matter disruption and memory 
impairment relevant to the study of vascular cognitive impairment and dementia. The associated 
mechanisms include inflammation and oxidative stress are proposed to drive disruption of myelinated 
axons within hypoperfused white matter. The aim of this study was to determine if increased 
endogenous anti-oxidant and anti-inflammatory signalling in astrocytes was protective in a model 
of mild cerebral hypoperfusion. Transgenically altered mice overexpressing the transcription factor 
Nrf2 (GFAP-Nrf2) and wild type littermates were subjected to bilateral carotid artery stenosis or sham 
surgery. Behavioural alterations were assessed using the radial arm maze and tissue was collected for 
pathology and transcriptome analysis six weeks post-surgery. GFAP-Nrf2 mice showed less pronounced 
behavioural impairments compared to wild types following hypoperfusion, paralleled by reduced optic 
tract white matter disruption and astrogliosis. There was no effect of hypoperfusion on anti-oxidant 
gene alterations albeit the levels were increased in GFAP-Nrf2 mice. Instead, pro-inflammatory gene 
expression was determined to be significantly upregulated in the optic tract of hypoperfused wild 
type mice but differentially affected in GFAP-Nrf2 mice. In particular, complement components (C4 
and C1q) were increased in wild type hypoperfused mice but expressed at levels similar to controls in 
hypoperfused GFAP-Nrf2 mice. This study provides evidence that overexpression of Nrf2 in astrocytes 
exerts beneficial effects through repression of inflammation and supports the potential use of Nrf2-
activators in the amelioration of cerebrovascular-related inflammation and white matter degeneration.
Vascular cognitive impairment (VCI) is a spectrum of mild cognitive impairment to vascular dementia and is 
influenced by risk factors including age, hypertension and atherosclerosis. The most common form of VCI is 
small vessel disease which is predominantly associated with white matter changes that can be detected as hyper-
intense signals on FLAIR or T2-weighted magnetic resonance images1,2. White matter changes correlate with cog-
nitive decline3,4 and are closely related to reduced cerebral perfusion5,6. The extent and presence of white matter 
changes can predict development of dementia in patients with mild cognitive impairment7,8. Thus, understanding 
pathophysiology of white matter changes has important implications in the treatment of dementia.
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Models of cerebral hypoperfusion have been important in providing mechanistic insight into the patho-
physiology of VCI; the best characterised is the bilateral carotid artery stenosis (BCAS) model in mice9,10. We 
and others have demonstrated that cerebral hypoperfusion in mice disrupts myelinated axons within the white 
matter11,12 causing impaired spatial working memory11,13,14. Increased inflammatory cells, particularly microglia, 
often parallel hypoperfusion-induced white matter damage9,15,16. Furthermore, there appears to be a close link 
between damage to white matter, microgliosis and white matter function in response to mild17 and severe cerebral 
hypoperfusion18. Our work demonstrated that the use of a broad spectrum anti-inflammatory drug, minocycline, 
markedly attenuates microgliosis and improves white matter function in a mouse model of cerebral hypoperfu-
sion17, and has also identified activation of pro-inflammatory genes within days in hypoperfused white matter12. 
Inflammation is often accompanied by indices of oxidative stress which is also proposed as a key contributor to 
pathology following cerebral hypoperfusion (reviewed by19,20). Increased levels of the reactive species superoxide, 
the superoxide-producing enzyme NADPH oxidase and oxidative damage to lipids, proteins and nucleic acids is 
found in hypoperfused white matter21–23. Reduced anti-oxidant and detoxifying enzymes and/or dysfunctional 
mitochondria are suggested underlying mechanisms24–26.
Deficiency of the transcription factor nuclear factor erythroid 2-related factor (Nrf2), a master regulator of 
endogenous cytoprotective anti-oxidant and anti-inflammatory gene pathways, is associated with white matter 
damage. Nrf2 knockout mice exhibit myelin pathology characterised by myelin unwinding, lipid peroxidation of 
the myelin sheath, and increased astrocytosis27, as well as reduced functional recovery and remyelination follow-
ing sciatic nerve crush and experimental autoimmune encephalitis (EAE)28,29. In contrast, activation of Nrf2 using 
dimethyl fumarate (DMF) has been shown to prevent myelin damage and astrocyte activation in EAE30, and DMF 
has since been approved for the treatment of relapsing-remitting multiple sclerosis (reviewed by31). Recently we 
have also shown that treatment with DMF, in a severe model of cerebral hypoperfusion, ameliorates white matter 
functional impairment and microgliosis18. Nrf2 expression has been shown to be several fold higher in astrocytes 
compared to neurons32 which have been shown to repress Nrf2 expression developmentally as redox-sensitive 
signalling pathways are important for proper maturation, and instead neurons rely on astrocytic support to pre-
vent oxidative damage33. Oligodendrocytes, also highly metabolically active cells, receive anti-oxidant support 
from astrocytes as well34, which may explain their comparably higher levels of Nrf2 expression. Studies using 
GFAP-Nrf2 mice in models of familial amytrophic lateral sclerosis, Huntington’s and Parkinson’s disease find 
increased production of glutathione and/or glutathione-related genes35–38, similarly seen in models of cerebral 
ischaemia39,40, all of which were associated with favourable outcomes.
Since astrocyte specific overexpression of Nrf2 has been shown to confer white matter protection in a number 
of disease models, we wished to build on this work to interrogate the effects of increased expression of astrocytic 
Nrf2 on white matter vulnerability and behavioural outcomes which are impaired in response to cerebral hypop-
erfusion. The novelty of the present study was to utlise a cell specific and genetic approach to investigate the 
putative protective effects of astrocytic Nrf2, unlike previous studies which have mainly used pharmacological 
approaches to indirectly assess the effects of Nrf2 in hypoperfusion models41,42. We hypothesised that overexpres-
sion of astrocytic Nrf2 would alleviate hypoperfusion induced cognitive impairment by reducing white matter 
disruption and inflammation, through glutathione-related mechanisms.
Results
Cortical cerebral blood flow is significantly reduced following bilateral carotid artery steno-
sis but is not influenced by astrocytic expression of Nrf2. Cortical cerebral blood flow (CBF) was 
evaluated user laser speckle imaging at baseline (before surgery) and then at 24 hours and 6 weeks after surgery 
to assess the temporal response to carotid artery stenosis and to determine if there was a difference between 
wild type and GFAP-Nrf2 mice (Fig. 1). CBF data for each animal was calculated as a percentage of its baseline 
CBF. Overall, there was a significant effect of time (F(2,64) = 57.02, p < 0.0001) and bilateral carotid artery steno-
sis surgery (F(1,32) = 55.20, p < 0.0001) and a significant interaction between time and surgery (F(2,64) = 32.63, 
p < 0.0001). Post hoc analysis indicated that CBF was significantly reduced in wild type and GFAP-Nrf2 hypop-
erfused mice from their corresponding sham controls at 24 hours (p < 0.001) and 6 weeks (WT; p < 0.001, GFAP-
Nrf2; p = 0.03). No overall effect of genotype was detected (F(1,32) = 0.03, p = 0.86), indicating that overexpression 
of Nrf2 does not affect resting cortical cerebral blood flow in sham or hypoperfused mice (Fig. 1a).
Cerebral hypoperfusion causes a behavioural impairment in wild type mice which is less pro-
nounced in GFAP-Nrf2 mice. Behaviour was assessed using an 8-arm radial arm maze which has pre-
viously been shown to be sensitive to hypoperfusion-induced disruption of frontocortical circuitry11,13. Sham 
wild type and GFAP-Nrf2 transgenic mice had different baseline performances and different patterns of learning 
over the trial blocks 1–8 (Fig. S1), and thus revisiting errors were analysed separately for these groups to inves-
tigate the effect of hypoperfusion over trial blocks 1–4 and 5–8. There was no significant difference in revis-
iting errors between wild type sham and hypoperfused mice in trials 1–4 (F(1,9) = 1.51, p = 0.25) but in trials 
5–8 wild type hypoperfused mice made significantly more revisiting errors than the sham controls (F(1,9) = 6.56, 
p = 0.03) (Fig. 2a). Post hoc analysis found significant differences between wild type sham and hypoperfused 
animals at block 5, 6 and 7 (p = 0.01, 0.04, 0.04 respectively). In contrast, GFAP-Nrf2 sham animals were not sig-
nificantly different from hypoperfused mice in trials 1–4 (F(1,17) = 0.33, p = 0.57) and in trials 5–8 (F(1,17) = 3.81, 
p = 0.07) (Fig. 2b). There was an overall significant effect of trial for both wild type (F(2.9,25.9) = 3.39, p = 0.04) and 
GFAP-Nrf2 mice (F(4,68.3) = 9.47, p < 0.0001) (Fig. 2a,b), indicative of learning.
To investigate whether there may be genotype differences between the groups, the fold difference of revisit-
ing errors of hypoperfused groups was calculated to respective sham controls and then compared between wild 
type and GFAP-Nrf2 mice. There was an overall genotype effect (F(1,13) = 4.79, p = 0.048) (Fig. 2c), a significant 
effect of trial (F(2.5,32.4) = 8.70, p < 0.0001) and a significant interaction between trial and genotype (F(2.5,32.4) = 3.36, 
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p = 0.04). Post hoc analysis identified significant differences in the fold change of revisiting errors between wild 
type and GFAP-Nrf2 groups at blocks 4, 5 and 6 (p = 0.046, 0.02, 0.03 respectively). Thus overall the data suggest 
a modest protective effect of Nrf2 overexpression on behavioural impairment following cerebral hypoperfusion.
Loss of optic tract white matter integrity caused by cerebral hypoperfusion is less severe in GFAP- 
Nrf2 mice. Behavioural performance in the radial arm maze is dependent on the integrity of myelinated 
axons within white matter for efficient communication. The corpus callosum, internal capsule and optic tract 
were immunostained for myelin associated glycoprotein (MAG) present at the axon-glial interface. The density 
of MAG+ immunostaining was quantified as percentage area. When the axon-glial interface is disrupted, there is 
an accumulation of MAG + debris indicating a loss of white matter integrity11.
There was no significant loss of white matter integrity as a result of hypoperfusion in the corpus callosum 
(F(1,32) = 2.63, p = 0.12) or the internal capsule (F(1,32) = 0.08, p = 0.78), and no effect of genotype (F(1,32) = 0.82, 
p = 0.37; F(1,32) = 0.17, p = 0.68 respectively) (Fig. 3a,b). However, there was a significant effect of hypoperfusion 
in the optic tract (F(1,31) = 13.57, p = 0.001) albeit no significant effect of genotype (F(1,32) = 0.6, p = 0.44). Post hoc 
analysis of the effect of hypoperfusion revealed a significant loss of white matter integrity in wild type hypoper-
fused mice compared to sham controls (p = 0.004), but the difference between hypoperfused GFAP-Nrf2 mice 
and sham controls narrowly missed accepted levels of statistical significance (p = 0.054) (Fig. 3c).
To investigate whether the magnitude of white matter integrity loss differs between genotypes, the fold differ-
ence of MAG+ debris compared to controls in the optic tract was calculated and compared between wild type 
and GFAP-Nrf2 mice (Fig. 3d). The fold difference was significantly higher in wild type mice (p = 0.03) (Fig. 3d), 
suggesting a modest protective effect of Nrf2 overexpression on white matter integrity following hypoperfusion.
Figure 1. Resting cortical cerebral blood flow (CBF) is significantly reduced following bilateral carotid artery 
stenosis in wild type and GFAP-Nrf2 mice. (a) Resting CBF was significantly reduced by 30–40% from baseline 
24 hours after bilateral carotid artery stenosis (BCAS) surgery and remained significantly reduced at 6 weeks for 
both groups. Effect of time F(2,64) = 57.02, p < 0.0001, effect of surgery F(1,32) = 55.20, p < 0.0001, no significant 
effect of genotype. (b) Representative images of laser speckle flowmetry at baseline and at 24 hr and 6weeks 
post-surgery. Repeated measures ANOVA with Bonferroni adjustment for post hoc analysis. Mean ± SEM. WT/
GFAP-Nrf2 ***/###p < 0.001, GFAP-Nrf2 #p = 0.03. n = 8–10 per group.
Figure 2. Cerebral hypoperfusion causes an impairment in behavioural performance in wild type mice which is 
less pronounced in GFAP-Nrf2 mice. Spatial behaviour was assessed by the radial arm maze as revisiting errors 
over consecutive trials. (a) Wild type (WT) hypoperfused animals committed significantly more revisiting 
errors than WT shams during blocks 5–8 (F(1,9) = 6.56, p = 0.03). (b) GFAP-Nrf2 hypoperfused animals did not 
make significantly more revisiting errors than the GFAP-Nrf2 shams during blocks 5–8 (F(1,17) = 3.81, p = 0.07) 
(c) Revisiting error fold difference compared to respective sham controls was used to investigate genotype 
effect and analysis revealed a significantly higher fold difference in wild type mice (F(1,13) = 4.79, p = 0.048). 
Mean ± SEM. Repeated measures ANOVA with Bonferroni adjustment for post hoc analysis. *p < 0.05. 
n = 5–10 per group.
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Cerebral hypoperfusion induces micro- and astrogliosis in the optic tract, and astrogliosis is 
ameliorated by Nrf2-overexpression. Previously it has been shown that inflammation is a key driver 
of white matter disruption in cerebral hypoperfusion17. To assess the microglial/macrophage inflammatory 
response, Iba1 immunostaining was used and microglia/macrophages were quantified as Iba1+ percentage area 
in the main white matter tracts; corpus callosum, internal capsule and optic tract. Glial fibrillary acidic protein 
(GFAP) immunostaining was utilised to assess the astroglial inflammatory response; quantified as GFAP+ per-
centage area in the corpus callosum, internal capsule and optic tract.
Cerebral hypoperfusion had a significant effect on Iba1 expression in the optic tract (F(1,32) = 14.74, p = 0.001) 
(Fig. 4c), but not in the corpus callosum or the internal capsule (F(1,32) = 2.41, p = 0.13, F(1,32) = 2.75, p = 0.11 
respectively) (Fig. 4a,b). Post hoc analysis revealed significantly greater Iba1+ percentage area in both wild type 
and GFAP-Nrf2 hypoperfused groups compared to their controls (p = 0.007, p = 0.02, respectively). There was no 
effect of genotype in any region (CC-F(1,32) = 3.12, p = 0.09; IC-F(1,32) = 2.23, p = 0.14; OT-F(1,32) = 0.18, p = 0.68).
GFAP + astrocytes were significantly affected by hypoperfusion in the optic tract (F(1,32) = 38.87, p < 0.0001) 
(Fig. 5c) but, similar to Iba1 expression and white matter integrity, not in the corpus callosum or the internal 
capsule (F(1,32) = 1.43, p = 0.24, F(1,32) = 2.01, p = 0.17 respectively) (Fig. 5a,b). There was also no effect of genotype 
in these regions (F(1,32) = 1.95, p = 0.17, F(1,32) = 3.34, p = 0.08 respectively). However, there was an effect of geno-
type in the optic tract (F(1,32) = 7.45, p = 0.01) and a significant interaction between hypoperfusion and genotype 
(F(1,32) = 7.05, p = 0.01). Post hoc tests identified significantly higher GFAP+ percentage are in hypoperfused 
wild type (p < 0.001) and GFAP-Nrf2 groups (p = 0.01) but also a significant reduction in the GFAP-Nrf2 hypop-
erfused group compared to the hypoperfused wild types (p = 0.001) (Fig. 5c). This data indicates that astrocytic 
Nrf2-overexpression reduces astrogliosis induced by cerebral hypoperfusion in the optic tract.
Anti-oxidant-related genes Slc7a11 and Gclm are increased by Nrf2-overexpression. Relative 
gene expression of Nrf2, Scl7a11 (xCT; encoding the glutamate/cystine antiporter) and Gclm, (glutamate-cysteine 
ligase enzyme subunit), two Nrf2-regulated genes involved in glutathione synthesis were measured in a whole 
brain slice corresponding to the level of pathological assessment using qPCR and compared across groups.
There was a significant 3.5-fold increase in Nrf2 mRNA expression in GFAP-Nrf2 animals compared to wild 
type (F(1,32) = 298, p < 0.0001), with no effect of hypoperfusion (F(1,32) = 0.16, p = 0.69) (Fig. 6a). In addition, 
these changes were accompanied by a ~2-fold increase in Slc7a11 and Gclm in GFAP-Nrf2 mice (F(1,32) = 74.05, 
p < 0.0001, F(1,32) = 737.5, p < 0.0001 respectively), again, with no effect of hypoperfusion (F(1,32) = 0.26, p = 0.61, 
F(1,32) = 0.08, p = 0.79). These results may indicate a greater anti-oxidant capacity of GFAP-Nrf2 animals compared 
to wild types. Since there was no effect of hypoperfusion on the expression levels of these genes we considered 
whether subtle alterations in gene expression in predominantly white matter may be masked by measurements 
of gene expression in total brain homogenates. We therefore next investigated gene expression in white matter 
enriched samples.
Figure 3. Loss of white matter integrity in response to hypoperfusion. (a) There was no significant loss of 
white matter integrity between groups in the corpus callosum, (b) nor in the internal capsule (c) but there was a 
significant effect of cerebral hypoperfusion in the optic tract (F(1,31) = 13.57, p = 0.001). (d) Fold change of white 
matter integrity loss compared to respective sham controls in the optic tract showed significantly more loss in 
wild type animals (p = 0.03). Dashed line indicates average sham level. (e) Representative images of MAG+ 
staining in the optic tract. Scale bar 100 µm. Mean ± SEM. (a–c) Two-way ANOVA with Bonferroni adjustment 
for post hoc analysis. (d) Unpaired one-tailed t-test. *p < 0.05, ** p < 0.01. n = 8–10 per group.
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Figure 4. Increased microglia/macrophages in response to hypoperfusion. (a) % Area of Iba1+ staining in 
the corpus callosum and (b) internal capsule was unchanged following cerebral hypoperfusion. (c) % Area of 
Iba1+ staining in the optic tract was significantly altered by cerebral hypoperfusion (F(1,32) = 14.74, p = 0.001), 
with no effect of genotype. (d) Representative images of Iba1+ staining in the optic tract. Scale bar 100 µm. 
Mean ± SEM. Two-way ANOVA with Bonferroni adjustment for post hoc analysis. *p < 0.05, ** p < 0.01. 
n = 8–10 per group.
Figure 5. Astrogliosis in response to hypoperfusion was less severe in GFAP-Nrf2 animals. (a) % Area 
of GFAP+ staining in the corpus callosum and (b) internal capsule was unchanged following cerebral 
hypoperfusion. (c) % Area of GFAP+ staining in the optic tract was significantly increased by cerebral 
hypoperfusion (F(1,32) = 38.87, p < 0.0001), with a significant effect of genotype (F(1,32) = 7.45, p = 0.01). (d) 
Representative images of GFAP+ staining in the optic tract. Scale bar 100 µm. Mean ± SEM. Two-way ANOVA 
with Bonferroni adjustment for post hoc analysis. *p < 0.05, **p < 0.01, ***p < 0.001. n = 8–10 per group.
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Cerebral hypoperfusion induces pro-inflammatory gene expression in the optic tract and 
Nrf2-overexpression reduces the expression of complement component 4. Alterations in gene 
expression were investigated in optic tract enriched samples since we had previously determined glial alterations 
in this region. Nrf2 expression in the optic tract was similar to that of the whole brain sample with an increase in 
GFAP-Nrf2 animals compared to wild type (F(1,32) = 116.4, p < 0.0001), and no further effect of hypoperfusion 
(F(1,32) = 0.47, p = 0.5) (Fig. 7a). To further investigate the involvement of the glutathione anti-oxidant system 
we measured Gclm expression in the optic tract enriched samples, but similarly found an effect of genotype 
only (F(1,31) = 49.83, p < 0.0001) and no effect of hypoperfusion (F(1,31) = 0.22, p = 0.65) (Fig. 7b). Collectively 
our results suggest that anti-oxidant gene alterations cannot explain the white matter protection conferred in 
hypoperfused GFAP-Nrf2 mice at this time. As an alternative, we explored the inflammatory milieu beyond the 
cellular responses as an alternative mechanism whereby Nrf2 may confer protection following hypoperfusion. We 
measured gene expression of complement component 4 and 1q (C4, C1q); initiatiors of the complement system 
which play an important role in the innate immune response43. In addition, we measured gene expression of two 
chemokines; Ccl3 (Mip-1α) and Ccl2 (Mcp-1), which have previously been shown to be upregulated at the protein 
level following severe hypoperfusion18.
Hypoperfusion significantly increased the expression of C4, C1q, and Ccl3 expression (F(1,32) = 8.07, p = 0.008, 
F(1,32) = 7.92, p = 0.008, F(1,29) = 8.68, p = 0.006; respectively) (Fig. 7c–e), whereas Ccl2 expression was reduced 
by hypoperfusion (F(1,31) = 6.09, p = 0.02). C4 expression was also significantly different in GFAP-Nrf2 ani-
mals (F(1,32) = 5.66, p = 0.02) and post hoc analysis found significant upregulation in wild type hypoperfused 
(p = 0.005) but not GFAP-Nrf2 hypoperfused animals (p = 0.39), and further that C4 expression was signifi-
cantly lower in GFAP-Nrf2 compared to wild type hypoperfused animals (p = 0.007). C1q expression followed 
a similar pattern, however there was no overall genotype effect (F(1,32) = 0.05, p = 0.83). Post hoc tests found 
a significant increase of C1q in hypoperfused wild types compared to shams (p = 0.02), but found no signif-
icant difference between GFAP-Nrf2 groups (p = 0.13). No effect of genotype was detected on Ccl3 and Ccl2 
expression (F(1,29) = 0.12, p = 0.73, F(1,31) = 1.62, p = 0.21; respectively), and post hoc analysis identified signifi-
cant differences between GFAP-Nrf2 groups (p = 0.03, p = 0.01; respectively) but not between wild type groups 
(p = 0.07, p = 0.35; respectively). Together the data indicates that cerebral hypoperfusion increases the expression 
of pro-inflammatory genes and that Nrf2-overexpression in astrocytes may protect white matter integrity and 
behavioural performance by selectively suppressing aspects of this inflammatory response.
Discussion
The present study demonstrates that astrocytic overexpression of Nrf2 exerts beneficial effects in a mouse model 
of chronic cerebral hypoperfusion and alleviates loss of white matter integrity and astrogliosis in the optic tract, 
in parallel with improved functional impairment. These protective effects appear to be mediated via repression of 
specific inflammatory genes.
In agreement with previous studies, we show that bilateral carotid artery stenosis (BCAS) induces mild, 
sustained cerebral hypoperfusion in wild type and Nrf2-overexpressing mice15. The extent of CBF reduction 
(~30–40% at 24 hours) and gradual amelioration over 6 weeks is comparable to previously published studies9,44,45. 
Notably, we found no difference in the extent of CBF reduction between wild type and GFAP-Nrf2 mice at 24 hours 
and 6 weeks post-BCAS. We may have expected differences between the groups as the absence of Nrf2 has pre-
viously been shown to have vascular related effects acting to impair angiogenic capacity in vitro46–48 and inhibit 
the upregulation of vascular endothelial growth factor (VEGF) in an in vivo model of venous hypertension49. 
We find increased VEGF expression and other angiogenic genes at 3 days following hypoperfusion12, and pro-
moting vascular remodelling is currently explored in models of hypoperfusion to establish its potential in the 
treatment of vascular dementia, as discussed in50. The current study found that astrocytic Nrf2-overexpression 
does not alter CBF responses following BCAS surgery, which therefore allowed us to investigate the effects of Nrf2 
without confounding flow-related differences.
Consistent with previous studies, we show that hypoperfusion induces impairments in spatial behaviour as 
measured by the radial arm maze in wild type mice following bilateral carotid artery stenosis11,13. Wild type 
and GFAP-Nrf2 sham mice were able to learn the task with increasing trial duration but the hypoperfused mice 
Figure 6. Nrf2, Slc7a11 and Gclm relative gene expression is higher in GFAP-Nrf2 animals with no effect of 
hypoperfusion. (a) Nrf2, (b) Slc7a11 and (c) Gclm expression was significantly higher in GFAP-Nrf2 animals 
(F(1,32) = 298, p < 0.0001, F(1,32) = 74.05, p < 0.0001, F(1,32) = 737.5, p < 0.0001; respectively), but this was not 
altered by hypoperfusion. Gene expression was normalised to Gapdh and expressed relative to WT sham 
controls. Dashed line indicates average WT sham level. Mean ± SEM. Two-way ANOVA. n = 8–10 per group.
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in both cohorts were impaired compared to their controls. It was noted that the baseline learning pattern was 
different in the wild type and GFAP-Nrf2 mice. To the best of our knowledge no previously published studies 
using this transgenic mouse line have investigated cognitive changes, and we found no reports of altered cog-
nition at baseline in models of Nrf2-overexpression/activation. One explanation may be a disruption in redox 
balance. Reactive oxygen species (ROS), albeit detrimental in excess, are cell signalling molecules51 important 
for synaptic plasticity52,53, and it is possible that Nrf2-overexpression affects spatial behaviour by excessive ROS 
depletion. Despite this different baseline learning pattern, GFAP-Nrf2 sham mice successfully learned the task 
Figure 7. Cerebral hypoperfusion induces pro-inflammatory gene expression in the optic tract and Nrf2-
overexpression reduces the expression of complement component 4. (a) Nrf2 and (b) Gclm expression in the 
optic tract was significantly higher in GFAP-Nrf2 animals (F(1,32) = 116.4, p < 0.0001, F(1,31) = 49.83, p < 0.0001 
respectively), but was not altered by hypoperfusion. (c) C4 expression in the optic tract was significantly 
increased by hypoperfusion (F(1,32) = 8.07, p = 0.008) with a significant effect of genotype (F(1,32) = 5.66, 
p = 0.02). (d) Hypoperfusion significantly increased C1q and (e) Ccl3 expression in the optic tract (F(1,32) = 7.92, 
p = 0.008, F(1,29) = 8.68, p = 0.006; respectively), but reduced the expression of Ccl2 (F(1,31) = 6.09, p = 0.02). 
There was no effect of genotype on the expression of C1q, Ccl3 or Ccl2. Gene expression was normalised to 
Gapdh or 18S and expressed relative to WT sham controls. Dashed line indicates average WT sham level. 
Mean ± SEM. Two-way ANOVA with Bonferroni adjustment for post hoc analysis. *p < 0.05, **p < 0.01, 
n = 8–10 per group.
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and the extent of impairment in spatial working memory in GFAP-Nrf2 hypoperfused mice was significantly less 
pronounced as compared to wild type mice. Thus the data supports our hypothesis that increased expression of 
Nrf2 may protect against hypoperfusion induced functional impairment.
Since the functional impairment was less pronounced in GFAP-Nrf2 mice this suggested that there may be 
less extensive pathological alterations. Previous studies, including ours, indicated that white matter is particularly 
vulnerable to cerebral hypoperfusion9–11,54. There is progressive axon-glial disruption,12,15, myelin disruption10,11,14 
and reduced corpus callosal volume following cerebral hypoperfusion55. The current study agrees with previous 
findings of hypoperfusion-induced loss of white matter integrity, however only in the optic tract where the extent 
of pathology is more severe than previously reported. The main difference between this study and former is the 
background strain on which the animals were bred; FVB/C57Bl/6J F1 compared to pure C57Bl/6J. There is a pos-
sibility that the optic tract in FVB/C57Bl/6J F1 mice is more vulnerable to hypoperfusion than C57Bl/6J mice due 
to genetic differences. It is also reported that the cerebral vasculature of different strains is differently organised 
and may therefore present with different spatial distribution and severity of hypoperfusion56. The heightened 
vulnerability of the optic tract may also account for the impaired behaviour in the radial arm maze in the hypop-
erfused mice. Pure FVB/N mice are known to be visually impaired from an early age due to a mutation causing 
retinal degeneration57. However, it is unlikely that the mice were visually impaired since our FVB/C57 first gener-
ation cross successfully learned the visual-dependent radial arm maze task and we observed no altered behaviour 
indicating visual impairment in any of the mice. However, we cannot discount that disruption of the optic tract 
in hypoperfused mice resulted in impaired visual acuity and impaired performance on the radial arm maze task.
Protection against white matter damage using Nrf2-activating compound DMF has been reported in a mouse 
model of experimental autoimmune encephalitis (EAE)30 and severe hypoperfusion18, both of which present with 
substantial white matter disruption. The subtle pathology observed in this study, compared to above and previ-
ously published 1 month hypoperfusion studies10–12,15, may have limited the ability to investigate the modulation 
of pathology with Nrf2-overexpression completely. Nonetheless, despite these confounds, there was an effect of 
GFAP-Nrf2 overexpression on the extent of white matter pathology in the optic tract and notably these mice also 
exhibited improved behavioural abilities. Thus the data indicate that astrocyte specific Nrf2-overexpression may 
alleviate behavioural impairments by preventing loss of white matter integrity in the optic tract.
We have shown previously in the hypoperfusion model that microgliosis precedes significant increases in reac-
tive astrocytes, and associations between microgliosis and impaired white matter function suggests that microglia 
are important contributors to the disease process17,18. Other groups have shown associations between astrogliosis 
and impaired white matter integrity58 and spatial working memory following cerebral hypoperfusion59, suggest-
edly through activation of the pro-inflammatory transcription factor NF-κB58 and reduced astroglial glutamate 
uptake59. In the current study, both micro- and astrogliosis were increased, however only in the optic tract of 
hypoperfused mice. The regional discrepancy between this study and previous may be attributed to the back-
ground strain, which as previously mentioned, may respond to hypoperfusion differently due to do variances in 
cerebrovascular arrangement56. Overexpression of Nrf2 reduced the extent of astrogliosis, but did not have an 
effect on microgliosis after hypoperfusion. This was somewhat unexpected as GFAP-Nrf2 mice have previously 
been shown to reduce both astro- and microgliosis in models of Parkinson’s Disease37,38, and Nrf2-deficiency 
induced robust microgliosis in a model of EAE29. There is conflicting evidence of the effect of Nrf2 on gliosis in 
other models, for example in the transgenic Alzheimer’s disease mouse model APP/PS1. One study found that 
only astrogliosis was reduced by Nrf260, and another found that both astro- and microgliosis were affected61, 
however both were associated with improved cognition. The differences may be accounted for by different means 
of Nrf2-activation; lentiviral-Nrf2 hippocampal injection60, oral administration of the Nrf2-activating compound 
methysticin61 or transgenic overexpression of Nrf2 in astrocytes37,38. Our contrasting results from previous studies 
in GFAP-Nrf2 mice may be explained by the different experimental models, and perhaps particularly by the com-
parably more subtle pathology. Importantly this study demonstrates that increased Nrf2 expression in astrocytes 
alone can have downstream beneficial effects on optic tract white matter integrity and behaviour. Together, these 
result further support the therapeutic potential of activating the Nrf2-pathway in cerebrovascular and neurode-
generative disease. A plethora of pharmacological compounds capable of activating the Nrf2-pathway are cur-
rently under investigation (reviewed in62,63).
To probe mechanisms by which Nrf2 overexpression may mediate protective effects, the levels of two 
glutathione-related genes; Slc7a11 (xCT) and Gclm were measured. The glutathione system forms an important 
part of cellular anti-oxidant capacity64 and has been shown previously to be upregulated by ischaemic precon-
ditioning in an Nrf2-dependent manner40, as well as in GFAP-Nrf2 mice in several models of neurodegenera-
tive disease35–37. We found an increase in both Slc7a11 and Gclm in GFAP-Nrf2 compared to wild type mice, 
however contrary to expectations there were no further increases in these genes with hypoperfusion. Given that 
hypoperfusion induces oxidative damage23,65, we expected increased anti-oxidant gene expression also in wild 
type hypoperfused animals indicative of Nrf2-pathway activation. Instead, anti-oxidant enzymes were determined 
to be increased only in GFAP-Nrf2 animals; in line with a study in a transgenic model of Parkinsons disease37. 
Our results suggest that hypoperfusion in wild type mice is insufficient to induce Nrf2 expression and activation 
directly, although the constitutively higher glutathione-related gene expression in the GFAP-Nrf2 animals may 
indicate a higher capacity of glutathione synthesis which may provide some protection to white matter follow-
ing hypoperfusion. However, we are unable to conclude this without direct measures of glutathione. A model of 
Alexander disease found glutathione-independent protective effects of GFAP-Nrf2 expression66, and a proteomic 
study of Nrf2-overexpressing astrocytes found important roles of detoxifying and anti-inflammatory enzymes cat-
alase, peroxiredoxin-6 and prostaglandin reductase 167 which could alternatively be implicated following hypop-
erfusion as opposed to increased glutathione synthesis. The inability to detect anti-oxidant gene expression may be 
explained by the lack of sensitivity of transcriptome measures in total brain homogenates but since we determined 
similar effects in optic-tract enriched samples, where prominent axon-glial alterations were detected, a lack of 
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gene alterations is unlikely due to sampling. An alternate explanation is that the protective effect seen in the study 
is mediated by modulation of the inflammatory environment rather than by anti-oxidant mechanisms. We inves-
tigated this by further qPCR analysis of optic tract-enriched samples of a panel of pro-inflammatory genes; C4 
and C1q; complement component 4 and 1q, and Ccl3 (MIP-1α) and Ccl2 (MCP-1); chemokine (C-C motif) ligand 
3 and 2. The complement system is an important part of the innate immune system, aiding early responses to 
infection or injury. It contributes to the adaptive immune system by interacting with antigen/antibody complexes 
eliciting a cascade of proteolytic events which ultimately boost phagocytosis and inflammation by the recruit-
ment of more inflammatory cells43. Ccl3/Ccl2 encode pro-inflammatory chemokines involved in the recruitment 
of microglia and astrocytes as well as peripheral monocyts and macrophages68,69. Increased expression of comple-
ment components as well as pro-inflammatory chemokines has long been recognised as an indication of chronic 
inflammation for example in Alzheimer’s disease70–72. Our previous work found increased expression of C4 and a 
putative receptor for C1q, in white matter at 72 hours post-hypoperfusion12 and in whole brain at 4 weeks follow-
ing mild hypoperfusion in wild type mice (unpublished obeservations) using microarray analysis, and increased 
protein levels of Ccl3 and Ccl2 following severe hypoperfusion18. Consistent with previous work, an increase in 
C4, C1q and Ccl3 expression following hypoperfusion was determined in wild type mice, indicative of ongoing 
inflammation. In Nrf2 overexpressing mice the extent of this increase in complement related genes was dampened. 
C1q as the initiating molecule in the classical complement pathway provides the downstream product for which 
C4 is a substrate73. Complement activation has been suggested to potentiate chronic inflammation and neurode-
generation74,75, and has been demonstrated to trigger neuroinflammation following traumatic brain injury76. Since 
direct inhibition of complement has been neuroprotective in mouse models of Alzheimer’s disease77 and cerebral 
ischaemia78,79, reduced complement activation may be a mechanism whereby Nrf2-overexpression is protective 
following hypoperfusion. A recently proposed hypothesis of neuroinflammation is that activated microglia release 
pro-inflammatory mediators (including complement C1q and C3) inducing astrocyte reactivity which in turn is 
detrimental to surrounding cells and tissues74. Our results in astrocyte-specific Nrf2-overexpressing animals find 
reduced astrogliosis but similar coverage of microglia as wild types, reflected also by comparable levels of expres-
sion of the chemokine Ccl3. If microglia are responsible for inducing astrogliosis, reduced astrogliosis in this study 
may result from less pro-inflammatory signalling from microglia in Nrf2-overexpressing animals. Recent evidence 
has demonstrated that Nrf2 not only induces the expression of cytoprotective genes, but is also able to suppress 
expression of pro-inflammatory genes directly80. Since the Nrf2-overexpression is selectively in astrocytes, another 
possibility is that these may also be more resistant to microglia-driven pro-inflammatory signalling as a result of 
increased Nrf2-signalling. In contrast to our previous work where Ccl2 protein was increased at 1 week after severe 
hypoperfusion,18, Ccl2 expression was determined to be downregulated with mild hypoperfusion at 6 weeks. The 
discrepancy may be due to differences in anatomical areas sampled which may display altered pro-inflammatory 
responses and/or the differing extent of hypoperfusion. Overall, the differential change in inflammatory gene 
expression likely reflects the spatial and temporal heterogeneity of inflammatory responses to hypoperfusion.
In conclusion, these results indicate that Nrf2 overexpression in astrocytes dampens aspects of 
hypoperfusion-induced inflammation in the optic tract, possibly by Nrf2-driven suppression of pro-inflammatory 
genes or by increased anti-inflammatory gene expression, ultimately reducing optic tract astrogliosis and loss of 
white matter integrity paralleled by improved functional outcome. This adds support to the use of Nrf2-activators 
as potential treatment for cerebrovascular-related inflammation and white-matter degeneration.
Methods
Animals. GFAP-Nrf2.2 mice were imported from Prof. JA Johnson, University of Wisconsin, and were on an 
FVB background. These mice were developed as previously described in35 and Nrf2-overexpression in astrocytes 
was driven by a GFAP promoter. GFAP-Nrf2 mice were then crossed with wild type C57Bl/6J in-house. The first 
generation crosses including transgenic GFAP-Nrf2 and wild type littermates aged 4–5 months were utilised for 
the study (GFAP-Nrf2, FVB/C57Bl/6J F1). All mice used for the studies were on the same genetic background. 
Animals were initially group housed on a 12-hour light/dark cycle with ad libitum access to food and water, and 
assigned experimental groups by genotype then randomly assigned surgery; wild type sham (n = 8), wild type 
hypoperfused (n = 10), GFAP-Nrf2 sham (n = 10), GFAP-Nrf2 hypoperfused (n = 12). All mice were male. All 
experiments were conducted in accordance with the Animal (Scientific Procedures) Act 1986 and local ethical 
approval at the University of Edinburgh, and were performed under personal and project licences granted by 
the Home Office according to ARRIVE guidelines. Four animals tolerated surgery poorly and had to be culled. 
Final numbers were hence as follows; wild type sham (n = 8), wild type hypoperfused (n = 8), GFAP-Nrf2 sham 
(n = 10), GFAP-Nrf2 hypoperfused (n = 10). Experimenters were blind to genotype and surgery status of the mice 
throughout data collection and analysis.
Bilateral carotid artery stenosis. Animals underwent bilateral carotid artery stenosis (BCAS) surgery 
as developed by9 under isoflurane anaesthesia using 0.18 mm internal diameter microcoils placed around both 
common carotid arteries. Sham surgery includes the entire procedure except for placement of the microcoils. All 
surgical procedures were conducted using aseptic techniques.
Laser speckle imaging. Baseline measurements of cortical cerebral perfusion were acquired prior to, 
24 hours and 6 weeks post-BCAS surgery using a Moor FLPI2 laser speckle contrast imager (Moor Instruments, 
UK). The animal was anaesthetised using isoflurane and its’ head held in position using a stereotactic frame. Body 
temperature was regulated using a heated pad and the skull was exposed by a midline incision and reflection of 
the skin of the head. Water-based gel was evenly spread on the exposed skull and a 2-min perfusion recording was 
acquired. The skull was then sutured and local anaesthetic applied to reduce any pain or discomfort to the animal 
which was then recovered in a heat regulated box.
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8-arm radial arm maze to assess behavioural alterations. Animals were singly housed and food 
restricted (maintained at 85% of initial body weight) one week prior to, and throughout the radial arm maze test, 
to promote motivation (12-hour light/dark cycle, ad libitum access to water). Following the last trial animals were 
again provided food ad libitum. The radial arm maze test was commenced one month after hypoperfusion.
The radial arm maze comprises a central platform (20 cm in diameter) surrounded by 8 arms (47 cm long by 
7 cm wide with 20 cm Plexiglas walls). Each arm has a 2-cm deep plastic well for placement of a sugar pellet and 
all arms can be isolated from the central platform by Plexiglas doors (remotely controlled using Any-Maze soft-
ware, Stoelting, UK). Large visual cues were placed on each of the four walls surrounding the maze, and a camera 
mounted on the ceiling was used for data acquisition (Any-Maze software, Stoelting, UK).
Pre-training consisted of one 5 min trial of free exploration with sugar pellets scattered at random, and one 
where each animal was allowed to walk down each arm from the central platform to retrieve sugar pellets from 
the plastic cups.
The training was carried out for 16 consecutive days (1 trial/day). Each arm was baited with a sugar pellet 
and the animal was placed in the central platform at the start of the trial. The animal was confined to the central 
platform for 5 seconds between each arm choice and the trial finished when the animal had retrieved all 8 pellets 
or when 25 minutes had elapsed. The number of revisiting errors (visits into unbaited arms) during each trial were 
recorded and analysed as a measure of behaviour.
Animals that explored less than 75% of the maze during 2 of the first 4 trials were excluded from analysis due 
to lack of motivation resulting in skewed learning profile. That resulted in the final numbers for the behavioural 
analysis; wild type sham (n = 5), wild type hypoperfused (n = 6) GFAP-Nrf2 sham (n = 10), GFAP-Nrf2 hypop-
erfused (n = 10).
Tissue processing. Following the behavioural testing, animals were sacrificed under deep anaesthesia by 
transcardiac perfusion and hemi brains were snap frozen in liquid nitrogen or post-fixed in 4% paraformaldehyde 
for 24 hours and further processed for paraffin embedding. 6 µm thick coronal tissue sections were collected at 
−1.70 mm posterior of bregma according to81 using a rotary microtome (Leica Biosystems, Germany). The corre-
sponding level of the frozen hemi brain was used for RNA extraction and qPCR analysis. In some experiments the 
optic tract was identified and isolated to produce preparations enriched in optic tract for qPCR analysis.
Immunohistochemistry. Standard laboratory procedures were utilised for immunostaining. Sections were 
deparaffinised and endogenous peroxidase quenched in 3% H2O2 in methanol and antigen retrieval was carried 
out when required (Iba1 and GFAP) in 10 mM citric acid buffer (pH 6.0) at 95 °C for 10 min. Sections were 
blocked with 10% normal serum and 0.5% bovine albumin serum before overnight primary antibody incubation 
at 4 °C. Biotinylated secondary antibodies were incubated for 1 hour at room temperature and then further ampli-
fied; 1 hour at room temperature in Vector ABC Elite Kit (Vector Labs, UK), before visualisation of peroxidase 
activity using 3,3′ diaminobenzidine tetrahydrochloride (DAB, Vector Labs, UK). Primary antibodies and con-
centration used were as follows; Iba1 rabbit polyclonal Menarini, cat no. MP-290, 1:1000; GFAP rat monoclonal 
Life Technologies, cat no. 13-0300, 1:1000; MAG mouse monoclonal Abcam, cat no. ab89780, 1:15,000. Images 
were acquired using an Olympus BX51 microscope (x20, Olympus, UK) and analysed using ImageJ software 
(v1.46, NIH, Bethesda, MD, USA). The density of MAG+, Iba1+ and GFAP+ immunostaining was quantified 
as percentage area. The background was subtracted and a global manual threshold applied. All stains were eval-
uated in the corpus callosum, the internal capsule and the optic tract which were manually delineated by the 
experimenter.
RNA extraction, reverse transcription-PCR and quantitative (q)-PCR. RNA was extracted using 
the QIAGEN RNeasy Lipid Tissue Mini Kit according to manufacturer’s instruction. Briefly, <100 mg fresh fro-
zen tissue was homogenised in 1 ml QIAzol® lysis reagent using the Qiagen automated tissue lyser system and 
metal beads. The homogenate was transferred to fresh RNase/DNase free tubes and incubated for a couple of 
minutes at room temperature with 200 µl chloroform. The upper aqueous phase was collected following 15 min 
centrifugation at 4 °C (12,000 × g), and RNA was subsequently purified in mini spin columns and washed with 
a series of buffers before it was eluted in RNase free water. RNase-free DNase I (Thermo Scientific) was used to 
remove genomic DNA according to manufacturer’s instruction. cDNA was synthesised from 0.1–1 µg RNA using 
the Roche Transcriptor First Strand cDNA Synthesis Kit, according to manufacturer’s instruction. Briefly, RNA 
was added to reverse transcriptase (RT) reaction mix and cycled through 10 min 25 °C; 30 min 55 °C; 5 min 85 °C. 
NoRT control was run alongside and cDNA was diluted to the equivalent of 3 ng initial RNA per 15 µl qPCR 
reaction. The CFX96 Real-Time PCR Machine (Bio Rad) was used with the DyNAmo ColorFlash SYBR Green 
qPCR kit according to manufacturer’s instructions (Thermo Scientific). cDNA template was mixed with SYBR 
green master mix, water and forward and reverse primer (200 nM each final concentration). Samples were run 
in duplicates alongside no template and no RT negative controls. Primers were validated to confirm efficiency 
prior to use and sequences used are as follows: Gapdh-F: 5′-GGGTGTGAACCACGAGAAAT-3′, Gapdh-R: 
5′-CCTTCCACAATGCCAAAGTT-3′, 18S-F: 5′-CCCAGTAAGTGCGGGTCAT-3′, 18S-R: 5′-CCGAGGG 
CCTCACTAAACC-3′, Nrf2-F: 5′-CAGCTCAAGGGCACAGTGC-3′, Nrf2-R: 5′-GTGGCCCAAGTCTT 
GCTCC-3′, Slc7a11-F: 5′-ATACTCCAGAACACGGGCAG-3′ , Slc7a11-R: 5′-AGTTCCACCCAGA 
CTCGAAC-3′, Gclm-F: 5′-GCACAGCGAGGAGCTTC-3′, Gclm-R: 5′-GAGCATGCCATGTCAACTG-3′, C4-F: 
5′-ACAACAAGGGAGACCCCCAG-3′, C4-R: 5′-GCTCAGAGAGCCAGAGTCCTA-3′, C1q-F: 5′-CAAGGACTG 
AAGGGCGTGAA-3′, C1q-R: 5′-CAAGCGTCATTGGGTTCTGC-3′, Ccl3-F: 5′-GCCAGGTGTCATT 
TTCCTGACT-3′, Ccl3-R: 5′-TCAGGCATTCAGTTCCAGGTC-3′, Ccl2-F: 5′-TCCCAAAGAAGCTGTAGT 
TTTTGTC-3′, Ccl2-R: 5′-CCCATTCCTTCTTGGGGTCA-3′.
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The qPCR cycling programme was 10 min at 95 °C; 40 cycles of 30 s at 95 °C, 30 s at 65 °C (/30 s at 62.5 °C for 
C1q and Ccl2 experiment/40 s at 60 °C for Gclm experiment, 62.5 °C) with detection of fluorescence, 30 s at 72 °C; 
1 cycle (for dissociation curve) of 1 min at 95 °C and 30 s at 55 °C with a ramp up to 30 s at 95 °C with continuous 
detection of fluorescence The C4 experiment was run at 7 min at 95 °C initially and then 40 cycles of 10 s at 95 °C, 
30 s at 65 °C (/30 s at 60 °C for Ccl3 experiment) with detection of fluorescence followed by the dissociation curve. 
Data was normalised to Gapdh or 18S expression as reference and expressed as fold change of wild type sham 
expression.
Due to minute volumes of optic tract enriched RNA samples, more variation was present in these qPCR 
experiements. Criteria were therefore defined to exclude samples from qPCR analysis if housekeeper gene was 
detected >3Ct away from the mean or if gene of interest expression was 1.5 interquartile ranges less than the 
first quartile, or 1.5 interquartile ranges more than the third quartile for each group mean. The Ccl3 experiment 
therefore had three samples exluded, and Gclm and Ccl2 experiments one sample each excluded from analysis. 
Final numbers for these experiments were hence as follows; Ccl3 -wild type sham (n = 7), wild type hypoperfused 
(n = 7) GFAP-Nrf2 sham (n = 10), GFAP-Nrf2 hypoperfused (n = 9), Gclm - wild type sham (n = 7), wild type 
hypoperfused (n = 8) GFAP-Nrf2 sham (n = 10), GFAP-Nrf2 hypoperfused (n = 10) and Ccl2 - wild type sham 
(n = 8), wild type hypoperfused (n = 7) GFAP-Nrf2 sham (n = 10), GFAP-Nrf2 hypoperfused (n = 10). All other 
qPCR experiments included all samples.
Statistical analysis. Statistical analysis was performed using SPSS (v22, IBM Corp.) or Graphpad Prism (v5, 
GraphPad Software Inc, La Jolla, USA). Data are presented as mean ± SEM. Normally distributed data was ana-
lysed by analysis of variance (ANOVA). Repeated measure ANOVA was used to analyse cerebral blood flow and 
revisiting errors over time/trials and 2-way ANOVA was performed to test for hypoperfusion/genotype effects of 
immunohistochemistry and qPCR data. Bonferroni adjustment was used for post hoc analysis. Significance was 
determined at p < 0.05.
Data availability. The data sets generated during the current study are available from the corresponding 
authors upon reasonable request.
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